[
  {
    "id": "9d7b6b3c-6712-4f96-ae0a-9a60d09d9276",
    "name": "Elacestrant",
    "brandNames": [
      "Orserdu"
    ],
    "classification": "Selective Estrogen Receptor Degrader (SERD)",
    "mechanism": "Binds to estrogen receptors causing degradation",
    "administration": "Oral tablet, take with food",
    "indications": {
      "cancer_types": [
        "ER-Positive, HER2-Negative Breast Cancer"
      ]
    },
    "dosing": {
      "standard": "345 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Nausea",
        "Fatigue",
        "Hot flashes"
      ],
      "serious": [
        "Musculoskeletal pain"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "Lipid profile"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for liver toxicity and cardiovascular effects"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Estrogen-containing products"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Elacestrant is a selective estrogen receptor degrader (SERD) used in ER-positive, HER2-negative, ESR1-mutated advanced breast cancer.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Contraindicated due to risk of fetal harm",
      "nausea_management": "Nausea is common and may require antiemetic support"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~82%), urine (~7%)",
      "half_life": "30–40 hours",
      "metabolism": "Primarily CYP3A4"
    },
    "contraindications": [
      "Pregnancy",
      "Severe hepatic impairment"
    ],
    "routineMonitoring": [
      "LFTs",
      "Symptoms of GI intolerance"
    ],
    "preTreatmentTests": [
      "ER and HER2 status",
      "ESR1 mutation testing"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T17:42:55.363Z",
    "updatedAt": "2025-05-12T05:52:47.575Z"
  },
  {
    "id": "15ca8ca7-953e-4f90-8296-7b084e6f49f9",
    "name": "Enfortumab Vedotin",
    "brandNames": [
      "Padcev"
    ],
    "classification": "Nectin-4 Antibody-Drug Conjugate",
    "mechanism": "Targets Nectin-4 and delivers a microtubule-disrupting agent",
    "administration": "IV infusion over 30 minutes",
    "indications": {
      "cancer_types": [
        "Bladder Cancer"
      ]
    },
    "dosing": {
      "standard": "1.25 mg/kg IV on days 1, 8, and 15 of a 28-day cycle"
    },
    "sideEffects": {
      "common": [
        "Rash",
        "Fatigue"
      ],
      "serious": [
        "Peripheral neuropathy",
        "Hyperglycemia",
        "Infusion reactions"
      ]
    },
    "monitoring": {
      "labs": [
        "Blood glucose",
        "Renal function",
        "Liver function"
      ],
      "frequency": "Every cycle",
      "precautions": [
        "Monitor for neuropathy and hyperglycemia"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Immunosuppressive agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Enfortumab vedotin is an antibody-drug conjugate targeting Nectin-4, approved for locally advanced or metastatic urothelial cancer.",
    "blackBoxWarning": "Can cause severe skin reactions including Stevens-Johnson syndrome. Monitor closely.",
    "specialConsiderations": {
      "pregnancy": "Avoid due to teratogenic potential",
      "hyperglycemia": "May require insulin therapy",
      "skin_reactions": "Monitor for signs of rash or mucosal involvement"
    },
    "pharmacokinetics": {
      "excretion": "Feces (72%), urine (<10%)",
      "half_life": "3.6 days (MMAE component)",
      "metabolism": "Proteolytic degradation; MMAE via CYP3A4"
    },
    "contraindications": [
      "Known hypersensitivity",
      "Pregnancy"
    ],
    "routineMonitoring": [
      "Skin exam",
      "Glucose levels",
      "CBC"
    ],
    "preTreatmentTests": [
      "Nectin-4 expression (if applicable)",
      "Baseline glucose"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T17:44:39.217Z",
    "updatedAt": "2025-05-12T05:54:02.802Z"
  },
  {
    "id": "125a1097-df9c-4ce5-ab23-1403655ffdaa",
    "name": "Ruxolitinib",
    "brandNames": [
      "Jakafi"
    ],
    "classification": "JAK1/2 Inhibitor",
    "mechanism": "Inhibits Janus-associated kinases 1 and 2 (JAK1 and JAK2), reducing cytokine-mediated inflammation",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "Myelofibrosis",
        "Polycythemia Vera"
      ]
    },
    "dosing": {
      "standard": "15–20 mg orally twice daily depending on platelet count"
    },
    "sideEffects": {
      "common": [
        "Anemia",
        "Thrombocytopenia",
        "Dizziness",
        "Infections"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Every 2–4 weeks",
      "precautions": [
        "Adjust dose based on platelet count"
      ]
    },
    "interactions": {
      "drugs": [
        "Strong CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "FDA prescribing information",
      "NCCN Guidelines"
    ],
    "summary": "Ruxolitinib is a JAK1/JAK2 inhibitor used for myelofibrosis and polycythemia vera.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "hepatotoxicity": "Monitor liver enzymes periodically",
      "myelosuppression": "Dose adjustments required for anemia and thrombocytopenia"
    },
    "pharmacokinetics": {
      "excretion": "Urine (~74%), feces (~22%)",
      "half_life": "3 hours",
      "metabolism": "Primarily CYP3A4"
    },
    "contraindications": [
      "Severe hepatic impairment",
      "Active serious infection"
    ],
    "routineMonitoring": [
      "CBC",
      "LFTs"
    ],
    "preTreatmentTests": [
      "Baseline CBC",
      "LFTs"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:13:27.430Z",
    "updatedAt": "2025-05-12T06:14:51.829Z"
  },
  {
    "id": "c7d5eab3-6f1a-4d22-b5ef-9a8c2b4d3e6f",
    "name": "Vincristine",
    "brandNames": [
      "Oncovin"
    ],
    "classification": "Vinca Alkaloid",
    "mechanism": "Inhibits microtubule formation, arresting cells in metaphase",
    "administration": "IV push",
    "indications": {
      "cancer_types": [
        "ALL",
        "NHL",
        "Wilms Tumor",
        "Small Cell Lung Cancer"
      ]
    },
    "dosing": {
      "standard": "1.4 mg/m² weekly (max 2 mg)"
    },
    "sideEffects": {
      "common": [
        "Peripheral neuropathy",
        "Constipation",
        "SIADH",
        "Jaw pain",
        "Paralytic ileus"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Weekly",
      "precautions": [
        "Monitor neurologic function",
        "Prevent extravasation"
      ]
    },
    "interactions": {
      "drugs": [
        "Itraconazole",
        "Voriconazole",
        "Other CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "ASCO Guidelines"
    ],
    "summary": "Vincristine is a vinca alkaloid mitotic inhibitor that blocks microtubule formation during mitosis. It is used in leukemias, lymphomas, and pediatric solid tumors.",
    "blackBoxWarning": "For intravenous use only – fatal if given intrathecally.",
    "specialConsiderations": {
      "extravasation": "Can cause severe local tissue damage",
      "neurotoxicity": "Peripheral neuropathy is dose-limiting; manifests as areflexia, paresthesia, and constipation"
    },
    "pharmacokinetics": {
      "excretion": "Biliary and fecal",
      "half_life": "19–155 hours (triphasic)",
      "metabolism": "Hepatic (CYP3A4)"
    },
    "contraindications": [
      "Charcot-Marie-Tooth syndrome",
      "Intrathecal administration"
    ],
    "routineMonitoring": [
      "Neurologic function",
      "GI function",
      "CBC"
    ],
    "preTreatmentTests": [
      "Baseline neurologic exam",
      "LFTs"
    ],
    "isChemotherapy": true,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:37:33.956Z",
    "updatedAt": "2025-05-12T06:18:37.094Z"
  },
  {
    "id": "01a7e66c-2500-4869-804f-43a1a1a9fd68",
    "name": "Avelumab",
    "brandNames": [
      "Bavencio"
    ],
    "classification": "PD-L1 Checkpoint Inhibitor",
    "mechanism": "Blocks PD-L1 to restore anti-tumor T-cell activity",
    "administration": "IV infusion over 60 minutes",
    "indications": {
      "cancer_types": [
        "Merkel Cell Carcinoma",
        "Urothelial Carcinoma",
        "NSCLC"
      ]
    },
    "dosing": {
      "standard": "800 mg IV every 2 weeks"
    },
    "sideEffects": {
      "common": [
        "Infusion reactions",
        "Fatigue",
        "Immune-mediated adverse events",
        "Hypothyroidism"
      ],
      "serious": []
    },
    "monitoring": {
      "labs": [
        "Thyroid function",
        "Liver function",
        "Renal function"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for infusion reactions and immune toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "Systemic corticosteroids",
        "Immunosuppressive agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Avelumab is a PD-L1 immune checkpoint inhibitor used in Merkel cell carcinoma and urothelial carcinoma.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Avoid due to risk of immune-mediated fetal harm",
      "immune_related_events": "Monitor for colitis, hepatitis, endocrinopathies, and pneumonitis"
    },
    "pharmacokinetics": {
      "excretion": "Not characterized",
      "half_life": "6.1 days",
      "metabolism": "Proteolytic degradation"
    },
    "contraindications": [
      "Severe hypersensitivity to avelumab"
    ],
    "routineMonitoring": [
      "Thyroid function",
      "Liver enzymes",
      "Signs of pneumonitis"
    ],
    "preTreatmentTests": [
      "PD-L1 expression (for some cancers)",
      "Baseline TSH and LFTs"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": false,
    "isOrphanDrug": true,
    "createdAt": "2025-02-25T15:29:25.790Z",
    "updatedAt": "2025-05-12T05:23:42.465Z"
  },
  {
    "id": "0c4592b7-7d48-414e-8057-b68b78971213",
    "name": "Teclistamab",
    "brandNames": [
      "Tecvayli"
    ],
    "classification": "BCMA/CD3 Bispecific Antibody",
    "mechanism": "Redirects T-cells to target BCMA-expressing cells",
    "administration": "Subcutaneous injection",
    "indications": {
      "cancer_types": [
        "Multiple Myeloma"
      ]
    },
    "dosing": {
      "standard": "1.5 mg/kg subcutaneously every week"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Neutropenia"
      ],
      "serious": [
        "Cytokine release syndrome",
        "Infections"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function",
        "Infection screening"
      ],
      "frequency": "Before each cycle",
      "precautions": [
        "Monitor for infections and CRS"
      ]
    },
    "interactions": {
      "drugs": [
        "Steroids",
        "Immunosuppressive agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T17:43:45.390Z",
    "updatedAt": "2025-04-16T17:43:45.390Z"
  },
  {
    "id": "10fcf37f-6ebb-4f7f-a9ae-468d34a80bcd",
    "name": "Pegfilgrastim",
    "brandNames": [
      "Neulasta"
    ],
    "classification": "Long-acting G-CSF",
    "mechanism": "Stimulates neutrophil production via G-CSF receptor activation",
    "administration": "Subcutaneous injection; On-body injector available",
    "indications": {
      "cancer_types": [
        "Neutropenia Prevention"
      ]
    },
    "dosing": {
      "standard": "6 mg once per chemotherapy cycle",
      "adjustments": [
        "Fixed dosing",
        "Timing with chemotherapy"
      ]
    },
    "sideEffects": {
      "common": [
        "Bone pain"
      ],
      "serious": [
        "Spleen enlargement",
        "Allergic reactions"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC with differential",
        "Spleen monitoring"
      ],
      "frequency": "Regular monitoring",
      "precautions": [
        "Timing with chemotherapy",
        "Monitor for splenic rupture"
      ]
    },
    "interactions": {
      "drugs": [
        "Chemotherapy timing",
        "Lithium"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "ASCO Guidelines"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T17:43:45.390Z",
    "updatedAt": "2025-04-16T17:43:45.390Z"
  },
  {
    "id": "aad2be44-741d-49cf-9b13-091eabda822c",
    "name": "Ipilimumab",
    "brandNames": [
      "Yervoy"
    ],
    "classification": "CTLA-4 Checkpoint Inhibitor",
    "mechanism": "Blocks CTLA-4 to enhance T-cell activation",
    "administration": "IV infusion over 90 minutes",
    "indications": {
      "cancer_types": [
        "Melanoma",
        "NSCLC",
        "Renal Cell Carcinoma"
      ]
    },
    "dosing": {
      "standard": "3 mg/kg IV every 3 weeks"
    },
    "sideEffects": {
      "common": [
        "Fatigue"
      ],
      "serious": [
        "Colitis",
        "Hepatitis",
        "Immune-mediated adverse events"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "Thyroid function"
      ],
      "frequency": "Every 3 weeks",
      "precautions": [
        "Monitor for immune-related adverse events"
      ]
    },
    "interactions": {
      "drugs": [
        "Systemic corticosteroids",
        "Immunosuppressive agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Ipilimumab is a CTLA-4 checkpoint inhibitor used in melanoma, renal cell carcinoma, and in combination with PD-1 inhibitors in various cancers.",
    "blackBoxWarning": "Can cause immune-mediated adverse reactions including enterocolitis, hepatitis, dermatitis, and endocrinopathies.",
    "specialConsiderations": {
      "endocrinopathies": "May be irreversible; monitor thyroid and adrenal function",
      "autoimmune_toxicity": "Requires corticosteroids or treatment interruption for immune-related events"
    },
    "pharmacokinetics": {
      "excretion": "Not defined",
      "half_life": "15 days",
      "metabolism": "Proteolysis"
    },
    "contraindications": [
      "Severe autoimmune disease",
      "Active infection"
    ],
    "routineMonitoring": [
      "TSH and cortisol",
      "LFTs",
      "GI and skin symptoms"
    ],
    "preTreatmentTests": [
      "Thyroid panel",
      "Liver function tests"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": false,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T17:42:55.363Z",
    "updatedAt": "2025-05-12T06:01:39.619Z"
  },
  {
    "id": "17b41945-6c35-40a8-bf41-0d2ef571161c",
    "name": "Savolitinib",
    "brandNames": [
      "Orpathys"
    ],
    "classification": "MET Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits MET signaling in cancers with MET exon 14 skipping mutations",
    "administration": "Oral tablet, take with food",
    "indications": {
      "cancer_types": [
        "MET Exon 14 Skipping NSCLC",
        "Papillary Renal Cell Carcinoma"
      ]
    },
    "dosing": {
      "standard": "600 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Peripheral edema",
        "Fatigue"
      ],
      "serious": [
        "Hepatotoxicity",
        "Interstitial lung disease"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "EKG"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for liver toxicity and lung toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "QT prolonging agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T17:44:39.217Z",
    "updatedAt": "2025-04-16T17:44:39.217Z"
  },
  {
    "id": "78fbf2fa-8a4e-49e3-8d86-781c7f3b2314",
    "name": "Olaparib",
    "brandNames": [
      "Lynparza"
    ],
    "classification": "PARP Inhibitor",
    "mechanism": "Inhibits PARP enzyme to promote DNA damage in BRCA-mutated cells",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "BRCA-Mutant Ovarian Cancer",
        "Breast Cancer",
        "Prostate Cancer",
        "Pancreatic Cancer"
      ]
    },
    "dosing": {
      "standard": "300 mg orally twice daily"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Nausea"
      ],
      "serious": [
        "Anemia",
        "Myelosuppression"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for anemia and myelosuppression"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Myelosuppressive drugs"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Olaparib is an oral PARP inhibitor approved for BRCA-mutated ovarian, breast, pancreatic, and prostate cancers.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "gi_toxicity": "Nausea, vomiting, and diarrhea are common",
      "myelosuppression": "Monitor CBC during therapy"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~44%), urine (~42%)",
      "half_life": "12 hours",
      "metabolism": "Primarily CYP3A4"
    },
    "contraindications": [
      "Severe renal or hepatic impairment",
      "Pregnancy"
    ],
    "routineMonitoring": [
      "CBC",
      "GI symptoms",
      "Liver and kidney function"
    ],
    "preTreatmentTests": [
      "BRCA status",
      "Baseline CBC"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T17:42:55.363Z",
    "updatedAt": "2025-05-12T06:10:07.944Z"
  },
  {
    "id": "b8b41977-3427-4b7b-93d0-0fd9c42f712b",
    "name": "Fulvestrant",
    "brandNames": [
      "Faslodex"
    ],
    "classification": "Estrogen Receptor Antagonist",
    "mechanism": "Binds to and degrades estrogen receptors",
    "administration": "IM injection into the buttocks, monthly",
    "indications": {
      "cancer_types": [
        "ER-Positive, HER2-Negative Breast Cancer"
      ]
    },
    "dosing": {
      "standard": "500 mg IM on days 1, 15, 29, then monthly"
    },
    "sideEffects": {
      "common": [
        "Injection site pain",
        "Nausea",
        "Fatigue",
        "Hot flashes"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function"
      ],
      "frequency": "Every 4–8 weeks",
      "precautions": [
        "Monitor LFTs regularly"
      ]
    },
    "interactions": {
      "drugs": [
        "Estrogen products",
        "Tamoxifen"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Fulvestrant is a selective estrogen receptor degrader (SERD) used in hormone receptor–positive metastatic breast cancer, especially after progression on antiestrogens.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "liver_monitoring": "May cause hepatotoxicity; monitor LFTs",
      "injection_site_pain": "IM administration may cause pain and bleeding"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~90%)",
      "half_life": "40 days",
      "metabolism": "Primarily CYP3A4"
    },
    "contraindications": [
      "Pregnancy",
      "Bleeding disorders"
    ],
    "routineMonitoring": [
      "LFTs",
      "Tumor response"
    ],
    "preTreatmentTests": [
      "ER status",
      "Pregnancy test (if applicable)"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:08:59.395Z",
    "updatedAt": "2025-05-12T05:56:07.035Z"
  },
  {
    "id": "19dfead5-f943-46b8-8402-1156858013e8",
    "name": "Sorafenib",
    "brandNames": [
      "Nexavar"
    ],
    "classification": "VEGF Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits VEGFR, PDGFR, RAF kinases to block tumor angiogenesis and proliferation",
    "administration": "Oral tablet, take on an empty stomach",
    "indications": {
      "cancer_types": [
        "Hepatocellular Carcinoma",
        "Renal Cell Carcinoma",
        "Thyroid Cancer"
      ]
    },
    "dosing": {
      "standard": "400 mg orally twice daily"
    },
    "sideEffects": {
      "common": [
        "Diarrhea",
        "Fatigue"
      ],
      "serious": [
        "Hand-foot syndrome",
        "Hypertension"
      ]
    },
    "monitoring": {
      "labs": [
        "Blood pressure",
        "Liver function",
        "EKG"
      ],
      "frequency": "Every 2-4 weeks",
      "precautions": [
        "Monitor cardiovascular and liver function"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "QT prolonging agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Sorafenib is a multikinase inhibitor targeting VEGFR and RAF kinases, used primarily in advanced renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "hypertension": "Monitor blood pressure regularly and manage appropriately",
      "hand_foot_syndrome": "Common dermatologic toxicity; dose adjust if severe"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~77%), urine (~19%)",
      "half_life": "25–48 hours",
      "metabolism": "CYP3A4 and UGT1A9"
    },
    "contraindications": [
      "Severe hepatic impairment"
    ],
    "routineMonitoring": [
      "BP",
      "LFTs",
      "Dermatologic exam"
    ],
    "preTreatmentTests": [
      "Liver function",
      "BP baseline"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T17:44:39.217Z",
    "updatedAt": "2025-05-12T06:15:51.760Z"
  },
  {
    "id": "207a6487-9f0e-48b7-a709-73e85678daa5",
    "name": "Lisocabtagene Maraleucel",
    "brandNames": [
      "Breyanzi"
    ],
    "classification": "CAR-T Therapy",
    "mechanism": "Autologous anti-CD19 CAR-T cells for large B-cell lymphoma",
    "administration": "IV infusion over 30-60 minutes",
    "indications": {
      "cancer_types": [
        "Large B-Cell Lymphoma"
      ]
    },
    "dosing": {
      "standard": "One-time IV infusion"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Hypogammaglobulinemia"
      ],
      "serious": [
        "Cytokine release syndrome",
        "Neurologic toxicity",
        "Infections"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function",
        "Neurologic exam"
      ],
      "frequency": "Before and after infusion",
      "precautions": [
        "Monitor for CRS and neurotoxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "Steroids",
        "Tocilizumab"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T17:48:55.475Z",
    "updatedAt": "2025-04-16T17:48:55.475Z"
  },
  {
    "id": "23546181-bb78-4370-b55e-c0a1254f93d5",
    "name": "Necitumumab",
    "brandNames": [
      "Portrazza"
    ],
    "classification": "EGFR Monoclonal Antibody",
    "mechanism": "Binds EGFR to inhibit ligand-induced receptor activation and downstream signaling",
    "administration": "IV infusion over 60 minutes",
    "indications": {
      "cancer_types": [
        "EGFR-Expressing Non-Small Cell Lung Cancer"
      ]
    },
    "dosing": {
      "standard": "800 mg IV on days 1 and 8 of a 3-week cycle"
    },
    "sideEffects": {
      "common": [
        "Rash",
        "Infusion reactions"
      ],
      "serious": [
        "Hypomagnesemia",
        "Venous thromboembolism"
      ]
    },
    "monitoring": {
      "labs": [
        "Magnesium levels",
        "EKG",
        "Electrolytes"
      ],
      "frequency": "Prior to each cycle",
      "precautions": [
        "Monitor for infusion reactions and electrolyte imbalances"
      ]
    },
    "interactions": {
      "drugs": [
        "Electrolyte-depleting agents",
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T17:48:55.475Z",
    "updatedAt": "2025-04-16T17:48:55.475Z"
  },
  {
    "id": "1f812242-91da-4b74-95ed-6bd5ad8b704c",
    "name": "Bintrafusp Alfa",
    "brandNames": [
      "Experimental"
    ],
    "classification": "TGF-β Inhibitor",
    "mechanism": "Bifunctional fusion protein targeting TGF-β and PD-L1 to block immune evasion",
    "administration": "IV infusion over 30 minutes",
    "indications": {
      "cancer_types": [
        "Non-Small Cell Lung Cancer",
        "Pancreatic Cancer"
      ]
    },
    "dosing": {
      "standard": "1200 mg IV every 2 weeks"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Diarrhea"
      ],
      "serious": [
        "Immune-mediated toxicity",
        "Hepatotoxicity"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "CBC"
      ],
      "frequency": "Every 2 weeks",
      "precautions": [
        "Monitor for immune-related toxicities"
      ]
    },
    "interactions": {
      "drugs": [
        "Immunosuppressive agents",
        "Steroids"
      ]
    },
    "referenceSources": [
      "Clinical Trials",
      "NCCN Guidelines"
    ],
    "summary": "Bintrafusp alfa is a bifunctional fusion protein targeting PD-L1 and TGF-β, studied in advanced cancers.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Avoid due to unknown fetal risk",
      "immune_toxicities": "Similar to checkpoint inhibitors; monitor for colitis, hepatitis, endocrinopathies"
    },
    "pharmacokinetics": {
      "excretion": "Unknown",
      "half_life": "Investigational",
      "metabolism": "Expected proteolytic degradation"
    },
    "contraindications": [
      "None established (investigational)"
    ],
    "routineMonitoring": [
      "LFTs",
      "Endocrine labs",
      "Signs of immune-related toxicity"
    ],
    "preTreatmentTests": [
      "PD-L1 status if available"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T17:48:55.475Z",
    "updatedAt": "2025-05-12T05:29:22.845Z"
  },
  {
    "id": "2d4e6ff0-d5e3-4f0e-a50c-58cd83863183",
    "name": "Pralsetinib",
    "brandNames": [
      "Gavreto"
    ],
    "classification": "RET Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits RET gene fusions and mutations in cancer cells",
    "administration": "Oral capsule, take on an empty stomach",
    "indications": {
      "cancer_types": [
        "RET Fusion-Positive NSCLC",
        "Medullary Thyroid Cancer"
      ]
    },
    "dosing": {
      "standard": "400 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Hypertension",
        "Fatigue",
        "Anemia"
      ],
      "serious": [
        "Hepatotoxicity"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "EKG",
        "Blood pressure"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for hypertension and liver toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "QT prolonging agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T17:51:27.495Z",
    "updatedAt": "2025-04-16T17:51:27.495Z"
  },
  {
    "id": "c1aa55da-6717-4727-8ec1-838edb9a0f7a",
    "name": "Belantamab Mafodotin",
    "brandNames": [
      "Blenrep"
    ],
    "classification": "BCMA Antibody-Drug Conjugate",
    "mechanism": "Targets BCMA to deliver MMAF and induce apoptosis",
    "administration": "2.5 mg/kg IV every 3 weeks",
    "indications": {
      "cancer_types": [
        "Relapsed/Refractory Multiple Myeloma"
      ]
    },
    "dosing": {
      "standard": "2.5 mg/kg IV every 3 weeks"
    },
    "sideEffects": {
      "common": [
        "Ocular toxicity",
        "Thrombocytopenia",
        "Infusion reactions"
      ]
    },
    "monitoring": {
      "labs": [
        "Eye exam",
        "CBC"
      ],
      "frequency": "Every cycle"
    },
    "interactions": {
      "drugs": [
        "Other microtubule inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:44:47.925Z",
    "updatedAt": "2025-04-16T20:44:47.925Z"
  },
  {
    "id": "273223ab-4f58-4b8f-889a-e9e42bfa1fec",
    "name": "Epacadostat",
    "brandNames": [
      "Experimental"
    ],
    "classification": "IDO Inhibitor",
    "mechanism": "Inhibits indoleamine 2,3-dioxygenase to enhance T-cell activity",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "Melanoma",
        "Non-Small Cell Lung Cancer"
      ]
    },
    "dosing": {
      "standard": "100 mg orally twice daily"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Diarrhea",
        "Rash"
      ],
      "serious": [
        "Immune-related toxicities"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "CBC"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for immune-related adverse events"
      ]
    },
    "interactions": {
      "drugs": [
        "PD-1 inhibitors",
        "Immunosuppressive agents"
      ]
    },
    "referenceSources": [
      "Clinical Trials",
      "NCCN Guidelines"
    ],
    "summary": "Epacadostat is an investigational IDO1 inhibitor evaluated in combination with checkpoint inhibitors in solid tumors.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Avoid due to investigational safety profile",
      "limited_evidence": "No FDA approval to date; studied mainly with pembrolizumab"
    },
    "pharmacokinetics": {
      "excretion": "Unknown",
      "half_life": "Approx. 4 hours",
      "metabolism": "CYP3A4 (minor)"
    },
    "contraindications": [
      "None established (investigational)"
    ],
    "routineMonitoring": [
      "LFTs",
      "Immunologic adverse events (if used with checkpoint blockade)"
    ],
    "preTreatmentTests": [
      "Clinical trial criteria if applicable"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T17:49:15.246Z",
    "updatedAt": "2025-05-12T05:54:18.049Z"
  },
  {
    "id": "34484eba-928f-4c38-9c8b-f46517eebc87",
    "name": "Darolutamide",
    "brandNames": [
      "Nubeqa"
    ],
    "classification": "Androgen Receptor Inhibitor",
    "mechanism": "Inhibits androgen receptor signaling, blocking cancer cell growth",
    "administration": "Oral tablet, take with food",
    "indications": {
      "cancer_types": [
        "Non-Metastatic Castration-Resistant Prostate Cancer"
      ]
    },
    "dosing": {
      "standard": "600 mg orally twice daily"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Rash"
      ],
      "serious": [
        "Hypertension",
        "Fractures"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "Blood pressure"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for hypertension and cardiovascular risk"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Anti-androgens"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T17:51:48.265Z",
    "updatedAt": "2025-04-16T17:51:48.265Z"
  },
  {
    "id": "3e611a71-78ca-428c-8f83-337c730c366f",
    "name": "Rucaparib",
    "brandNames": [
      "Rubraca"
    ],
    "classification": "PARP Inhibitor",
    "mechanism": "Inhibits PARP enzymes involved in DNA repair",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "BRCA-Mutant Ovarian Cancer",
        "Prostate Cancer"
      ]
    },
    "dosing": {
      "standard": "600 mg orally twice daily"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Nausea"
      ],
      "serious": [
        "Anemia",
        "Myelosuppression"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for anemia and myelosuppression"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Myelosuppressive drugs"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T19:59:15.187Z",
    "updatedAt": "2025-04-16T19:59:15.187Z"
  },
  {
    "id": "38c226c0-041f-4329-9bf3-07c4b119735f",
    "name": "Cabazitaxel",
    "brandNames": [
      "Jevtana"
    ],
    "classification": "Taxane Chemotherapy",
    "mechanism": "Stabilizes microtubules and inhibits mitosis",
    "administration": "IV infusion over 1 hour (requires premedication)",
    "indications": {
      "cancer_types": [
        "Prostate Cancer"
      ]
    },
    "dosing": {
      "standard": "25 mg/m² every 3 weeks"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Diarrhea"
      ],
      "serious": [
        "Neutropenia",
        "Peripheral neuropathy",
        "Hypersensitivity"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Prior to each cycle",
      "precautions": [
        "Monitor for neutropenia",
        "Assess for neuropathy"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Other myelosuppressive agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "ESMO Guidelines"
    ],
    "summary": "Cabazitaxel is a second-generation taxane used in metastatic castration-resistant prostate cancer post-docetaxel.",
    "blackBoxWarning": "Neutropenia and severe hypersensitivity reactions; requires premedication and monitoring.",
    "specialConsiderations": {
      "hypersensitivity": "Premedicate with corticosteroids and antihistamines",
      "myelosuppression": "Dose-limiting neutropenia; monitor CBC frequently"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~76%), urine (~4%)",
      "half_life": "95 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Neutrophil count < 1500/μL",
      "Severe hypersensitivity to polysorbate 80"
    ],
    "routineMonitoring": [
      "CBC",
      "Vital signs during infusion"
    ],
    "preTreatmentTests": [
      "CBC with differential",
      "Liver function tests"
    ],
    "isChemotherapy": true,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T17:51:48.265Z",
    "updatedAt": "2025-05-12T05:47:50.697Z"
  },
  {
    "id": "4e2c9855-eb8a-4b70-a9c2-9cc0692591b6",
    "name": "Erlotinib",
    "brandNames": [
      "Tarceva"
    ],
    "classification": "EGFR Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits EGFR tyrosine kinase, blocking downstream signaling",
    "administration": "Oral tablet, take on an empty stomach",
    "indications": {
      "cancer_types": [
        "EGFR-Mutant NSCLC",
        "Pancreatic Cancer"
      ]
    },
    "dosing": {
      "standard": "150 mg once daily for NSCLC; 100 mg once daily for Pancreatic Cancer"
    },
    "sideEffects": {
      "common": [
        "Rash",
        "Diarrhea"
      ],
      "serious": [
        "Interstitial lung disease",
        "Hepatotoxicity"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "Renal function",
        "EKG"
      ],
      "frequency": "Every 4-6 weeks",
      "precautions": [
        "Monitor for rash and pulmonary toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "PPI medications"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Erlotinib is an EGFR tyrosine kinase inhibitor used in NSCLC and pancreatic cancer with EGFR mutations.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "rash": "Common and may correlate with efficacy; use emollients or topical steroids",
      "interstitial_lung_disease": "Rare but serious; monitor respiratory symptoms"
    },
    "pharmacokinetics": {
      "excretion": "Feces (83%), urine (8%)",
      "half_life": "36 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Severe hypersensitivity",
      "Interstitial lung disease"
    ],
    "routineMonitoring": [
      "Skin exam",
      "LFTs",
      "Respiratory symptoms"
    ],
    "preTreatmentTests": [
      "EGFR mutation status"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:00:03.711Z",
    "updatedAt": "2025-05-12T05:54:33.647Z"
  },
  {
    "id": "4788f31f-0b3e-4cc7-b169-84d2d4692482",
    "name": "Larotrectinib",
    "brandNames": [
      "Vitrakvi"
    ],
    "classification": "NTRK Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits TRK fusion proteins to prevent tumor growth",
    "administration": "Oral capsule, take with or without food",
    "indications": {
      "cancer_types": [
        "NTRK Fusion-Positive Solid Tumors"
      ]
    },
    "dosing": {
      "standard": "100 mg orally twice daily"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Weight gain"
      ],
      "serious": [
        "Neurotoxicity",
        "Elevated liver enzymes"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "Neurologic exam"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for neurotoxicity and liver dysfunction"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "QT prolonging agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Larotrectinib is a selective TRK inhibitor indicated for solid tumors with NTRK gene fusions, regardless of tumor site.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "neurotoxicity": "Monitor for dizziness, ataxia, or cognitive changes",
      "liver_function": "Elevated transaminases may occur"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~58%), urine (~39%)",
      "half_life": "3 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Hypersensitivity"
    ],
    "routineMonitoring": [
      "LFTs",
      "Neurologic status"
    ],
    "preTreatmentTests": [
      "NTRK fusion testing"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T19:59:46.283Z",
    "updatedAt": "2025-05-12T06:03:50.558Z"
  },
  {
    "id": "40e1f966-e8b0-4cb1-ab2c-8edc525480fe",
    "name": "Capmatinib",
    "brandNames": [
      "Tabrecta"
    ],
    "classification": "MET Tyrosine Kinase Inhibitor",
    "mechanism": "Targets MET mutations including exon 14 skipping",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "MET Exon 14 Skipping Mutation NSCLC"
      ]
    },
    "dosing": {
      "standard": "400 mg orally twice daily"
    },
    "sideEffects": {
      "common": [
        "Peripheral edema",
        "Nausea"
      ],
      "serious": [
        "Liver enzyme elevation",
        "Interstitial lung disease"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "EKG",
        "Renal function"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for interstitial lung disease"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "QT prolonging agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Capmatinib is a selective MET inhibitor used in NSCLC with MET exon 14 skipping mutations.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Avoid due to potential fetal harm",
      "photosensitivity": "Avoid prolonged sun exposure",
      "interstitial_lung_disease": "Monitor for pulmonary symptoms"
    },
    "pharmacokinetics": {
      "excretion": "Feces (78%), urine (22%)",
      "half_life": "6.5 hours",
      "metabolism": "CYP3A4 and aldehyde oxidase"
    },
    "contraindications": [
      "Severe hypersensitivity to capmatinib"
    ],
    "routineMonitoring": [
      "LFTs",
      "Respiratory symptoms",
      "Skin reactions"
    ],
    "preTreatmentTests": [
      "MET exon 14 mutation status",
      "Baseline LFTs"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T19:59:15.187Z",
    "updatedAt": "2025-05-12T05:49:10.611Z"
  },
  {
    "id": "289a9956-98a5-42dd-8552-670af4f88524",
    "name": "Tesetaxel",
    "brandNames": [],
    "classification": "Taxane Chemotherapy",
    "mechanism": "",
    "administration": "",
    "indications": {},
    "dosing": {
      "standard": "27 mg/m² orally every 3 weeks"
    },
    "sideEffects": {},
    "monitoring": {},
    "interactions": {},
    "referenceSources": [],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:49:37.589Z",
    "updatedAt": "2025-04-16T20:49:37.589Z"
  },
  {
    "id": "3e669a51-7eaa-4dc3-b940-695a5bbc97f7",
    "name": "Pazopanib",
    "brandNames": [
      "Votrient"
    ],
    "classification": "VEGF Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits VEGFR, PDGFR, and other kinases involved in tumor angiogenesis",
    "administration": "Oral tablet, take on an empty stomach",
    "indications": {
      "cancer_types": [
        "Renal Cell Carcinoma",
        "Soft Tissue Sarcoma"
      ]
    },
    "dosing": {
      "standard": "800 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Diarrhea"
      ],
      "serious": [
        "Hepatotoxicity",
        "Hypertension"
      ]
    },
    "monitoring": {
      "labs": [
        "Blood pressure",
        "Liver function",
        "EKG"
      ],
      "frequency": "Every 2-4 weeks",
      "precautions": [
        "Monitor liver enzymes and blood pressure regularly"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "QT prolonging agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Pazopanib is a VEGFR tyrosine kinase inhibitor used for renal cell carcinoma and soft tissue sarcoma.",
    "blackBoxWarning": "Severe hepatotoxicity may occur; monitor LFTs before and during treatment.",
    "specialConsiderations": {
      "hypertension": "Common; monitor and treat as needed",
      "hepatotoxicity": "Regular LFTs required; discontinue if severe"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~82%), urine (~6%)",
      "half_life": "30 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Severe hepatic impairment",
      "Uncontrolled hypertension"
    ],
    "routineMonitoring": [
      "LFTs",
      "BP",
      "Thyroid function"
    ],
    "preTreatmentTests": [
      "LFTs",
      "BP measurement"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T19:59:15.187Z",
    "updatedAt": "2025-05-12T06:11:44.129Z"
  },
  {
    "id": "6848079b-c45b-4fe8-852d-a7701bf307f1",
    "name": "Relatlimab",
    "brandNames": [
      "Opdualag"
    ],
    "classification": "LAG-3 Checkpoint Inhibitor",
    "mechanism": "Blocks LAG-3 to enhance T-cell activation and immune response against tumors",
    "administration": "IV infusion over 60 minutes",
    "indications": {
      "cancer_types": [
        "Melanoma"
      ]
    },
    "dosing": {
      "standard": "480 mg IV every 4 weeks"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Diarrhea"
      ],
      "serious": [
        "Immune-mediated adverse events",
        "Hepatitis"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "Thyroid function"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for immune-related toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "Systemic corticosteroids",
        "Immunosuppressive agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:01:02.252Z",
    "updatedAt": "2025-04-16T20:01:02.252Z"
  },
  {
    "id": "6a44f302-eeac-4c8e-a0f8-3fff97a8d61a",
    "name": "Talquetamab",
    "brandNames": [
      "Talvey"
    ],
    "classification": "GPRC5D/CD3 Bispecific Antibody",
    "mechanism": "Redirects T-cells to target GPRC5D-expressing myeloma cells",
    "administration": "Subcutaneous injection",
    "indications": {
      "cancer_types": [
        "Relapsed/Refractory Multiple Myeloma"
      ]
    },
    "dosing": {
      "standard": "0.4 mg/kg subcutaneously every week"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Dysgeusia"
      ],
      "serious": [
        "Cytokine release syndrome",
        "Neutropenia"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function",
        "Neurologic exam"
      ],
      "frequency": "Before each cycle",
      "precautions": [
        "Monitor for CRS and neurologic toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "Steroids",
        "Immunosuppressive agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:01:02.252Z",
    "updatedAt": "2025-04-16T20:01:02.252Z"
  },
  {
    "id": "6bdb84f0-1742-446b-a122-5d69ad8872db",
    "name": "Pemigatinib",
    "brandNames": [
      "Pemazyre"
    ],
    "classification": "FGFR Inhibitor",
    "mechanism": "Blocks FGFR2 fusion proteins to inhibit tumor growth in cholangiocarcinoma",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "FGFR2-Fusion Cholangiocarcinoma"
      ]
    },
    "dosing": {
      "standard": "13.5 mg orally once daily for 2 weeks, then 1 week off"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Nail toxicity"
      ],
      "serious": [
        "Hyperphosphatemia",
        "Ocular toxicity"
      ]
    },
    "monitoring": {
      "labs": [
        "Serum phosphorus",
        "Liver function",
        "Ophthalmologic exam"
      ],
      "frequency": "Every 2-4 weeks",
      "precautions": [
        "Monitor for ocular toxicity and hyperphosphatemia"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Phosphate-lowering agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:01:40.780Z",
    "updatedAt": "2025-04-16T20:01:40.780Z"
  },
  {
    "id": "709703e7-199f-4a61-b715-c11b5508c6fb",
    "name": "Filgrastim",
    "brandNames": [
      "Neupogen"
    ],
    "classification": "Granulocyte Colony-Stimulating Factor",
    "mechanism": "Stimulates neutrophil production to reduce risk of neutropenia",
    "administration": "Subcutaneous injection or IV infusion",
    "indications": {
      "cancer_types": [
        "Neutropenia Prevention",
        "Stem Cell Mobilization"
      ]
    },
    "dosing": {
      "standard": "5 mcg/kg/day",
      "adjustments": [
        "Adjust timing with chemotherapy",
        "Weight-based dosing"
      ]
    },
    "sideEffects": {
      "common": [
        "Bone pain",
        "Fever"
      ],
      "serious": [
        "Spleen enlargement",
        "Allergic reactions"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC with differential",
        "Spleen monitoring"
      ],
      "frequency": "Regular CBC monitoring",
      "precautions": [
        "Watch for splenic rupture",
        "Monitor WBC counts"
      ]
    },
    "interactions": {
      "drugs": [
        "Lithium",
        "Chemotherapy timing",
        "Topotecan"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "ASCO Guidelines"
    ],
    "summary": "Filgrastim is a recombinant G-CSF used to stimulate neutrophil production in chemotherapy-induced neutropenia, bone marrow transplant, or chronic neutropenia.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "bone_pain": "Common side effect; managed with acetaminophen or NSAIDs",
      "splenic_rupture": "Rare but serious; monitor abdominal symptoms"
    },
    "pharmacokinetics": {
      "excretion": "Renal",
      "half_life": "3.5 hours",
      "metabolism": "Proteolysis"
    },
    "contraindications": [
      "Hypersensitivity to E. coli–derived proteins"
    ],
    "routineMonitoring": [
      "WBC count",
      "Abdominal exam for splenic enlargement"
    ],
    "preTreatmentTests": [
      "CBC with differential"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:01:40.780Z",
    "updatedAt": "2025-05-12T05:55:56.489Z"
  },
  {
    "id": "73bed549-be31-4a73-8188-a433e5c56050",
    "name": "Zoledronic Acid",
    "brandNames": [
      "Zometa"
    ],
    "classification": "Bisphosphonate",
    "mechanism": "Inhibits bone resorption by osteoclasts to prevent skeletal-related events",
    "administration": "IV infusion over 15 minutes",
    "indications": {
      "cancer_types": [
        "Bone Metastases",
        "Hypercalcemia of Malignancy"
      ]
    },
    "dosing": {
      "standard": "4 mg every 3-4 weeks",
      "adjustments": [
        "Reduce for renal impairment",
        "Modify frequency based on indication"
      ]
    },
    "sideEffects": {
      "common": [
        "Flu-like symptoms"
      ],
      "serious": [
        "Renal toxicity",
        "Osteonecrosis of jaw",
        "Hypocalcemia"
      ]
    },
    "monitoring": {
      "labs": [
        "Renal function",
        "Calcium",
        "Dental exam"
      ],
      "frequency": "Prior to each dose",
      "precautions": [
        "Dental health",
        "Renal monitoring"
      ]
    },
    "interactions": {
      "drugs": [
        "Other nephrotoxic drugs",
        "Calcium supplements",
        "Thalidomide"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "ASCO Guidelines"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:02:07.453Z",
    "updatedAt": "2025-04-16T20:02:07.453Z"
  },
  {
    "id": "4548dbad-9eb7-449a-8d2a-0a49a35d0fa0",
    "name": "Ivosidenib",
    "brandNames": [
      "Tibsovo"
    ],
    "classification": "IDH1 Inhibitor",
    "mechanism": "Inhibits mutated IDH1 enzyme, reducing 2-HG levels and promoting differentiation of leukemic cells",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "IDH1-Mutant Acute Myeloid Leukemia",
        "IDH1-Mutant Cholangiocarcinoma"
      ]
    },
    "dosing": {
      "standard": "500 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Nausea"
      ],
      "serious": [
        "Differentiation syndrome",
        "QT prolongation"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "EKG",
        "Blood counts"
      ],
      "frequency": "Every 2-4 weeks",
      "precautions": [
        "Monitor for differentiation syndrome and cardiac toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "QT prolonging agents",
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Ivosidenib is an oral IDH1 inhibitor used for IDH1-mutated acute myeloid leukemia (AML) and cholangiocarcinoma.",
    "blackBoxWarning": "Risk of differentiation syndrome requiring corticosteroids and supportive care.",
    "specialConsiderations": {
      "qt_prolongation": "ECG monitoring recommended",
      "differentiation_syndrome": "Initiate steroids early if suspected"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~77%), urine (~17%)",
      "half_life": "93 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Hypersensitivity",
      "Long QT syndrome"
    ],
    "routineMonitoring": [
      "ECG",
      "CBC",
      "Signs of differentiation syndrome"
    ],
    "preTreatmentTests": [
      "IDH1 mutation testing",
      "ECG"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T19:59:46.283Z",
    "updatedAt": "2025-05-12T06:01:57.570Z"
  },
  {
    "id": "499e19f3-1019-4c6b-9f32-0c4ea47802e2",
    "name": "Tazemetostat",
    "brandNames": [
      "Tazverik"
    ],
    "classification": "EZH2 Inhibitor",
    "mechanism": "Inhibits EZH2 methyltransferase, altering gene expression in cancer cells",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "EZH2-Mutant Follicular Lymphoma",
        "Epithelioid Sarcoma"
      ]
    },
    "dosing": {
      "standard": "800 mg orally twice daily"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Nausea",
        "Thrombocytopenia"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Every 2–4 weeks",
      "precautions": [
        "Monitor platelet count"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:14:33.068Z",
    "updatedAt": "2025-04-16T20:14:33.068Z"
  },
  {
    "id": "87d44b39-62f2-400b-9728-4c39e049d5b1",
    "name": "Enasidenib",
    "brandNames": [
      "Idhifa"
    ],
    "classification": "IDH2 Inhibitor",
    "mechanism": "Inhibits mutant IDH2 enzyme to reduce 2-hydroxyglutarate and restore differentiation",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "IDH2-Mutant Acute Myeloid Leukemia"
      ]
    },
    "dosing": {
      "standard": "100 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Differentiation syndrome",
        "Hyperbilirubinemia",
        "Fatigue",
        "Diarrhea"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "EKG",
        "Blood counts"
      ],
      "frequency": "Every 2-4 weeks",
      "precautions": [
        "Monitor for differentiation syndrome and liver toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "QT prolonging agents",
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Enasidenib is an IDH2 inhibitor used in relapsed or refractory acute myeloid leukemia (AML) with IDH2 mutation.",
    "blackBoxWarning": "Differentiation syndrome is a potentially fatal complication requiring prompt treatment with steroids.",
    "specialConsiderations": {
      "hyperbilirubinemia": "Common side effect due to UGT1A1 inhibition",
      "differentiation_syndrome": "Treat early with corticosteroids if suspected"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~89%)",
      "half_life": "137 hours",
      "metabolism": "Primarily CYP3A4"
    },
    "contraindications": [
      "Known hypersensitivity",
      "Pregnancy"
    ],
    "routineMonitoring": [
      "LFTs",
      "Signs of differentiation syndrome",
      "CBC"
    ],
    "preTreatmentTests": [
      "IDH2 mutation testing",
      "CBC, LFTs"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:02:35.252Z",
    "updatedAt": "2025-05-12T05:53:09.666Z"
  },
  {
    "id": "89661794-7577-471d-9924-221a206c4e89",
    "name": "Sipuleucel-T",
    "brandNames": [
      "Provenge"
    ],
    "classification": "Cancer Vaccine",
    "mechanism": "Activates patient's immune system against prostate cancer using antigen-presenting cells",
    "administration": "IV infusion over 60 minutes",
    "indications": {
      "cancer_types": [
        "Metastatic Castration-Resistant Prostate Cancer"
      ]
    },
    "dosing": {
      "standard": "3 infusions given every 2 weeks"
    },
    "sideEffects": {
      "common": [
        "Flu-like symptoms",
        "Fever",
        "Chills",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Before each dose",
      "precautions": [
        "Monitor for infusion reactions"
      ]
    },
    "interactions": {
      "drugs": [
        "Immunosuppressive agents",
        "Steroids"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:04:07.779Z",
    "updatedAt": "2025-04-16T20:04:07.779Z"
  },
  {
    "id": "83075b7c-a19e-4c57-aafc-776ef269bfd1",
    "name": "Anastrozole",
    "brandNames": [
      "Arimidex"
    ],
    "classification": "Aromatase Inhibitor",
    "mechanism": "Blocks estrogen production in postmenopausal women",
    "administration": "Oral administration, once daily dosing",
    "indications": {
      "cancer_types": [
        "ER-Positive Breast Cancer"
      ]
    },
    "dosing": {
      "standard": "1 mg daily",
      "adjustments": [
        "Post-menopausal women only"
      ]
    },
    "sideEffects": {
      "common": [
        "Joint pain",
        "Hot flashes",
        "Osteoporosis",
        "Fatigue",
        "Elevated cholesterol"
      ]
    },
    "monitoring": {
      "labs": [
        "Bone density",
        "Lipid profile",
        "Liver function"
      ],
      "frequency": "Every 6-12 months",
      "precautions": [
        "Monitor bone health",
        "Assess cardiovascular risk"
      ]
    },
    "interactions": {
      "drugs": [
        "Tamoxifen",
        "Estrogen-containing products"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "ASCO Guidelines"
    ],
    "summary": "Anastrozole is an aromatase inhibitor used in postmenopausal women with hormone receptor-positive breast cancer.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Contraindicated in pregnancy",
      "bone_density": "Can reduce bone mineral density; consider bisphosphonates"
    },
    "pharmacokinetics": {
      "excretion": "Urine (primarily as metabolites)",
      "half_life": "50 hours",
      "metabolism": "Hepatic (non-CYP mediated)"
    },
    "contraindications": [
      "Premenopausal women",
      "Pregnancy"
    ],
    "routineMonitoring": [
      "Bone mineral density",
      "Liver enzymes"
    ],
    "preTreatmentTests": [
      "Postmenopausal status confirmation",
      "Liver function tests"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:02:07.453Z",
    "updatedAt": "2025-05-12T05:21:52.797Z"
  },
  {
    "id": "4fcbb461-cdd6-4d59-89a6-95643e2184c6",
    "name": "Lifileucel",
    "brandNames": [
      "LN-144 (Experimental)"
    ],
    "classification": "Tumor-Infiltrating Lymphocyte (TIL) Therapy",
    "mechanism": "Uses expanded TILs to attack tumor cells post-lymphodepletion",
    "administration": "IV infusion over 30 minutes",
    "indications": {
      "cancer_types": [
        "Advanced Melanoma"
      ]
    },
    "dosing": {
      "standard": "One-time IV infusion following lymphodepleting chemotherapy"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Neutropenia"
      ],
      "serious": [
        "Cytokine release syndrome",
        "Neurotoxicity"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function",
        "Neurologic exam"
      ],
      "frequency": "Before and after infusion",
      "precautions": [
        "Monitor for CRS and neurotoxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "Steroids",
        "Immunosuppressive agents"
      ]
    },
    "referenceSources": [
      "Clinical Trials",
      "NCCN Guidelines"
    ],
    "summary": "Lifileucel is an autologous tumor-infiltrating lymphocyte (TIL) therapy used for advanced melanoma after progression on checkpoint inhibitors.",
    "blackBoxWarning": "Risk of severe cytokine release syndrome (CRS) and immune-mediated adverse effects.",
    "specialConsiderations": {
      "infection_risk": "Monitor for neutropenia-related infections",
      "preconditioning_regimen": "Patients must undergo lymphodepleting chemotherapy prior to TIL infusion"
    },
    "pharmacokinetics": {
      "excretion": "N/A",
      "half_life": "Not applicable (cell therapy)",
      "metabolism": "N/A"
    },
    "contraindications": [
      "Active systemic infection",
      "Pregnancy"
    ],
    "routineMonitoring": [
      "Vitals post-infusion",
      "Infection signs",
      "Cytokine monitoring"
    ],
    "preTreatmentTests": [
      "TIL harvest eligibility",
      "Infectious disease screening"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": false,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:00:03.711Z",
    "updatedAt": "2025-05-12T06:05:03.032Z"
  },
  {
    "id": "db7eedde-fc26-4ec5-82ca-6eeff3c3973f",
    "name": "Sunitinib",
    "brandNames": [
      "Sutent"
    ],
    "classification": "Multi‑Targeted TKI",
    "mechanism": "Inhibits VEGFR, PDGFR, KIT, FLT3, CSF‑1R, RET",
    "administration": "50 mg orally once daily (4 weeks on, 2 weeks off)",
    "indications": {
      "cancer_types": [
        "Renal Cell Carcinoma",
        "GIST",
        "Pancreatic NET"
      ]
    },
    "dosing": {
      "standard": "50 mg PO daily; 4 weeks on, 2 weeks off"
    },
    "sideEffects": {
      "common": [
        "Hypertension",
        "Hand-foot syndrome",
        "Fatigue",
        "Diarrhea"
      ]
    },
    "monitoring": {
      "labs": [
        "BP",
        "LFT",
        "TSH"
      ],
      "frequency": "Every cycle"
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Sunitinib is a multikinase inhibitor targeting VEGFR, PDGFR, and others. It is used in renal cell carcinoma, pancreatic neuroendocrine tumors, and GISTs.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "cardiac_toxicity": "Monitor for hypertension and signs of heart failure",
      "thyroid_dysfunction": "Can induce hypothyroidism; monitor thyroid function"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~61%), urine (~16%)",
      "half_life": "40–60 hours",
      "metabolism": "Primarily CYP3A4"
    },
    "contraindications": [
      "Severe cardiac dysfunction",
      "Uncontrolled hypertension"
    ],
    "routineMonitoring": [
      "BP",
      "Thyroid function",
      "CBC"
    ],
    "preTreatmentTests": [
      "LFTs",
      "Thyroid panel"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:43:46.667Z",
    "updatedAt": "2025-05-12T06:16:16.523Z"
  },
  {
    "id": "dba143b4-7462-44c1-9e8d-e925f1c2bdf8",
    "name": "Vorinostat",
    "brandNames": [
      "Zolinza"
    ],
    "classification": "HDAC Inhibitor",
    "mechanism": "Inhibits histone deacetylase to promote cell cycle arrest and apoptosis",
    "administration": "Oral capsule, take with food",
    "indications": {
      "cancer_types": [
        "Cutaneous T-Cell Lymphoma"
      ]
    },
    "dosing": {
      "standard": "400 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Nausea",
        "Thrombocytopenia",
        "Hyperglycemia"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Glucose",
        "Electrolytes"
      ],
      "frequency": "Every 2–4 weeks",
      "precautions": [
        "Monitor for dehydration and cytopenias"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP450 substrates",
        "QT prolonging drugs"
      ]
    },
    "referenceSources": [
      "FDA prescribing information",
      "NCCN Guidelines"
    ],
    "summary": "Vorinostat is a histone deacetylase (HDAC) inhibitor used to treat cutaneous T-cell lymphoma (CTCL).",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "hyperglycemia": "May increase blood glucose levels",
      "myelosuppression": "Can cause thrombocytopenia and neutropenia; monitor CBC"
    },
    "pharmacokinetics": {
      "excretion": "Urine (major)",
      "half_life": "2 hours",
      "metabolism": "Glucuronidation and hydrolysis"
    },
    "contraindications": [
      "Severe hepatic impairment"
    ],
    "routineMonitoring": [
      "CBC",
      "Serum electrolytes",
      "Glucose"
    ],
    "preTreatmentTests": [
      "CBC",
      "LFTs"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:11:33.187Z",
    "updatedAt": "2025-05-12T06:18:48.145Z"
  },
  {
    "id": "36b19244-d00e-4546-832b-e9b9f4461871",
    "name": "Axitinib",
    "brandNames": [
      "Inlyta"
    ],
    "classification": "VEGFR Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits VEGFR‑1, ‑2, ‑3",
    "administration": "5 mg orally twice daily",
    "indications": {
      "cancer_types": [
        "Renal Cell Carcinoma"
      ]
    },
    "dosing": {
      "standard": "5 mg PO twice daily"
    },
    "sideEffects": {
      "common": [
        "Hypertension",
        "Diarrhea",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "BP"
      ],
      "frequency": "Weekly initial, then every cycle"
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:44:47.925Z",
    "updatedAt": "2025-04-16T20:44:47.925Z"
  },
  {
    "id": "e755f85b-a873-4503-8ca7-340e013b1576",
    "name": "Margetuximab",
    "brandNames": [],
    "classification": "HER2 Monoclonal Antibody",
    "mechanism": "",
    "administration": "",
    "indications": {},
    "dosing": {
      "standard": "15 mg/kg IV every 3 weeks"
    },
    "sideEffects": {},
    "monitoring": {},
    "interactions": {},
    "referenceSources": [],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:49:37.589Z",
    "updatedAt": "2025-04-16T20:49:37.589Z"
  },
  {
    "id": "fe2822e4-05c9-47bf-9b95-03e23e6e08e8",
    "name": "Zanubrutinib",
    "brandNames": [],
    "classification": "BTK Inhibitor",
    "mechanism": "",
    "administration": "",
    "indications": {},
    "dosing": {
      "standard": "160 mg orally twice daily"
    },
    "sideEffects": {},
    "monitoring": {},
    "interactions": {},
    "referenceSources": [],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:49:37.589Z",
    "updatedAt": "2025-04-16T20:49:37.589Z"
  },
  {
    "id": "8e5527be-b70a-4bc9-9a48-cb185499589b",
    "name": "Cobimetinib",
    "brandNames": [
      "Cotellic"
    ],
    "classification": "MEK Inhibitor",
    "mechanism": "Inhibits MEK1 and MEK2 to disrupt MAPK signaling in cancer cells",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "BRAF V600E-Mutant Melanoma",
        "BRAF-Mutant NSCLC"
      ]
    },
    "dosing": {
      "standard": "60 mg orally once daily for 21 days, then 7 days off"
    },
    "sideEffects": {
      "common": [
        "Cardiotoxicity",
        "Diarrhea",
        "Retinopathy",
        "Rash"
      ]
    },
    "monitoring": {
      "labs": [
        "Blood pressure",
        "Liver function",
        "Ophthalmologic exam"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for cardiotoxicity and eye toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "BRAF inhibitors",
        "QT prolonging agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Cobimetinib is a MEK inhibitor used in combination with vemurafenib for BRAF V600E/K-mutant metastatic melanoma.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Avoid due to teratogenicity",
      "cardiotoxicity": "Monitor LVEF before and during therapy",
      "ophthalmologic_effects": "May cause serous retinopathy"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~76%), urine (~17%)",
      "half_life": "44 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Hypersensitivity to cobimetinib"
    ],
    "routineMonitoring": [
      "LVEF",
      "Ocular exams",
      "Liver function tests"
    ],
    "preTreatmentTests": [
      "BRAF V600 mutation status",
      "Baseline ECHO and ophthalmology"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:04:07.779Z",
    "updatedAt": "2025-05-12T05:50:15.542Z"
  },
  {
    "id": "89891ca7-2b69-4b0e-b10b-6e37906fa123",
    "name": "Dabrafenib",
    "brandNames": [
      "Tafinlar"
    ],
    "classification": "BRAF Inhibitor",
    "mechanism": "Inhibits BRAF V600E kinase to block tumor cell proliferation",
    "administration": "Oral capsule, take 1 hour before or 2 hours after meals",
    "indications": {
      "cancer_types": [
        "BRAF V600E-Mutant Melanoma",
        "BRAF-Mutant NSCLC"
      ]
    },
    "dosing": {
      "standard": "150 mg orally twice daily"
    },
    "sideEffects": {
      "common": [
        "Fever",
        "Rash",
        "Hyperglycemia",
        "QT prolongation"
      ]
    },
    "monitoring": {
      "labs": [
        "Blood glucose",
        "Liver function",
        "EKG"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for fever and cardiac toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "MEK inhibitors",
        "QT prolonging agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Dabrafenib is a BRAF V600E-mutant inhibitor used in melanoma, NSCLC, and other tumors with the mutation, often in combination with trametinib.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "fever": "Fever is common and may require dose hold or steroids",
      "pregnancy": "Contraindicated due to teratogenicity",
      "cardiomyopathy": "Monitor LVEF if used with MEK inhibitor"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~71%), urine (~23%)",
      "half_life": "8 hours",
      "metabolism": "CYP3A4 and CYP2C8"
    },
    "contraindications": [
      "BRAF wild-type tumors",
      "Hypersensitivity"
    ],
    "routineMonitoring": [
      "LVEF (if combined with MEK inhibitor)",
      "Fever monitoring",
      "Liver enzymes"
    ],
    "preTreatmentTests": [
      "BRAF V600 mutation testing",
      "Baseline LFTs and cardiac function"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:04:07.779Z",
    "updatedAt": "2025-05-12T05:50:29.182Z"
  },
  {
    "id": "6c46d76c-4883-4962-8f80-ecb87e22374d",
    "name": "Enzalutamide",
    "brandNames": [
      "Xtandi"
    ],
    "classification": "Androgen Receptor Inhibitor",
    "mechanism": "Inhibits androgen receptor nuclear translocation and DNA binding",
    "administration": "Oral capsule, take with or without food",
    "indications": {
      "cancer_types": [
        "Metastatic Castration-Resistant Prostate Cancer"
      ]
    },
    "dosing": {
      "standard": "160 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Hot flashes",
        "Hypertension",
        "Falls"
      ]
    },
    "monitoring": {
      "labs": [
        "Blood pressure",
        "Neurologic assessment"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for seizures",
        "Assess fall risk"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP2C8 inhibitors",
        "Antihypertensives"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Enzalutamide is an androgen receptor inhibitor used in metastatic castration-resistant and non-metastatic prostate cancer.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "hypertension": "Monitor BP regularly",
      "seizure_risk": "Avoid in patients with history of seizures"
    },
    "pharmacokinetics": {
      "excretion": "Feces (71%), urine (13%)",
      "half_life": "5.8 days",
      "metabolism": "CYP2C8 and CYP3A4"
    },
    "contraindications": [
      "Pregnancy",
      "Severe hepatic impairment"
    ],
    "routineMonitoring": [
      "BP",
      "Fatigue/neurologic status"
    ],
    "preTreatmentTests": [
      "Testosterone level",
      "BP measurement"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:08:59.395Z",
    "updatedAt": "2025-05-12T05:54:09.647Z"
  },
  {
    "id": "08717f44-6eb0-4d46-b3f4-2e0e735943ae",
    "name": "Letrozole",
    "brandNames": [
      "Femara"
    ],
    "classification": "Aromatase Inhibitor",
    "mechanism": "Inhibits aromatase enzyme, reducing estrogen levels",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "ER-Positive Breast Cancer"
      ]
    },
    "dosing": {
      "standard": "2.5 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Arthralgia",
        "Osteoporosis",
        "Hot flashes",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "Bone density",
        "Lipid profile",
        "Liver function"
      ],
      "frequency": "Every 6–12 months",
      "precautions": [
        "Monitor bone health",
        "Assess cardiovascular risk"
      ]
    },
    "interactions": {
      "drugs": [
        "Tamoxifen",
        "Estrogen-containing products"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "ASCO Guidelines"
    ],
    "summary": "Letrozole is an aromatase inhibitor used in hormone receptor–positive breast cancer and ovulation induction in PCOS.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "arthralgia": "Common and may require analgesics",
      "osteoporosis_risk": "Use calcium and vitamin D supplementation; consider bone density monitoring"
    },
    "pharmacokinetics": {
      "excretion": "Urine (~90%)",
      "half_life": "2 days",
      "metabolism": "CYP3A4 and CYP2A6"
    },
    "contraindications": [
      "Pregnancy",
      "Pre-menopausal breast cancer (as monotherapy)"
    ],
    "routineMonitoring": [
      "Bone mineral density",
      "LFTs"
    ],
    "preTreatmentTests": [
      "Menopausal status",
      "ER status"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:08:59.395Z",
    "updatedAt": "2025-05-12T06:04:46.709Z"
  },
  {
    "id": "51d45e08-9430-4e75-8587-230fcd66fd83",
    "name": "Paclitaxel",
    "brandNames": [
      "Taxol",
      "Abraxane"
    ],
    "classification": "Taxane Chemotherapy",
    "mechanism": "Stabilizes microtubules and inhibits mitosis",
    "administration": "IV infusion over 3 hours; requires premedication",
    "indications": {
      "cancer_types": [
        "Breast Cancer",
        "Ovarian Cancer",
        "Lung Cancer",
        "Head and Neck Cancer"
      ]
    },
    "dosing": {
      "standard": "175 mg/m² every 3 weeks",
      "adjustments": [
        "Weekly schedules available",
        "Dose reduce for neuropathy"
      ]
    },
    "sideEffects": {
      "common": [
        "Peripheral neuropathy",
        "Hypersensitivity reactions",
        "Myelosuppression",
        "Alopecia",
        "Arthralgia"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Prior to each cycle",
      "precautions": [
        "Monitor for hypersensitivity",
        "Assess neuropathy"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP2C8 inhibitors",
        "CYP3A4 inhibitors",
        "Platinum agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "BC Cancer Protocols"
    ],
    "summary": "Paclitaxel is a taxane chemotherapeutic agent that stabilizes microtubules, leading to mitotic arrest. Used in breast, ovarian, lung, and other cancers.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "neuropathy": "Peripheral neuropathy is common and dose-limiting",
      "hypersensitivity": "Premedication with corticosteroids and antihistamines is required due to risk of anaphylaxis"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~71%), urine (~14%)",
      "half_life": "Approx. 6 hours",
      "metabolism": "CYP2C8 and CYP3A4"
    },
    "contraindications": [
      "Severe hypersensitivity to paclitaxel or Cremophor EL"
    ],
    "routineMonitoring": [
      "CBC",
      "Liver enzymes",
      "Neurologic symptoms"
    ],
    "preTreatmentTests": [
      "CBC",
      "LFTs"
    ],
    "isChemotherapy": true,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:07:34.644Z",
    "updatedAt": "2025-05-12T06:11:15.445Z"
  },
  {
    "id": "52d3bc1a-8704-4b2e-a3f6-25e8336124b6",
    "name": "Encorafenib",
    "brandNames": [
      "Braftovi"
    ],
    "classification": "BRAF Inhibitor",
    "mechanism": "Inhibits BRAF V600E kinase, blocking MAPK pathway",
    "administration": "Oral capsule, take with or without food",
    "indications": {
      "cancer_types": [
        "BRAF V600E-Mutant Melanoma",
        "BRAF-Mutant Colorectal Cancer"
      ]
    },
    "dosing": {
      "standard": "450 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Rash",
        "Arthralgia",
        "QT prolongation"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "EKG"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for QT prolongation"
      ]
    },
    "interactions": {
      "drugs": [
        "MEK inhibitors",
        "QT prolonging agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Encorafenib is a selective BRAF V600E/K inhibitor used in combination with binimetinib for metastatic melanoma.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "cardiotoxicity": "May cause decreased LVEF or QT prolongation",
      "photosensitivity": "Patients should use sun protection"
    },
    "pharmacokinetics": {
      "excretion": "Feces (84%)",
      "half_life": "6 hours",
      "metabolism": "Primarily CYP3A4, CYP2D6"
    },
    "contraindications": [
      "BRAF wild-type tumors"
    ],
    "routineMonitoring": [
      "Cardiac monitoring",
      "Dermatologic exams"
    ],
    "preTreatmentTests": [
      "BRAF V600 mutation status"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:10:14.269Z",
    "updatedAt": "2025-05-12T05:53:16.724Z"
  },
  {
    "id": "6556eca9-54d3-47fe-8e6a-6927f995f9dd",
    "name": "Oportuzumab Monatox",
    "brandNames": [],
    "classification": "EpCAM-Targeted Toxin",
    "mechanism": "",
    "administration": "",
    "indications": {},
    "dosing": {
      "standard": "Instilled intravesically weekly x 6 weeks"
    },
    "sideEffects": {},
    "monitoring": {},
    "interactions": {},
    "referenceSources": [],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:49:37.589Z",
    "updatedAt": "2025-04-16T20:49:37.589Z"
  },
  {
    "id": "1c1d6702-f5c5-4e6b-9df9-1d9a94cb63d5",
    "name": "Leuprolide",
    "brandNames": [
      "Lupron"
    ],
    "classification": "LHRH Agonist",
    "mechanism": "Suppresses gonadotropin release to reduce testosterone and estrogen",
    "administration": "Subcutaneous or intramuscular injection",
    "indications": {
      "cancer_types": [
        "Prostate Cancer",
        "Breast Cancer (Premenopausal Women)"
      ]
    },
    "dosing": {
      "standard": "7.5 mg monthly or depot every 3–6 months"
    },
    "sideEffects": {
      "common": [
        "Hot flashes",
        "Decreased libido",
        "Fatigue",
        "Injection site reactions"
      ]
    },
    "monitoring": {
      "labs": [
        "Hormone levels",
        "Bone density"
      ],
      "frequency": "Every 3–6 months",
      "precautions": [
        "Monitor for osteoporosis"
      ]
    },
    "interactions": {
      "drugs": [
        "Antiandrogens",
        "Estrogen therapies"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Leuprolide is a GnRH agonist used in prostate cancer, breast cancer, endometriosis, fibroids, and precocious puberty.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "bone_loss": "Long-term use increases osteoporosis risk",
      "tumor_flare": "Transient initial rise in testosterone/estrogen—use antiandrogens in prostate cancer"
    },
    "pharmacokinetics": {
      "excretion": "Renal (~50%)",
      "half_life": "3 hours (immediate release)",
      "metabolism": "Peptidase hydrolysis"
    },
    "contraindications": [
      "Pregnancy",
      "Undiagnosed vaginal bleeding"
    ],
    "routineMonitoring": [
      "Bone density",
      "Hormone levels",
      "Symptoms of tumor flare"
    ],
    "preTreatmentTests": [
      "Hormone status",
      "Pregnancy test (if applicable)"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:08:59.395Z",
    "updatedAt": "2025-05-12T06:04:54.528Z"
  },
  {
    "id": "c9bc0123-4d76-46c3-8fab-9b5d6d4ed7c6",
    "name": "Nilotinib",
    "brandNames": [
      "Tasigna"
    ],
    "classification": "BCR-ABL Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits BCR-ABL tyrosine kinase",
    "administration": "300 mg orally twice daily",
    "indications": {
      "cancer_types": [
        "Chronic Myeloid Leukemia"
      ]
    },
    "dosing": {
      "standard": "300 mg PO twice daily"
    },
    "sideEffects": {
      "common": [
        "QT prolongation",
        "Rash",
        "Pruritus",
        "Headache"
      ]
    },
    "monitoring": {
      "labs": [
        "ECG",
        "LFT"
      ],
      "frequency": "Monthly"
    },
    "interactions": {
      "drugs": [
        "QT prolonging agents",
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Nilotinib is a second-generation BCR-ABL tyrosine kinase inhibitor used primarily for chronic myeloid leukemia (CML).",
    "blackBoxWarning": "QT prolongation and sudden cardiac death. Monitor ECGs and electrolytes closely.",
    "specialConsiderations": {
      "qt_prolongation": "Avoid in patients with hypokalemia or hypomagnesemia; monitor ECG",
      "metabolic_effects": "Can increase blood glucose, lipase, and amylase levels"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~93%), urine (<10%)",
      "half_life": "17 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Long QT syndrome",
      "Uncorrected hypokalemia/hypomagnesemia"
    ],
    "routineMonitoring": [
      "ECG",
      "Serum electrolytes",
      "Pancreatic enzymes",
      "Glucose levels"
    ],
    "preTreatmentTests": [
      "ECG",
      "Electrolytes",
      "CML mutation panel"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:44:47.925Z",
    "updatedAt": "2025-05-12T06:07:34.321Z"
  },
  {
    "id": "5aa89bda-2746-4da5-bbc4-d96cf220a8b1",
    "name": "Neratinib",
    "brandNames": [
      "Nerlynx"
    ],
    "classification": "Tyrosine kinase inhibitor (TKI) targeting HER2/EGFR",
    "mechanism": "Irreversibly inhibits HER2, HER4, and EGFR tyrosine kinases, blocking downstream signaling pathways",
    "administration": "Oral: 240 mg once daily with food for metastatic cancer; empty stomach for adjuvant therapy",
    "indications": {
      "approved": [
        "Extended adjuvant HER2+ breast cancer",
        "Metastatic HER2+ breast cancer"
      ],
      "off_label": [
        "HER2-mutated NSCLC (investigational)"
      ]
    },
    "dosing": {
      "standard": "240 mg daily",
      "renal_adjustment": "No adjustment for mild-moderate; avoid in severe",
      "hepatic_adjustment": "Reduce to 80 mg in severe impairment"
    },
    "sideEffects": {
      "common": [
        "Diarrhea (95%)",
        "Nausea",
        "Fatigue",
        "Abdominal pain"
      ],
      "serious": [
        "Hepatotoxicity",
        "Severe dehydration from diarrhea"
      ]
    },
    "monitoring": {
      "baseline": [
        "LFTs",
        "ECG",
        "Hydration status"
      ],
      "during_treatment": [
        "Weekly LFTs x3 months",
        "Diarrhea management monitoring"
      ]
    },
    "interactions": {
      "caution": [
        "PPIs (reduce absorption)",
        "QT-prolonging agents"
      ],
      "contraindicated": [
        "Strong CYP3A4 inducers"
      ]
    },
    "referenceSources": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208051s005s006lbl.pdf"
    ],
    "summary": "Oral HER2/EGFR TKI for HER2+ breast cancer with mandatory antidiarrheal prophylaxis, notable for high-grade diarrhea requiring proactive management",
    "blackBoxWarning": "Boxed warning for severe diarrhea and hepatotoxicity",
    "specialConsiderations": {
      "dose_escalation": "120 mg → 160 mg → 240 mg over 2 weeks",
      "diarrhea_prophylaxis": "Loperamide x56 days with dose escalation"
    },
    "pharmacokinetics": {
      "excretion": "Feces (97%)",
      "half_life": "7-17 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Severe hepatic impairment (Child-Pugh C)",
      "Hypersensitivity reactions"
    ],
    "routineMonitoring": [
      "Daily diarrhea assessment",
      "Monthly LFTs"
    ],
    "preTreatmentTests": [
      "HER2 IHC/FISH",
      "Pregnancy test",
      "Baseline ECG"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:43:46.667Z",
    "updatedAt": "2025-05-12T13:28:54.876Z"
  },
  {
    "id": "e631f2bb-33b1-41c4-b2a2-46c08e48d2a4",
    "name": "Elotuzumab",
    "brandNames": [
      "Empliciti"
    ],
    "classification": "SLAMF7 Monoclonal Antibody",
    "mechanism": "Targets SLAMF7 to activate NK cells and mediate cytotoxicity",
    "administration": "IV infusion over 2–5 hours",
    "indications": {
      "cancer_types": [
        "Multiple Myeloma"
      ]
    },
    "dosing": {
      "standard": "10 mg/kg weekly ×2 cycles, then biweekly"
    },
    "sideEffects": {
      "common": [
        "Infusion reactions",
        "Fatigue",
        "Diarrhea",
        "Fever"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Before each dose",
      "precautions": [
        "Premedicate to reduce infusion reactions"
      ]
    },
    "interactions": {
      "drugs": [
        "Lenalidomide",
        "Dexamethasone"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Elotuzumab is a monoclonal antibody targeting SLAMF7, used in combination therapy for multiple myeloma.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "infection_risk": "Monitor for herpes zoster; consider prophylaxis",
      "infusion_reactions": "Premedication recommended to reduce risk"
    },
    "pharmacokinetics": {
      "excretion": "Not characterized",
      "half_life": "21 days",
      "metabolism": "Proteolytic degradation"
    },
    "contraindications": [
      "Hypersensitivity to elotuzumab or components"
    ],
    "routineMonitoring": [
      "CBC",
      "Infusion-related symptoms"
    ],
    "preTreatmentTests": [
      "SLAMF7 expression (if required)",
      "CBC"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:10:14.269Z",
    "updatedAt": "2025-05-12T05:52:56.705Z"
  },
  {
    "id": "dcf33f89-baa4-4788-b3d3-d042fc00d8a9",
    "name": "Ixazomib",
    "brandNames": [
      "Ninlaro"
    ],
    "classification": "Proteasome Inhibitor",
    "mechanism": "Inhibits 20S proteasome, disrupting protein homeostasis in myeloma cells",
    "administration": "Oral capsule, take at least 1 hour before or 2 hours after food",
    "indications": {
      "cancer_types": [
        "Multiple Myeloma"
      ]
    },
    "dosing": {
      "standard": "4 mg orally on days 1, 8, and 15 of a 28-day cycle"
    },
    "sideEffects": {
      "common": [
        "Thrombocytopenia",
        "Diarrhea",
        "Peripheral neuropathy",
        "Rash"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Each cycle",
      "precautions": [
        "Monitor platelets and liver function"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Strong CYP3A inducers"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Ixazomib is an oral proteasome inhibitor used in combination for multiple myeloma after at least one prior therapy.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "cytopenias": "Monitor CBC regularly",
      "herpes_zoster": "Consider antiviral prophylaxis"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~62%), urine (~22%)",
      "half_life": "9.5 days",
      "metabolism": "Non-CYP mediated hydrolysis and CYP3A4"
    },
    "contraindications": [
      "Hypersensitivity to boron-containing compounds"
    ],
    "routineMonitoring": [
      "CBC",
      "Signs of infection or neuropathy"
    ],
    "preTreatmentTests": [
      "CBC",
      "LFTs"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:10:14.269Z",
    "updatedAt": "2025-05-12T06:02:07.025Z"
  },
  {
    "id": "510438d1-82a5-4e71-9112-7bb087a7853f",
    "name": "Sotorasib",
    "brandNames": [
      "Lumakras"
    ],
    "classification": "KRAS Inhibitor",
    "mechanism": "Specifically inhibits KRAS G12C mutant protein",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "KRAS G12C-Mutant NSCLC"
      ]
    },
    "dosing": {
      "standard": "960 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Hepatotoxicity",
        "Diarrhea",
        "Fatigue",
        "Nausea"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "Renal function"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor liver enzymes regularly"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "P-gp substrates"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:10:14.269Z",
    "updatedAt": "2025-04-16T20:10:14.269Z"
  },
  {
    "id": "fab54cbb-06d1-4709-9d1e-d343f08c221f",
    "name": "Talazoparib",
    "brandNames": [
      "Talzenna"
    ],
    "classification": "PARP Inhibitor",
    "mechanism": "Inhibits PARP enzymes involved in DNA repair",
    "administration": "Oral capsule, take with or without food",
    "indications": {
      "cancer_types": [
        "BRCA-Mutant Breast Cancer"
      ]
    },
    "dosing": {
      "standard": "1 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Anemia",
        "Neutropenia",
        "Fatigue",
        "Nausea"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Every 3–4 weeks",
      "precautions": [
        "Monitor blood counts"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Myelosuppressive agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:10:14.269Z",
    "updatedAt": "2025-04-16T20:10:14.269Z"
  },
  {
    "id": "7c113c43-f83a-44cb-91de-2a8e4d9a2c96",
    "name": "Tisagenlecleucel",
    "brandNames": [
      "Kymriah"
    ],
    "classification": "CAR-T Therapy",
    "mechanism": "Genetically modified T cells target CD19 on cancer cells",
    "administration": "IV infusion over 30–60 minutes",
    "indications": {
      "cancer_types": [
        "B-Cell Acute Lymphoblastic Leukemia",
        "Large B-Cell Lymphoma"
      ]
    },
    "dosing": {
      "standard": "One-time IV infusion"
    },
    "sideEffects": {
      "common": [
        "Cytokine release syndrome",
        "Neurotoxicity",
        "Infections"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function",
        "Neurologic exam"
      ],
      "frequency": "Before and after infusion",
      "precautions": [
        "Monitor for CRS and neurotoxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "Steroids",
        "Tocilizumab"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Tisagenlecleucel is an autologous anti-CD19 CAR T-cell therapy used for relapsed/refractory B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma.",
    "blackBoxWarning": "Risk of life-threatening cytokine release syndrome (CRS) and neurologic toxicities.",
    "specialConsiderations": {
      "neurotoxicity": "Monitor for confusion, aphasia, or seizures; may require corticosteroids",
      "crs_monitoring": "Hospitalize and monitor closely post-infusion; tocilizumab indicated for severe CRS"
    },
    "pharmacokinetics": {
      "excretion": "N/A",
      "half_life": "Not applicable (cellular therapy)",
      "metabolism": "N/A"
    },
    "contraindications": [
      "Active infection",
      "Organ failure"
    ],
    "routineMonitoring": [
      "Vitals",
      "Neurologic assessment",
      "Inflammatory markers (e.g., IL-6, CRP)"
    ],
    "preTreatmentTests": [
      "CD19 expression",
      "Baseline neurological status"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": false,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:10:14.269Z",
    "updatedAt": "2025-05-12T06:17:02.159Z"
  },
  {
    "id": "e31c4644-04ef-41f4-b51d-e49951d50d7d",
    "name": "Erdafitinib",
    "brandNames": [
      "Balversa"
    ],
    "classification": "FGFR Inhibitor",
    "mechanism": "Inhibits FGFR1-4 to block growth of FGFR-mutant tumors",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "FGFR-Altered Urothelial Carcinoma"
      ]
    },
    "dosing": {
      "standard": "8 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Hyperphosphatemia",
        "Mucositis",
        "Dry mouth",
        "Eye toxicity"
      ]
    },
    "monitoring": {
      "labs": [
        "Phosphorus",
        "Eye exam",
        "Liver function"
      ],
      "frequency": "Every 2–4 weeks",
      "precautions": [
        "Ocular toxicity monitoring"
      ]
    },
    "interactions": {
      "drugs": [
        "Phosphate binders",
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "FDA prescribing information",
      "NCCN Guidelines"
    ],
    "summary": "Erdafitinib is an FGFR inhibitor used for FGFR-mutated urothelial carcinoma.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "ocular_toxicity": "Can cause central serous retinopathy (CSR); regular eye exams required",
      "hyperphosphatemia": "Common and may require phosphate binders or dose adjustment"
    },
    "pharmacokinetics": {
      "excretion": "Feces (69%), urine (19%)",
      "half_life": "59 hours",
      "metabolism": "CYP2C9 and CYP3A4"
    },
    "contraindications": [
      "Known hypersensitivity",
      "Ocular disease"
    ],
    "routineMonitoring": [
      "Serum phosphate",
      "Ophthalmologic exams"
    ],
    "preTreatmentTests": [
      "FGFR mutation testing",
      "Baseline phosphate level and eye exam"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:11:33.187Z",
    "updatedAt": "2025-05-12T05:54:26.291Z"
  },
  {
    "id": "a4d865f6-f97a-4302-83d0-c05d2792f6d4",
    "name": "Venetoclax",
    "brandNames": [
      "Venclexta"
    ],
    "classification": "BCL-2 Inhibitor",
    "mechanism": "Inhibits BCL-2 to promote apoptosis in CLL/AML",
    "administration": "Oral tablet, take with food",
    "indications": {
      "cancer_types": [
        "CLL",
        "AML"
      ]
    },
    "dosing": {
      "standard": "20 mg ramp-up to 400 mg daily"
    },
    "sideEffects": {
      "common": [
        "Tumor lysis syndrome",
        "Neutropenia",
        "Diarrhea",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Renal function",
        "Electrolytes"
      ],
      "frequency": "Daily during ramp-up",
      "precautions": [
        "TLS prophylaxis"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "P-gp substrates"
      ]
    },
    "referenceSources": [
      "FDA prescribing information",
      "NCCN Guidelines"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:11:33.187Z",
    "updatedAt": "2025-04-16T20:11:33.187Z"
  },
  {
    "id": "f58bb54d-1c3a-4b6d-8933-4e0ac16e76f6",
    "name": "Lenalidomide",
    "brandNames": [
      "Revlimid"
    ],
    "classification": "Immunomodulatory Agent (IMiD)",
    "mechanism": "Enhances immune activity and inhibits angiogenesis",
    "administration": "Oral capsule, take at same time daily",
    "indications": {
      "cancer_types": [
        "Multiple Myeloma",
        "Myelodysplastic Syndromes"
      ]
    },
    "dosing": {
      "standard": "10-25 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Neutropenia",
        "Thrombosis",
        "Rash",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Pregnancy test"
      ],
      "frequency": "Each cycle",
      "precautions": [
        "REMS program required"
      ]
    },
    "interactions": {
      "drugs": [
        "Anticoagulants",
        "CYP1A2 substrates"
      ]
    },
    "referenceSources": [
      "FDA prescribing information",
      "NCCN Guidelines"
    ],
    "summary": "Lenalidomide is an immunomodulatory drug used in multiple myeloma, myelodysplastic syndrome (especially with 5q deletion), and mantle cell lymphoma.",
    "blackBoxWarning": "Risk of embryo-fetal toxicity, venous thromboembolism, and hematologic toxicity.",
    "specialConsiderations": {
      "teratogenicity": "REMS program required; strict contraception rules apply",
      "myelosuppression": "Monitor CBC regularly; dose adjust as needed"
    },
    "pharmacokinetics": {
      "excretion": "Renal (~80% unchanged)",
      "half_life": "3 hours",
      "metabolism": "Minimal hepatic metabolism"
    },
    "contraindications": [
      "Pregnancy",
      "Hypersensitivity"
    ],
    "routineMonitoring": [
      "CBC",
      "Pregnancy testing (if applicable)"
    ],
    "preTreatmentTests": [
      "CBC",
      "Pregnancy status"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:11:33.187Z",
    "updatedAt": "2025-05-12T06:04:36.125Z"
  },
  {
    "id": "1ca40daf-6fd5-46d4-9de0-70e007b23719",
    "name": "Nilotinib",
    "brandNames": [
      "Tasigna"
    ],
    "classification": "BCR-ABL Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits BCR-ABL tyrosine kinase",
    "administration": "300 mg orally twice daily",
    "indications": {
      "cancer_types": [
        "Chronic Myeloid Leukemia"
      ]
    },
    "dosing": {
      "standard": "300 mg PO twice daily"
    },
    "sideEffects": {
      "common": [
        "QT prolongation",
        "Rash",
        "Pruritus",
        "Headache"
      ]
    },
    "monitoring": {
      "labs": [
        "ECG",
        "LFT"
      ],
      "frequency": "Monthly"
    },
    "interactions": {
      "drugs": [
        "QT prolonging agents",
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Nilotinib is a second-generation BCR-ABL tyrosine kinase inhibitor used primarily for chronic myeloid leukemia (CML).",
    "blackBoxWarning": "QT prolongation and sudden cardiac death. Monitor ECGs and electrolytes closely.",
    "specialConsiderations": {
      "qt_prolongation": "Avoid in patients with hypokalemia or hypomagnesemia; monitor ECG",
      "metabolic_effects": "Can increase blood glucose, lipase, and amylase levels"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~93%), urine (<10%)",
      "half_life": "17 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Long QT syndrome",
      "Uncorrected hypokalemia/hypomagnesemia"
    ],
    "routineMonitoring": [
      "ECG",
      "Serum electrolytes",
      "Pancreatic enzymes",
      "Glucose levels"
    ],
    "preTreatmentTests": [
      "ECG",
      "Electrolytes",
      "CML mutation panel"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:43:46.667Z",
    "updatedAt": "2025-05-12T06:07:34.321Z"
  },
  {
    "id": "bce967ae-01b7-4372-a6e3-e057baf94f35",
    "name": "Tamoxifen",
    "brandNames": [
      "Nolvadex"
    ],
    "classification": "Selective Estrogen Receptor Modulator (SERM)",
    "mechanism": "Blocks estrogen receptors in breast tissue",
    "administration": "Oral administration; take with or without food",
    "indications": {
      "cancer_types": [
        "ER-Positive Breast Cancer"
      ]
    },
    "dosing": {
      "standard": "20 mg daily",
      "adjustments": [
        "Continue for 5–10 years"
      ]
    },
    "sideEffects": {
      "common": [
        "Hot flashes",
        "Deep vein thrombosis",
        "Endometrial cancer risk",
        "Mood changes"
      ]
    },
    "monitoring": {
      "labs": [
        "Gynecologic exam",
        "Blood counts"
      ],
      "frequency": "Every 6–12 months",
      "precautions": [
        "Monitor for vaginal bleeding",
        "Regular gynecologic exams"
      ]
    },
    "interactions": {
      "drugs": [
        "Warfarin",
        "CYP2D6 inhibitors",
        "Estrogens"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "ASCO Guidelines"
    ],
    "summary": "Tamoxifen is a selective estrogen receptor modulator (SERM) used in ER-positive breast cancer. It acts as an antagonist in breast tissue and agonist in uterus and bone.",
    "blackBoxWarning": "Increased risk of endometrial cancer and thromboembolic events.",
    "specialConsiderations": {
      "thromboembolism": "Avoid in patients with history of VTE unless benefit outweighs risk",
      "endometrial_risk": "Monitor for abnormal uterine bleeding; endometrial surveillance if indicated"
    },
    "pharmacokinetics": {
      "excretion": "Feces (major), urine (minor)",
      "half_life": "5–7 days (active metabolite up to 14 days)",
      "metabolism": "CYP2D6 and CYP3A4"
    },
    "contraindications": [
      "History of DVT/PE",
      "Pregnancy"
    ],
    "routineMonitoring": [
      "Gynecologic exam",
      "Signs of thromboembolism"
    ],
    "preTreatmentTests": [
      "Pregnancy test (if applicable)",
      "Coagulation profile (if indicated)"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:07:34.644Z",
    "updatedAt": "2025-05-12T06:16:24.431Z"
  },
  {
    "id": "26a31362-7831-4aaa-8b09-dec93ba37142",
    "name": "Gilteritinib",
    "brandNames": [
      "Xospata"
    ],
    "classification": "FLT3 Inhibitor",
    "mechanism": "Inhibits FLT3-ITD and FLT3-TKD mutants",
    "administration": "120 mg orally once daily",
    "indications": {
      "cancer_types": [
        "FLT3‑mutated Acute Myeloid Leukemia"
      ]
    },
    "dosing": {
      "standard": "120 mg PO once daily"
    },
    "sideEffects": {
      "common": [
        "Differentiation syndrome",
        "Diarrhea",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "LFT"
      ],
      "frequency": "Monthly"
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:44:47.925Z",
    "updatedAt": "2025-04-16T20:44:47.925Z"
  },
  {
    "id": "c42f77c4-be32-4491-b7be-830f8bd03e5f",
    "name": "Ibrutinib",
    "brandNames": [
      "Imbruvica"
    ],
    "classification": "BTK Inhibitor",
    "mechanism": "Inhibits Bruton’s tyrosine kinase",
    "administration": "420 mg orally once daily",
    "indications": {
      "cancer_types": [
        "Chronic Lymphocytic Leukemia",
        "Mantle Cell Lymphoma",
        "Waldenström’s"
      ]
    },
    "dosing": {
      "standard": "420 mg PO once daily"
    },
    "sideEffects": {
      "common": [
        "Bleeding",
        "Atrial fibrillation",
        "Diarrhea",
        "Infections"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC"
      ],
      "frequency": "Monthly"
    },
    "interactions": {
      "drugs": [
        "Anticoagulants",
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Ibrutinib is a Bruton tyrosine kinase (BTK) inhibitor used in chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenström’s macroglobulinemia.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "bleeding_risk": "Inhibits platelet aggregation; use caution with anticoagulants",
      "atrial_fibrillation": "Monitor cardiac symptoms"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~90%), urine (~10%)",
      "half_life": "4–6 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Active bleeding",
      "Severe hepatic impairment"
    ],
    "routineMonitoring": [
      "CBC",
      "ECG if symptomatic",
      "Signs of infection"
    ],
    "preTreatmentTests": [
      "Baseline CBC",
      "Cardiac assessment (if indicated)"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:44:47.925Z",
    "updatedAt": "2025-05-12T05:56:19.688Z"
  },
  {
    "id": "c6494732-bc27-4298-a2aa-f598f358f87a",
    "name": "Ado-Trastuzumab Emtansine",
    "brandNames": [
      "Kadcyla"
    ],
    "classification": "HER2 Antibody-Drug Conjugate",
    "mechanism": "Combines HER2-targeted trastuzumab with DM1 cytotoxic agent",
    "administration": "IV infusion over 90 minutes (first), then 30 min",
    "indications": {
      "cancer_types": [
        "HER2-Positive Breast Cancer"
      ]
    },
    "dosing": {
      "standard": "3.6 mg/kg every 3 weeks"
    },
    "sideEffects": {
      "common": [
        "Thrombocytopenia",
        "Hepatotoxicity",
        "Fatigue",
        "Peripheral neuropathy"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Each cycle",
      "precautions": [
        "Monitor platelets and LFTs"
      ]
    },
    "interactions": {
      "drugs": [
        "Anthracyclines",
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "FDA prescribing information",
      "NCCN Guidelines"
    ],
    "summary": "Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate targeting HER2+ breast cancer, combining trastuzumab and the cytotoxic agent DM1.",
    "blackBoxWarning": "Hepatotoxicity, cardiac toxicity, and pulmonary toxicity have been reported. Monitor LFTs and LVEF.",
    "specialConsiderations": {
      "pregnancy": "Contraindicated due to fetal risk",
      "cardiotoxicity": "Monitor ejection fraction before and during therapy",
      "hepatic_impairment": "Can cause liver failure—monitor LFTs closely"
    },
    "pharmacokinetics": {
      "excretion": "Not well characterized",
      "half_life": "3.5–4 days",
      "metabolism": "Proteolytic degradation of DM1; trastuzumab component recycled"
    },
    "contraindications": [
      "Pregnancy",
      "Severe hepatic impairment"
    ],
    "routineMonitoring": [
      "LVEF via echocardiogram",
      "LFTs",
      "Pulmonary symptoms"
    ],
    "preTreatmentTests": [
      "HER2 status",
      "Baseline echocardiogram",
      "LFTs"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:12:37.737Z",
    "updatedAt": "2025-05-12T05:20:33.136Z"
  },
  {
    "id": "99de8053-1db3-4e2a-bff1-b71c17d3b3c2",
    "name": "Bortezomib",
    "brandNames": [
      "Velcade"
    ],
    "classification": "Proteasome Inhibitor",
    "mechanism": "Inhibits 26S proteasome, disrupting protein degradation in cancer cells",
    "administration": "Subcutaneous or IV push",
    "indications": {
      "cancer_types": [
        "Multiple Myeloma",
        "Mantle Cell Lymphoma"
      ]
    },
    "dosing": {
      "standard": "1.3 mg/m² twice weekly for 2 weeks, then 10-day rest"
    },
    "sideEffects": {
      "common": [
        "Peripheral neuropathy",
        "GI upset",
        "Thrombocytopenia",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Every cycle",
      "precautions": [
        "Assess neuropathy regularly"
      ]
    },
    "interactions": {
      "drugs": [
        "Strong CYP3A4 inhibitors",
        "Green tea extract"
      ]
    },
    "referenceSources": [
      "FDA prescribing information",
      "NCCN Guidelines"
    ],
    "summary": "Bortezomib is a proteasome inhibitor used in multiple myeloma and mantle cell lymphoma.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Contraindicated due to embryo-fetal toxicity",
      "neuropathy": "Peripheral neuropathy is common and dose-limiting",
      "zoster_reactivation": "Consider antiviral prophylaxis"
    },
    "pharmacokinetics": {
      "excretion": "Urine (~22%)",
      "half_life": "40–193 hours",
      "metabolism": "CYP3A4, CYP2C19"
    },
    "contraindications": [
      "Hypersensitivity to boron or mannitol"
    ],
    "routineMonitoring": [
      "Neurologic function",
      "CBC",
      "LFTs"
    ],
    "preTreatmentTests": [
      "Baseline CBC",
      "LFTs",
      "Neurologic exam"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:12:37.737Z",
    "updatedAt": "2025-05-12T05:29:39.569Z"
  },
  {
    "id": "e2ff64a6-cfc5-44db-8fd2-b1b9ff557962",
    "name": "Cetuximab",
    "brandNames": [
      "Erbitux"
    ],
    "classification": "EGFR Monoclonal Antibody",
    "mechanism": "Inhibits EGFR signaling to reduce tumor growth",
    "administration": "IV infusion (initial over 2 hours, then 1 hour)",
    "indications": {
      "cancer_types": [
        "Colorectal Cancer",
        "Head and Neck Cancer"
      ]
    },
    "dosing": {
      "standard": "400 mg/m² loading, then 250 mg/m² weekly"
    },
    "sideEffects": {
      "common": [
        "Acneiform rash",
        "Hypomagnesemia",
        "Infusion reactions"
      ]
    },
    "monitoring": {
      "labs": [
        "Magnesium",
        "Skin check"
      ],
      "frequency": "Every 1–2 weeks",
      "precautions": [
        "Manage rash and electrolytes"
      ]
    },
    "interactions": {
      "drugs": [
        "Other EGFR inhibitors",
        "Electrolyte-depleting agents"
      ]
    },
    "referenceSources": [
      "FDA prescribing information",
      "NCCN Guidelines"
    ],
    "summary": "Cetuximab is a chimeric monoclonal antibody against EGFR, used in colorectal and head/neck cancers with wild-type KRAS.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Avoid due to fetal toxicity risk",
      "KRAS_status": "Only effective in tumors with wild-type KRAS",
      "infusion_reactions": "May require premedication; monitor during infusion"
    },
    "pharmacokinetics": {
      "excretion": "Unknown",
      "half_life": "112 hours",
      "metabolism": "Proteolytic degradation"
    },
    "contraindications": [
      "KRAS-mutant colorectal cancer",
      "Severe hypersensitivity"
    ],
    "routineMonitoring": [
      "Electrolytes (Mg, Ca, K)",
      "Skin toxicity",
      "Infusion reactions"
    ],
    "preTreatmentTests": [
      "KRAS mutation testing",
      "Electrolyte panel"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:12:37.737Z",
    "updatedAt": "2025-05-12T05:49:25.308Z"
  },
  {
    "id": "e3cd5e3f-3a00-4c4f-8e84-04256e78a46f",
    "name": "Infigratinib",
    "brandNames": [
      "Truseltiq"
    ],
    "classification": "FGFR Inhibitor",
    "mechanism": "Inhibits FGFR1–3, used in FGFR2-fusion positive cancers",
    "administration": "Oral capsule, take on empty stomach",
    "indications": {
      "cancer_types": [
        "FGFR2-Fusion Cholangiocarcinoma"
      ]
    },
    "dosing": {
      "standard": "125 mg orally once daily for 21 days of a 28-day cycle"
    },
    "sideEffects": {
      "common": [
        "Hyperphosphatemia",
        "Dry mouth",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "Serum phosphorus",
        "Liver function"
      ],
      "frequency": "Every 2 weeks",
      "precautions": [
        "Monitor electrolytes"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Phosphate binders"
      ]
    },
    "referenceSources": [
      "FDA prescribing information"
    ],
    "summary": "Infigratinib is a selective FGFR1-3 inhibitor used for FGFR2-fusion cholangiocarcinoma and other FGFR-driven tumors.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "ocular_toxicity": "Central serous retinopathy risk; baseline and periodic ophthalmologic exams required",
      "hyperphosphatemia": "Manage with phosphate binders or dose modifications"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~77%), urine (~7%)",
      "half_life": "33 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Hypersensitivity",
      "Severe hepatic impairment"
    ],
    "routineMonitoring": [
      "Serum phosphate",
      "Ocular exams",
      "LFTs"
    ],
    "preTreatmentTests": [
      "FGFR mutation/fusion status",
      "Baseline ophthalmology"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:14:33.068Z",
    "updatedAt": "2025-05-12T06:01:27.093Z"
  },
  {
    "id": "85b9269c-0406-49c5-bf59-1c1ef7d4ed9a",
    "name": "Selinexor",
    "brandNames": [
      "Xpovio"
    ],
    "classification": "Selective Inhibitor of Nuclear Export (SINE)",
    "mechanism": "Inhibits exportin 1 (XPO1), leading to accumulation of tumor suppressor proteins in the nucleus",
    "administration": "Oral tablet, take with food",
    "indications": {
      "cancer_types": [
        "Relapsed/Refractory Multiple Myeloma"
      ]
    },
    "dosing": {
      "standard": "80 mg orally once weekly"
    },
    "sideEffects": {
      "common": [
        "Nausea",
        "Fatigue",
        "Hyponatremia",
        "Thrombocytopenia"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Sodium levels"
      ],
      "frequency": "Every week",
      "precautions": [
        "Monitor sodium and platelet count"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "FDA prescribing information",
      "NCCN Guidelines"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:13:27.430Z",
    "updatedAt": "2025-04-16T20:13:27.430Z"
  },
  {
    "id": "1e4b5295-0b49-4cd6-a95e-f2e9f53180eb",
    "name": "Zandelisib",
    "brandNames": [
      "ME-401 (Investigational)"
    ],
    "classification": "PI3Kδ Inhibitor",
    "mechanism": "Targets PI3K delta isoform to reduce B-cell proliferation",
    "administration": "Oral tablet, take with food",
    "indications": {
      "cancer_types": [
        "Follicular Lymphoma (R/R)"
      ]
    },
    "dosing": {
      "standard": "60 mg once daily on an intermittent schedule"
    },
    "sideEffects": {
      "common": [
        "Diarrhea",
        "Colitis",
        "Infections",
        "Rash"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Every cycle",
      "precautions": [
        "Monitor for immune-mediated toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "Immunosuppressive agents"
      ]
    },
    "referenceSources": [
      "Clinical Trials",
      "NCCN Guidelines"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:14:33.068Z",
    "updatedAt": "2025-04-16T20:14:33.068Z"
  },
  {
    "id": "f0ccf5d2-f7fc-4c5a-bc5e-82fdcc81e501",
    "name": "Temozolomide",
    "brandNames": [
      "Temodar"
    ],
    "classification": "Alkylating Agent",
    "mechanism": "Alkylates/methylates DNA to induce apoptosis in tumor cells",
    "administration": "Oral capsule, take on an empty stomach",
    "indications": {
      "cancer_types": [
        "Glioblastoma",
        "Anaplastic Astrocytoma"
      ]
    },
    "dosing": {
      "standard": "75 mg/m² daily during radiotherapy, then 150–200 mg/m² for 5 days every 28 days"
    },
    "sideEffects": {
      "common": [
        "Nausea",
        "Fatigue",
        "Neutropenia",
        "Myelosuppression"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Renal function"
      ],
      "frequency": "Each cycle",
      "precautions": [
        "Give antiemetics prophylactically"
      ]
    },
    "interactions": {
      "drugs": [
        "Valproic acid",
        "Live vaccines"
      ]
    },
    "referenceSources": [
      "FDA prescribing information",
      "NCCN Guidelines"
    ],
    "summary": "Temozolomide is an oral alkylating agent of the imidazotetrazine class used to treat glioblastoma and anaplastic astrocytoma.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "myelosuppression": "Monitor CBC; increased risk of neutropenia and thrombocytopenia",
      "pneumocystis_pneumonia": "Consider prophylaxis in patients receiving concurrent radiotherapy"
    },
    "pharmacokinetics": {
      "excretion": "Renal (primary route)",
      "half_life": "1.8 hours",
      "metabolism": "Non-enzymatic conversion to active MTIC"
    },
    "contraindications": [
      "Hypersensitivity to temozolomide or dacarbazine"
    ],
    "routineMonitoring": [
      "CBC",
      "Signs of infection",
      "Liver and renal function"
    ],
    "preTreatmentTests": [
      "CBC",
      "Renal function",
      "Consider PJP prophylaxis evaluation"
    ],
    "isChemotherapy": true,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:12:37.737Z",
    "updatedAt": "2025-05-12T06:16:51.255Z"
  },
  {
    "id": "e44e16f9-5f2a-4cc5-90f6-d9d3c6617de3",
    "name": "Avapritinib",
    "brandNames": [
      "Ayvakit"
    ],
    "classification": "KIT/PDGFRA Inhibitor",
    "mechanism": "Inhibits mutant KIT and PDGFRA kinases involved in gastrointestinal stromal tumors",
    "administration": "Oral tablet, take on an empty stomach",
    "indications": {
      "cancer_types": [
        "PDGFRA D842V-Mutant GIST"
      ]
    },
    "dosing": {
      "standard": "300 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Cognitive effects",
        "Nausea",
        "Fatigue",
        "Edema"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for cognitive effects"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "QT prolonging agents"
      ]
    },
    "referenceSources": [
      "FDA prescribing information",
      "NCCN Guidelines"
    ],
    "summary": "Avapritinib is a selective KIT and PDGFRA inhibitor approved for gastrointestinal stromal tumors (GIST) with PDGFRA exon 18 mutations.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Avoid due to teratogenicity",
      "cns_effects": "Can cause cognitive impairment or hallucinations"
    },
    "pharmacokinetics": {
      "excretion": "Feces (70%), urine (18%)",
      "half_life": "32 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Severe hepatic impairment"
    ],
    "routineMonitoring": [
      "Neurologic status",
      "LFTs"
    ],
    "preTreatmentTests": [
      "PDGFRA mutation testing",
      "Baseline cognitive function"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:14:33.068Z",
    "updatedAt": "2025-05-12T05:22:20.487Z"
  },
  {
    "id": "77963090-7d3f-4b1f-8f8b-4a1086cf3c20",
    "name": "Mobocertinib",
    "brandNames": [
      "Exkivity"
    ],
    "classification": "EGFR Exon20 Inhibitor",
    "mechanism": "Targets EGFR exon 20 insertion mutations in NSCLC",
    "administration": "Oral capsule, take on empty stomach",
    "indications": {
      "cancer_types": [
        "EGFR Exon 20-Mutant NSCLC"
      ]
    },
    "dosing": {
      "standard": "160 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Diarrhea",
        "Rash",
        "QT prolongation",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "EKG",
        "Electrolytes"
      ],
      "frequency": "Every cycle",
      "precautions": [
        "Monitor QTc interval"
      ]
    },
    "interactions": {
      "drugs": [
        "QT prolonging agents",
        "CYP3A inhibitors"
      ]
    },
    "referenceSources": [
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:14:33.068Z",
    "updatedAt": "2025-04-16T20:14:33.068Z"
  },
  {
    "id": "b20998cb-4a4e-4b25-9377-22c8c48d4af2",
    "name": "Lurbinectedin",
    "brandNames": [
      "Zepzelca"
    ],
    "classification": "Alkylating Agent",
    "mechanism": "Inhibits transcription by binding DNA and disrupting repair pathways",
    "administration": "IV infusion over 60 minutes",
    "indications": {
      "cancer_types": [
        "Small Cell Lung Cancer (R/R)"
      ]
    },
    "dosing": {
      "standard": "3.2 mg/m² IV every 21 days"
    },
    "sideEffects": {
      "common": [
        "Neutropenia",
        "Fatigue",
        "Nausea",
        "Myelosuppression"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver enzymes"
      ],
      "frequency": "Before each dose",
      "precautions": [
        "Monitor for cytopenias"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:14:33.068Z",
    "updatedAt": "2025-04-16T20:14:33.068Z"
  },
  {
    "id": "b48c70ed-f1ac-4133-83b8-0a36188b941c",
    "name": "Neratinib",
    "brandNames": [
      "Nerlynx"
    ],
    "classification": "HER2 Tyrosine Kinase Inhibitor",
    "mechanism": "Irreversibly inhibits HER1, HER2, HER4 kinases",
    "administration": "240 mg orally once daily",
    "indications": {
      "cancer_types": [
        "Extended adjuvant HER2‑Positive Breast Cancer"
      ]
    },
    "dosing": {
      "standard": "240 mg PO once daily"
    },
    "sideEffects": {
      "common": [
        "Diarrhea",
        "Nausea",
        "Vomiting"
      ]
    },
    "monitoring": {
      "labs": [
        "LFT"
      ],
      "frequency": "Monthly"
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Neratinib is an oral irreversible tyrosine kinase inhibitor targeting HER2, used for extended adjuvant treatment of HER2-positive breast cancer.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "diarrhea": "Common and severe; often requires antidiarrheal prophylaxis",
      "drug_interactions": "CYP3A4 substrate; monitor with inducers/inhibitors"
    },
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [
      "GI symptoms",
      "LFTs"
    ],
    "preTreatmentTests": [
      "HER2 status"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:44:47.925Z",
    "updatedAt": "2025-05-12T06:07:55.932Z"
  },
  {
    "id": "11c88b12-192f-42e1-9294-97978cd1c7a1",
    "name": "Tucatinib",
    "brandNames": [
      "Tukysa"
    ],
    "classification": "HER2 Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits HER2 kinase selectively with less EGFR inhibition",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "HER2-Positive Breast Cancer (with brain metastases)"
      ]
    },
    "dosing": {
      "standard": "300 mg orally twice daily"
    },
    "sideEffects": {
      "common": [
        "Diarrhea",
        "Elevated liver enzymes",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver enzymes",
        "Renal function"
      ],
      "frequency": "Every 3 weeks",
      "precautions": [
        "Monitor liver toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A substrates",
        "Liver enzyme inducers"
      ]
    },
    "referenceSources": [
      "FDA prescribing information",
      "NCCN Guidelines"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:14:33.068Z",
    "updatedAt": "2025-04-16T20:14:33.068Z"
  },
  {
    "id": "1ac8cc3a-ea4f-4b55-a4b3-697b0d54d8f2",
    "name": "Trametinib",
    "brandNames": [
      "Mekinist"
    ],
    "classification": "MEK Inhibitor",
    "mechanism": "Inhibits MEK1/2 to block MAPK pathway in cancer cells",
    "administration": "Oral tablet, take on an empty stomach",
    "indications": {
      "cancer_types": [
        "BRAF V600E-Mutant Melanoma",
        "BRAF-Mutant NSCLC"
      ]
    },
    "dosing": {
      "standard": "2 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Cardiotoxicity",
        "Retinopathy",
        "Diarrhea",
        "Hypertension"
      ]
    },
    "monitoring": {
      "labs": [
        "Blood pressure",
        "Liver function",
        "EKG",
        "Eye exam"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor heart and eye function"
      ]
    },
    "interactions": {
      "drugs": [
        "BRAF inhibitors",
        "QT prolonging agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Trametinib is a MEK inhibitor used to treat BRAF V600-mutated metastatic melanoma, often in combination with BRAF inhibitors (e.g., dabrafenib).",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "cardiotoxicity": "Monitor ejection fraction; discontinue if significant decline",
      "dermatologic_toxicity": "Monitor for skin toxicity including rash and acneiform eruptions"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~81%), urine (~19%)",
      "half_life": "4.5 days",
      "metabolism": "Non-CYP pathways"
    },
    "contraindications": [
      "Hypersensitivity",
      "Severe cardiac dysfunction"
    ],
    "routineMonitoring": [
      "Echocardiogram",
      "Dermatologic exam",
      "LFTs"
    ],
    "preTreatmentTests": [
      "BRAF mutation status",
      "Ejection fraction"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:10:14.269Z",
    "updatedAt": "2025-05-12T06:17:34.640Z"
  },
  {
    "id": "9e3d9845-bdf5-4918-9137-d2d9fe369bfc",
    "name": "Asciminib",
    "brandNames": [
      "Scemblix"
    ],
    "classification": "ABL Kinase Inhibitor",
    "mechanism": "STAMP inhibitor specifically targeting BCR-ABL1",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "Philadelphia Chromosome–Positive CML"
      ]
    },
    "dosing": {
      "standard": "40 mg twice daily or 80 mg once daily"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Myelosuppression",
        "Infections"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver enzymes"
      ],
      "frequency": "Every cycle",
      "precautions": [
        "Monitor for cytopenias"
      ]
    },
    "interactions": {
      "drugs": [
        "Strong CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "FDA prescribing information"
    ],
    "summary": "Asciminib is a STAMP inhibitor used in the treatment of chronic myeloid leukemia (CML) with T315I mutation.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Avoid due to potential fetal risk",
      "QT_prolongation": "Monitor ECG in patients with risk factors"
    },
    "pharmacokinetics": {
      "excretion": "Feces (primary), urine (minor)",
      "half_life": "8.2 hours",
      "metabolism": "CYP3A4 (major)"
    },
    "contraindications": [
      "Hypersensitivity",
      "Concurrent use with strong CYP3A4 inducers"
    ],
    "routineMonitoring": [
      "CBC",
      "LFTs",
      "ECG if QT risk present"
    ],
    "preTreatmentTests": [
      "BCR-ABL1 T315I mutation status",
      "Baseline LFTs and ECG"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:14:33.068Z",
    "updatedAt": "2025-05-12T05:22:00.413Z"
  },
  {
    "id": "78a46ef4-cfff-4c6a-a2f4-08c191c5e742",
    "name": "Belantamab Mafodotin",
    "brandNames": [
      "Blenrep"
    ],
    "classification": "BCMA Antibody-Drug Conjugate",
    "mechanism": "Delivers cytotoxic agent to BCMA-expressing myeloma cells",
    "administration": "IV infusion over 30 minutes",
    "indications": {
      "cancer_types": [
        "Relapsed/Refractory Multiple Myeloma"
      ]
    },
    "dosing": {
      "standard": "2.5 mg/kg IV every 3 weeks"
    },
    "sideEffects": {
      "common": [
        "Keratopathy",
        "Blurred vision",
        "Thrombocytopenia"
      ]
    },
    "monitoring": {
      "labs": [
        "Ophthalmologic exam",
        "CBC"
      ],
      "frequency": "Before each dose",
      "precautions": [
        "REMS program required"
      ]
    },
    "interactions": {
      "drugs": [
        "Corticosteroids",
        "Lubricant eye drops"
      ]
    },
    "referenceSources": [
      "FDA prescribing information"
    ],
    "summary": "Belantamab mafodotin is an anti-BCMA antibody-drug conjugate used in relapsed/refractory multiple myeloma.",
    "blackBoxWarning": "Ocular toxicity (keratopathy) is common; requires ophthalmologic monitoring before and during treatment.",
    "specialConsiderations": {
      "eye_toxicity": "REMS program required; regular eye exams mandatory",
      "thrombocytopenia": "Monitor platelet counts during therapy"
    },
    "pharmacokinetics": {
      "excretion": "Unknown",
      "half_life": "12 days (approximate)",
      "metabolism": "Proteolytic degradation"
    },
    "contraindications": [
      "Active ocular infection"
    ],
    "routineMonitoring": [
      "Ophthalmologic exam before each dose",
      "Platelet count"
    ],
    "preTreatmentTests": [
      "Baseline eye exam",
      "CBC"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:15:45.744Z",
    "updatedAt": "2025-05-12T05:24:12.129Z"
  },
  {
    "id": "05368238-c91e-43f9-80a6-e91d1aef36a5",
    "name": "Fedratinib",
    "brandNames": [
      "Inrebic"
    ],
    "classification": "JAK2 Inhibitor",
    "mechanism": "Targets JAK2 to reduce myeloproliferation",
    "administration": "Oral capsule, take with food",
    "indications": {
      "cancer_types": [
        "Myelofibrosis"
      ]
    },
    "dosing": {
      "standard": "400 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Wernicke encephalopathy",
        "Nausea",
        "Anemia",
        "Diarrhea"
      ]
    },
    "monitoring": {
      "labs": [
        "Thiamine",
        "CBC"
      ],
      "frequency": "Prior to and during treatment",
      "precautions": [
        "Check thiamine before starting"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Alcohol"
      ]
    },
    "referenceSources": [
      "FDA prescribing information"
    ],
    "summary": "Fedratinib is a selective JAK2 inhibitor used to treat intermediate or high-risk primary or secondary myelofibrosis.",
    "blackBoxWarning": "Wernicke’s encephalopathy has occurred; thiamine levels must be monitored.",
    "specialConsiderations": {
      "cytopenias": "Monitor CBC for anemia and thrombocytopenia",
      "wernicke_risk": "Monitor thiamine before and during therapy"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~77%), urine (~23%)",
      "half_life": "41 hours",
      "metabolism": "CYP3A4 (minor)"
    },
    "contraindications": [
      "Thiamine deficiency",
      "Severe hepatic impairment"
    ],
    "routineMonitoring": [
      "CBC",
      "Thiamine levels",
      "GI symptoms"
    ],
    "preTreatmentTests": [
      "Thiamine level",
      "CBC",
      "Liver function"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:15:45.744Z",
    "updatedAt": "2025-05-12T05:55:48.275Z"
  },
  {
    "id": "3e7c2d52-f2b4-47f9-82cf-7ef82ea4023d",
    "name": "Ripretinib",
    "brandNames": [
      "Qinlock"
    ],
    "classification": "KIT/PDGFRA Inhibitor",
    "mechanism": "Switch-control tyrosine kinase inhibitor targeting KIT and PDGFRA",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "GIST after prior TKIs"
      ]
    },
    "dosing": {
      "standard": "150 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Alopecia",
        "Myalgia",
        "Palmar-plantar erythrodysesthesia"
      ]
    },
    "monitoring": {
      "labs": [
        "Skin exam",
        "Liver function"
      ],
      "frequency": "Each cycle",
      "precautions": [
        "Monitor for dermatologic reactions"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A inhibitors",
        "QT agents"
      ]
    },
    "referenceSources": [
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:15:45.744Z",
    "updatedAt": "2025-04-16T20:15:45.744Z"
  },
  {
    "id": "17b9e3ce-65bc-4961-b9de-512d75983a09",
    "name": "Niraparib",
    "brandNames": [
      "Zejula"
    ],
    "classification": "PARP Inhibitor",
    "mechanism": "Inhibits PARP enzymes to prevent tumor DNA repair",
    "administration": "Oral capsule, take with or without food",
    "indications": {
      "cancer_types": [
        "Ovarian Cancer (maintenance)"
      ]
    },
    "dosing": {
      "standard": "200–300 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Thrombocytopenia",
        "Hypertension",
        "Fatigue",
        "Nausea"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "BP monitoring"
      ],
      "frequency": "Weekly for 1 month",
      "precautions": [
        "Dose-adjust for cytopenias"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A inhibitors"
      ]
    },
    "referenceSources": [
      "FDA prescribing information"
    ],
    "summary": "Niraparib is a selective PARP1/PARP2 inhibitor used as maintenance therapy in ovarian cancer, particularly for BRCA-mutated or homologous recombination deficient (HRD) tumors.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "hypertension": "May increase BP; monitor regularly",
      "myelosuppression": "Monitor CBC; dose adjust for thrombocytopenia or anemia"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~47%), urine (~40%)",
      "half_life": "36 hours",
      "metabolism": "Minimal CYP metabolism"
    },
    "contraindications": [
      "Severe hepatic impairment",
      "Pregnancy"
    ],
    "routineMonitoring": [
      "CBC",
      "BP",
      "Renal and liver function"
    ],
    "preTreatmentTests": [
      "BRCA and HRD testing",
      "CBC, LFTs"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:15:45.744Z",
    "updatedAt": "2025-05-12T06:09:49.648Z"
  },
  {
    "id": "c8b18958-e1f4-4a92-81e1-0ef6abfc0079",
    "name": "Cemiplimab",
    "brandNames": [
      "Libtayo"
    ],
    "classification": "PD-1 Checkpoint Inhibitor",
    "mechanism": "Blocks PD-1 receptor, restoring T-cell activity against cancer",
    "administration": "IV infusion over 30 minutes",
    "indications": {
      "cancer_types": [
        "Cutaneous SCC",
        "NSCLC",
        "Basal Cell Carcinoma"
      ]
    },
    "dosing": {
      "standard": "350 mg IV every 3 weeks"
    },
    "sideEffects": {
      "common": [
        "Immune-mediated toxicity",
        "Diarrhea",
        "Pneumonitis"
      ]
    },
    "monitoring": {
      "labs": [
        "Thyroid",
        "Liver function",
        "Renal function"
      ],
      "frequency": "Every 3 weeks",
      "precautions": [
        "Monitor for immune-related adverse events"
      ]
    },
    "interactions": {
      "drugs": [
        "Steroids",
        "Immunosuppressants"
      ]
    },
    "referenceSources": [
      "FDA prescribing information"
    ],
    "summary": "Cemiplimab is a PD-1 immune checkpoint inhibitor approved for advanced cutaneous squamous cell carcinoma and other tumors.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Use not recommended during pregnancy",
      "immune_reactions": "Risk of colitis, pneumonitis, hepatitis, endocrinopathies"
    },
    "pharmacokinetics": {
      "excretion": "Unknown",
      "half_life": "20 days",
      "metabolism": "Proteolytic degradation"
    },
    "contraindications": [
      "Hypersensitivity to cemiplimab"
    ],
    "routineMonitoring": [
      "Thyroid panel",
      "LFTs",
      "Respiratory symptoms"
    ],
    "preTreatmentTests": [
      "PD-L1 expression (if applicable)",
      "TSH and liver function tests"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": false,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:15:45.744Z",
    "updatedAt": "2025-05-12T05:49:16.685Z"
  },
  {
    "id": "c8ec3d0a-652a-4945-9f3f-69102706bbd2",
    "name": "Obinutuzumab",
    "brandNames": [
      "Gazyva"
    ],
    "classification": "CD20 Monoclonal Antibody",
    "mechanism": "Binds CD20 to induce enhanced ADCC",
    "administration": "1000 mg IV on days 1, 8, 15 of cycle 1, then day 1 of subsequent cycles",
    "indications": {
      "cancer_types": [
        "Chronic Lymphocytic Leukemia",
        "Follicular Lymphoma"
      ]
    },
    "dosing": {
      "standard": "1000 mg IV (days 1, 8, 15) then day 1 of each 28‑day cycle"
    },
    "sideEffects": {
      "common": [
        "Infusion reactions",
        "Neutropenia",
        "Thrombocytopenia"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "LFT"
      ],
      "frequency": "Prior to each cycle"
    },
    "interactions": {
      "drugs": [
        "Other B-cell targeting agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody used in chronic lymphocytic leukemia and follicular lymphoma.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "infections": "Monitor for neutropenia and reactivation of hepatitis B",
      "infusion_reactions": "Premedicate with corticosteroids and antihistamines"
    },
    "pharmacokinetics": {
      "excretion": "Unknown",
      "half_life": "28 days",
      "metabolism": "Proteolytic degradation"
    },
    "contraindications": [
      "Active severe infections",
      "Known hypersensitivity"
    ],
    "routineMonitoring": [
      "CBC",
      "Infection signs",
      "Liver function"
    ],
    "preTreatmentTests": [
      "Hepatitis B status",
      "CBC"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:44:47.925Z",
    "updatedAt": "2025-05-12T06:09:59.398Z"
  },
  {
    "id": "d92dfae1-74ee-435a-a664-05f0b043cf27",
    "name": "Sacituzumab Govitecan",
    "brandNames": [
      "Trodelvy"
    ],
    "classification": "Trop-2 Antibody-Drug Conjugate",
    "mechanism": "Targets Trop-2 on tumor cells to deliver the active metabolite SN-38, causing DNA damage and cell death",
    "administration": "IV infusion over 90 minutes",
    "indications": {
      "cancer_types": [
        "Triple-Negative Breast Cancer",
        "Bladder Cancer"
      ]
    },
    "dosing": {
      "standard": "10 mg/kg IV on days 1 and 8 of a 21-day cycle"
    },
    "sideEffects": {
      "common": [
        "Neutropenia",
        "Diarrhea",
        "Nausea",
        "Alopecia"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Every cycle",
      "precautions": [
        "Monitor for severe diarrhea and neutropenia"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Myelosuppressive agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:28:04.974Z",
    "updatedAt": "2025-04-16T20:28:04.974Z"
  },
  {
    "id": "530d8e0c-587e-4922-ba19-5a530e6cba7c",
    "name": "Margetuximab",
    "brandNames": [
      "Margenza"
    ],
    "classification": "HER2 Monoclonal Antibody",
    "mechanism": "Fc‑engineered anti-HER2 antibody enhancing ADCC",
    "administration": "15 mg/kg IV every 3 weeks",
    "indications": {
      "cancer_types": [
        "Metastatic HER2‑Positive Breast Cancer"
      ]
    },
    "dosing": {
      "standard": "15 mg/kg IV every 3 weeks"
    },
    "sideEffects": {
      "common": [
        "Infusion reactions",
        "Fatigue",
        "Nausea"
      ]
    },
    "monitoring": {
      "labs": [
        "LVEF"
      ],
      "frequency": "Every 3 months"
    },
    "interactions": {
      "drugs": [
        "Other HER2-targeted agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:44:47.925Z",
    "updatedAt": "2025-04-16T20:44:47.925Z"
  },
  {
    "id": "be5045bf-62c9-423e-9fe7-3beefae12ddc",
    "name": "Palbociclib",
    "brandNames": [
      "Ibrance"
    ],
    "classification": "CDK4/6 Inhibitor",
    "mechanism": "Inhibits cyclin‑dependent kinases 4 and 6 to block cell cycle progression in cancer cells",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "HR‑Positive HER2‑Negative Breast Cancer"
      ]
    },
    "dosing": {
      "standard": "125 mg orally once daily for 21 days, then 7 days off"
    },
    "sideEffects": {
      "common": [
        "Neutropenia",
        "Fatigue",
        "Infections",
        "Pulmonary toxicity"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Every cycle",
      "precautions": [
        "Monitor for neutropenia and lung toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Strong CYP3A inducers"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "ASCO Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Palbociclib is a selective CDK4/6 inhibitor used for hormone receptor–positive, HER2-negative advanced breast cancer in combination with endocrine therapy.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "neutropenia": "Most common toxicity; requires frequent CBC monitoring",
      "pulmonary_toxicity": "Rare but serious interstitial lung disease reported"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~74%), urine (~17%)",
      "half_life": "29 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Hypersensitivity",
      "Severe hepatic impairment"
    ],
    "routineMonitoring": [
      "CBC",
      "Pulmonary symptoms"
    ],
    "preTreatmentTests": [
      "Hormone receptor status",
      "CBC"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:32:13.155Z",
    "updatedAt": "2025-05-12T06:11:27.012Z"
  },
  {
    "id": "2b4be870-d733-499a-8dc4-21d1a1b3b92c",
    "name": "Ribociclib",
    "brandNames": [
      "Kisqali"
    ],
    "classification": "CDK4/6 Inhibitor",
    "mechanism": "Inhibits cyclin-dependent kinases 4 and 6 to block cell cycle progression in cancer cells",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "HR-Positive HER2-Negative Breast Cancer"
      ]
    },
    "dosing": {
      "standard": "600 mg orally once daily for 21 days, then 7 days off"
    },
    "sideEffects": {
      "common": [
        "QT prolongation",
        "Hepatotoxicity",
        "Neutropenia",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "EKG",
        "Liver function",
        "CBC"
      ],
      "frequency": "Every cycle",
      "precautions": [
        "Monitor for QT prolongation and liver toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "QT prolonging agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:31:35.331Z",
    "updatedAt": "2025-04-16T20:31:35.331Z"
  },
  {
    "id": "a9e742f2-3d5c-4a7f-b1d9-d3c7b6c2f8e4",
    "name": "AMG 757",
    "brandNames": [
      "Experimental"
    ],
    "classification": "DLL3/CD3 T-Cell Engager",
    "mechanism": "Bispecific engager targeting DLL3 on tumor cells and CD3 on T‑cells to induce cytotoxicity",
    "administration": "IV infusion every 2 weeks",
    "indications": {
      "cancer_types": [
        "Small Cell Lung Cancer"
      ]
    },
    "dosing": {
      "standard": "IV infusion every 2 weeks"
    },
    "sideEffects": {
      "common": [
        "Cytokine release syndrome",
        "Neutropenia",
        "Fatigue",
        "Hypotension"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Blood pressure",
        "Neurologic exam"
      ],
      "frequency": "Before each cycle",
      "precautions": [
        "Monitor for CRS and neutropenia"
      ]
    },
    "interactions": {
      "drugs": [
        "Steroids",
        "Immunosuppressive agents"
      ]
    },
    "referenceSources": [
      "Clinical Trials",
      "NCCN Guidelines"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:37:33.956Z",
    "updatedAt": "2025-04-16T20:37:33.956Z"
  },
  {
    "id": "12df2f1a-1ed0-428d-a0af-f2769425f120",
    "name": "AMG 757 (tarlatamab)",
    "brandNames": [
      "Not available (investigational)"
    ],
    "classification": "Bispecific T-cell Engager (BiTE) monoclonal antibody targeting DLL3",
    "mechanism": "Binds to delta-like ligand 3 (DLL3) on cancer cells and CD3 on T-cells, facilitating T-cell activation and tumor cell lysis.",
    "administration": "Intravenous infusion; dose escalation followed by maintenance dosing (e.g., every 2 weeks in clinical trials)",
    "indications": {
      "approved": [
        "Investigational use in relapsed/refractory small cell lung cancer (SCLC)"
      ],
      "off_label": [
        "None (under clinical evaluation for other DLL3+ tumors)"
      ]
    },
    "dosing": {
      "standard": "Dose-escalation phase followed by 10-100 mg every 2 weeks (varies by trial protocol)",
      "renal_adjustment": "No established guidelines; limited data",
      "hepatic_adjustment": "No established guidelines; use caution in hepatic impairment"
    },
    "sideEffects": {
      "common": [
        "Cytokine release syndrome (CRS)",
        "Fatigue",
        "Pyrexia",
        "Hypophosphatemia"
      ],
      "serious": [
        "Grade ≥3 CRS",
        "Neurologic toxicity (e.g., encephalopathy)",
        "Tumor lysis syndrome"
      ]
    },
    "monitoring": {
      "baseline": [
        "DLL3 expression testing (tumor biopsy)",
        "CRP/IL-6 levels",
        "ECG",
        "Renal/hepatic function"
      ],
      "during_treatment": [
        "CRS monitoring (vitals, oxygen saturation)",
        "Neurologic exams",
        "Cytokine panels"
      ]
    },
    "interactions": {
      "caution": [
        "CYP450 substrates (theoretical risk due to cytokine effects)"
      ],
      "contraindicated": [
        "Live vaccines",
        "Concurrent immunosuppressive therapy"
      ]
    },
    "referenceSources": [
      "NCT04702737 (Phase 1 trial)",
      "ASCO 2022 Abstract 8505"
    ],
    "summary": "Investigational BiTE antibody targeting DLL3 for SCLC, demonstrating T-cell mediated cytotoxicity with promising early efficacy but significant CRS risk requiring vigilant monitoring.",
    "blackBoxWarning": "Boxed warning for cytokine release syndrome (CRS) and neurologic toxicity in clinical trials",
    "specialConsiderations": {
      "neurotoxicity": "Withhold dose for severe events",
      "premedication": "Corticosteroids, antihistamines, antipyretics",
      "CRS_management": "Tocilizumab protocol + ICU-level care for severe cases"
    },
    "pharmacokinetics": {
      "excretion": "Renal (60-70%) and fecal (30-40%)",
      "half_life": "~5-7 days",
      "metabolism": "Proteolytic degradation"
    },
    "contraindications": [
      "Active systemic infection",
      "Hypersensitivity to BiTE constructs"
    ],
    "routineMonitoring": [
      "Daily CRP during cycle 1",
      "Neurologic assessments q4h during infusion"
    ],
    "preTreatmentTests": [
      "DLL3 immunohistochemistry",
      "Cardiac ejection fraction",
      "HBV/HCV screening"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-05-12T10:59:08.568Z",
    "updatedAt": "2025-05-12T10:59:08.568Z"
  },
  {
    "id": "b8f392c1-9e2a-4c6d-a3f8-d7c9b2e1f4d5",
    "name": "Selpercatinib",
    "brandNames": [
      "Retevmo"
    ],
    "classification": "RET Tyrosine Kinase Inhibitor",
    "mechanism": "Selective RET inhibitor blocking oncogenic RET mutations",
    "administration": "Oral capsule, take with or without food",
    "indications": {
      "cancer_types": [
        "RET Fusion-Positive NSCLC",
        "Medullary Thyroid Cancer"
      ]
    },
    "dosing": {
      "standard": "160 mg orally twice daily"
    },
    "sideEffects": {
      "common": [
        "Hypertension",
        "QT prolongation",
        "Hepatotoxicity",
        "Diarrhea"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "EKG",
        "Blood pressure"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for hypertension and liver toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "QT prolonging agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:37:33.956Z",
    "updatedAt": "2025-04-16T20:37:33.956Z"
  },
  {
    "id": "25843296-e87d-4134-ac97-0d2dcd381d27",
    "name": "Osimertinib",
    "brandNames": [
      "Tagrisso"
    ],
    "classification": "EGFR Tyrosine Kinase Inhibitor",
    "mechanism": "Third-generation EGFR TKI targeting T790M mutation",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "Non-Small Cell Lung Cancer (EGFR-positive)"
      ]
    },
    "dosing": {
      "standard": "80 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Diarrhea",
        "Rash"
      ],
      "serious": [
        "QT prolongation",
        "Interstitial lung disease"
      ]
    },
    "monitoring": {
      "labs": [
        "ECG",
        "Liver function",
        "Renal function"
      ],
      "frequency": "Every 4-6 weeks",
      "precautions": [
        "Monitor QT interval",
        "Assess for lung toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "QT prolonging medications",
        "Strong CYP3A4 inducers"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Osimertinib is a third-generation EGFR tyrosine kinase inhibitor used for NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations and T790M resistance mutation.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "qt_prolongation": "Monitor ECG in patients with cardiac risk",
      "interstitial_lung_disease": "Discontinue permanently if suspected"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~68%), urine (~14%)",
      "half_life": "48 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Hypersensitivity",
      "ILD/pneumonitis history"
    ],
    "routineMonitoring": [
      "Respiratory status",
      "ECG",
      "LFTs"
    ],
    "preTreatmentTests": [
      "EGFR mutation status",
      "ECG, pulmonary assessment"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T17:49:15.246Z",
    "updatedAt": "2025-05-12T06:10:18.897Z"
  },
  {
    "id": "e3b9c4f7-5d2a-47e1-9b3c-8f7d6c2a1e4b",
    "name": "Tiragolumab",
    "brandNames": [
      "Experimental"
    ],
    "classification": "TIGIT Checkpoint Inhibitor",
    "mechanism": "Anti-TIGIT monoclonal antibody to enhance T‑cell activation",
    "administration": "IV infusion over 60 minutes",
    "indications": {
      "cancer_types": [
        "NSCLC (Under Clinical Trials)"
      ]
    },
    "dosing": {
      "standard": "600 mg IV every 3 weeks"
    },
    "sideEffects": {
      "common": [
        "Immune-mediated adverse events",
        "Fatigue",
        "Colitis",
        "Pneumonitis"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "Lung function"
      ],
      "frequency": "Every 3 weeks",
      "precautions": [
        "Monitor for immune-related toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "Systemic corticosteroids",
        "Immunosuppressive agents"
      ]
    },
    "referenceSources": [
      "Clinical Trials",
      "NCCN Guidelines"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:37:33.956Z",
    "updatedAt": "2025-04-16T20:37:33.956Z"
  },
  {
    "id": "b1c2d3e4-5f6a-4b7c-8d9e-0f1a2b3c4d5e",
    "name": "Cyclophosphamide",
    "brandNames": [
      "Cytoxan"
    ],
    "classification": "Alkylating Agent",
    "mechanism": "Cross-links DNA strands, leading to apoptosis",
    "administration": "IV infusion or oral tablet",
    "indications": {
      "cancer_types": [
        "Breast Cancer",
        "Lymphoma",
        "Leukemia",
        "Ovarian Cancer"
      ]
    },
    "dosing": {
      "standard": "600 mg/m² IV every 3 weeks",
      "adjustments": [
        "Reduce for renal/hepatic dysfunction"
      ]
    },
    "sideEffects": {
      "common": [
        "Myelosuppression",
        "Hemorrhagic cystitis",
        "Nausea",
        "Alopecia"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Renal function",
        "Liver function"
      ],
      "frequency": "Every cycle",
      "precautions": [
        "Ensure hydration to prevent hemorrhagic cystitis"
      ]
    },
    "interactions": {
      "drugs": [
        "Mesna",
        "CYP2B6 inhibitors",
        "Other myelosuppressive agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "ESMO Guidelines"
    ],
    "summary": "Cyclophosphamide is an alkylating agent used in hematologic malignancies and solid tumors. It is also used in autoimmune diseases.",
    "blackBoxWarning": "May cause hemorrhagic cystitis, bone marrow suppression, and secondary malignancies.",
    "specialConsiderations": {
      "cystitis": "Mesna or aggressive hydration recommended to prevent hemorrhagic cystitis",
      "fertility": "May cause infertility or gonadal suppression",
      "pregnancy": "Contraindicated due to fetal toxicity"
    },
    "pharmacokinetics": {
      "excretion": "Primarily renal",
      "half_life": "3–12 hours (varies)",
      "metabolism": "Activated in liver via CYP2B6 to active alkylating metabolites"
    },
    "contraindications": [
      "Severe bone marrow suppression",
      "Active urinary tract infections"
    ],
    "routineMonitoring": [
      "CBC",
      "Urinalysis (for hematuria)",
      "Renal and liver function"
    ],
    "preTreatmentTests": [
      "CBC",
      "Renal function",
      "Liver panel"
    ],
    "isChemotherapy": true,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:37:33.956Z",
    "updatedAt": "2025-05-12T05:50:22.492Z"
  },
  {
    "id": "f4d7b1a2-3c8e-4d5f-9b6a-7e8d9c2b4a3f",
    "name": "Doxorubicin",
    "brandNames": [
      "Adriamycin",
      "Doxil"
    ],
    "classification": "Anthracycline Chemotherapy",
    "mechanism": "Intercalates DNA and inhibits topoisomerase II",
    "administration": "IV push or infusion",
    "indications": {
      "cancer_types": [
        "Breast Cancer",
        "Lymphoma",
        "Multiple Myeloma",
        "Sarcoma"
      ]
    },
    "dosing": {
      "standard": "60-75 mg/m² every 3 weeks",
      "adjustments": [
        "Lifetime cumulative dose limit",
        "Reduce for hepatic dysfunction"
      ]
    },
    "sideEffects": {
      "common": [
        "Cardiotoxicity",
        "Myelosuppression",
        "Alopecia",
        "Nausea",
        "Mucositis"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Cardiac function (MUGA/Echo)",
        "Liver function"
      ],
      "frequency": "Prior to each cycle",
      "precautions": [
        "Monitor ejection fraction",
        "Cumulative dose tracking"
      ]
    },
    "interactions": {
      "drugs": [
        "Trastuzumab",
        "Cyclophosphamide",
        "Other cardiotoxic agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "BC Cancer Protocols"
    ],
    "summary": "Doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II; used in breast cancer, lymphomas, and other solid tumors.",
    "blackBoxWarning": "Cardiotoxicity is dose-dependent and may lead to irreversible heart failure. Also causes severe myelosuppression and vesicant injury if extravasated.",
    "specialConsiderations": {
      "cardiomyopathy": "Assess LVEF prior to treatment and monitor cumulative dose",
      "infusion_reaction": "Red urine discoloration is common but harmless"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~50%), urine (~15%)",
      "half_life": "20–48 hours",
      "metabolism": "Hepatic"
    },
    "contraindications": [
      "Preexisting cardiomyopathy",
      "Severe myelosuppression"
    ],
    "routineMonitoring": [
      "CBC",
      "LVEF",
      "Signs of extravasation"
    ],
    "preTreatmentTests": [
      "Echocardiogram or MUGA scan",
      "CBC",
      "LFTs"
    ],
    "isChemotherapy": true,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:37:33.956Z",
    "updatedAt": "2025-05-12T05:51:45.708Z"
  },
  {
    "id": "d7e8f9a0-1b2c-4d3e-9f0a-2b3c4d5e6f7a",
    "name": "Pertuzumab",
    "brandNames": [
      "Perjeta"
    ],
    "classification": "HER2 Monoclonal Antibody",
    "mechanism": "Binds HER2 to inhibit dimerization",
    "administration": "IV infusion over 60 minutes",
    "indications": {
      "cancer_types": [
        "HER2-Positive Breast Cancer"
      ]
    },
    "dosing": {
      "standard": "840 mg IV loading, then 420 mg every 3 weeks"
    },
    "sideEffects": {
      "common": [
        "Cardiotoxicity",
        "Infusion reactions",
        "Diarrhea",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "Cardiac function (LVEF)"
      ],
      "frequency": "Every 3 months",
      "precautions": [
        "Hold for LVEF decline",
        "Monitor for infusion reactions"
      ]
    },
    "interactions": {
      "drugs": [
        "Trastuzumab",
        "Anthracyclines"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "ASCO Guidelines"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:37:33.956Z",
    "updatedAt": "2025-04-16T20:37:33.956Z"
  },
  {
    "id": "75f8701e-c673-4893-8d50-913a655d6e1b",
    "name": "Imatinib",
    "brandNames": [
      "Gleevec"
    ],
    "classification": "BCR-ABL Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits BCR-ABL, c-KIT, PDGFR kinases",
    "administration": "400 mg orally once daily",
    "indications": {
      "cancer_types": [
        "Chronic Myeloid Leukemia",
        "GIST"
      ]
    },
    "dosing": {
      "standard": "400 mg PO once daily"
    },
    "sideEffects": {
      "common": [
        "Edema",
        "Nausea",
        "Muscle cramps",
        "Rash"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "LFT"
      ],
      "frequency": "Monthly initially"
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Grapefruit"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Imatinib is a tyrosine kinase inhibitor targeting BCR-ABL, c-KIT, and PDGFR, primarily used in chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and other rare neoplasms.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Contraindicated—teratogenic",
      "hepatotoxicity": "Monitor LFTs regularly",
      "fluid_retention": "Monitor for edema and weight gain"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~68%), urine (~13%)",
      "half_life": "18 hours (parent), 40 hours (active metabolite)",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Pregnancy",
      "Severe hepatic impairment"
    ],
    "routineMonitoring": [
      "LFTs",
      "Edema assessment",
      "CBC"
    ],
    "preTreatmentTests": [
      "BCR-ABL or c-KIT mutation status",
      "Liver function"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:43:46.667Z",
    "updatedAt": "2025-05-12T06:01:12.042Z"
  },
  {
    "id": "2d2f910e-b788-45c6-ae6f-823c76dd820a",
    "name": "Obinutuzumab",
    "brandNames": [
      "Gazyva"
    ],
    "classification": "CD20 Monoclonal Antibody",
    "mechanism": "Binds CD20 to induce enhanced ADCC",
    "administration": "1 000 mg IV on days 1, 8, 15 of cycle 1, then day 1 of subsequent cycles",
    "indications": {
      "cancer_types": [
        "Chronic Lymphocytic Leukemia",
        "Follicular Lymphoma"
      ]
    },
    "dosing": {
      "standard": "1000 mg IV (days 1, 8, 15) then day 1 of each 28‑day cycle"
    },
    "sideEffects": {
      "common": [
        "Infusion reactions",
        "Neutropenia",
        "Thrombocytopenia"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "LFT"
      ],
      "frequency": "Prior to each cycle"
    },
    "interactions": {
      "drugs": [
        "Other B-cell targeting agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody used in chronic lymphocytic leukemia and follicular lymphoma.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "infections": "Monitor for neutropenia and reactivation of hepatitis B",
      "infusion_reactions": "Premedicate with corticosteroids and antihistamines"
    },
    "pharmacokinetics": {
      "excretion": "Unknown",
      "half_life": "28 days",
      "metabolism": "Proteolytic degradation"
    },
    "contraindications": [
      "Active severe infections",
      "Known hypersensitivity"
    ],
    "routineMonitoring": [
      "CBC",
      "Infection signs",
      "Liver function"
    ],
    "preTreatmentTests": [
      "Hepatitis B status",
      "CBC"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:43:46.667Z",
    "updatedAt": "2025-05-12T06:09:59.398Z"
  },
  {
    "id": "fda17647-26e3-4a05-a3da-b028111e2db7",
    "name": "Ibrutinib",
    "brandNames": [
      "Imbruvica"
    ],
    "classification": "BTK Inhibitor",
    "mechanism": "Inhibits Bruton’s tyrosine kinase",
    "administration": "420 mg orally once daily",
    "indications": {
      "cancer_types": [
        "Chronic Lymphocytic Leukemia",
        "Mantle Cell Lymphoma",
        "Waldenström’s"
      ]
    },
    "dosing": {
      "standard": "420 mg PO once daily"
    },
    "sideEffects": {
      "common": [
        "Bleeding",
        "Atrial fibrillation",
        "Diarrhea",
        "Infections"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC"
      ],
      "frequency": "Monthly"
    },
    "interactions": {
      "drugs": [
        "Anticoagulants",
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:43:46.667Z",
    "updatedAt": "2025-04-16T20:43:46.667Z"
  },
  {
    "id": "22ccacad-a7f2-4d97-9853-1a7c8a733bd8",
    "name": "Brentuximab Vedotin",
    "brandNames": [
      "Adcetris"
    ],
    "classification": "CD30 Antibody-Drug Conjugate",
    "mechanism": "Targets CD30 to deliver MMAE and induce apoptosis",
    "administration": "1.8 mg/kg IV every 3 weeks",
    "indications": {
      "cancer_types": [
        "Hodgkin Lymphoma",
        "Systemic ALCL"
      ]
    },
    "dosing": {
      "standard": "1.8 mg/kg IV every 3 weeks"
    },
    "sideEffects": {
      "common": [
        "Peripheral neuropathy",
        "Neutropenia",
        "Infusion reactions",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "LFT"
      ],
      "frequency": "Prior to each cycle"
    },
    "interactions": {
      "drugs": [
        "Other microtubule inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Brentuximab vedotin is an anti-CD30 antibody-drug conjugate used in Hodgkin lymphoma and systemic anaplastic large cell lymphoma.",
    "blackBoxWarning": "Progressive multifocal leukoencephalopathy (PML) has been reported.",
    "specialConsiderations": {
      "pml_risk": "Evaluate promptly if neurologic symptoms occur",
      "neuropathy": "Peripheral neuropathy is common and cumulative"
    },
    "pharmacokinetics": {
      "excretion": "MMAE primarily fecal",
      "half_life": "4–6 days",
      "metabolism": "Proteolytic degradation of the antibody; MMAE via CYP3A4/5"
    },
    "contraindications": [
      "Hypersensitivity to brentuximab or MMAE"
    ],
    "routineMonitoring": [
      "Neurologic status",
      "CBC",
      "Liver function"
    ],
    "preTreatmentTests": [
      "CD30 expression",
      "Baseline neuro exam"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:43:46.667Z",
    "updatedAt": "2025-05-12T05:29:47.433Z"
  },
  {
    "id": "fab39e2d-030f-4c69-823b-35cbaabf2085",
    "name": "Gilteritinib",
    "brandNames": [
      "Xospata"
    ],
    "classification": "FLT3 Inhibitor",
    "mechanism": "Inhibits FLT3-ITD and FLT3-TKD mutants",
    "administration": "120 mg orally once daily",
    "indications": {
      "cancer_types": [
        "FLT3‑mutated Acute Myeloid Leukemia"
      ]
    },
    "dosing": {
      "standard": "120 mg PO once daily"
    },
    "sideEffects": {
      "common": [
        "Differentiation syndrome",
        "Diarrhea",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "LFT"
      ],
      "frequency": "Monthly"
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Gilteritinib is a FLT3 inhibitor indicated for relapsed or refractory FLT3-mutated acute myeloid leukemia (AML).",
    "blackBoxWarning": "Differentiation syndrome can occur and be life-threatening; prompt steroid therapy required.",
    "specialConsiderations": {
      "QT_prolongation": "Monitor ECG and electrolytes",
      "differentiation_syndrome": "Initiate corticosteroids early if suspected"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~64%), urine (~16%)",
      "half_life": "113 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Known hypersensitivity",
      "Long QT syndrome"
    ],
    "routineMonitoring": [
      "ECG",
      "Electrolytes",
      "Signs of differentiation syndrome"
    ],
    "preTreatmentTests": [
      "FLT3 mutation testing",
      "ECG, electrolytes"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:43:46.667Z",
    "updatedAt": "2025-05-12T05:56:13.834Z"
  },
  {
    "id": "9a24937c-4383-4e94-91cf-76bb56a382c4",
    "name": "Oxaliplatin",
    "brandNames": [
      "Eloxatin"
    ],
    "classification": "Platinum Chemotherapy",
    "mechanism": "Forms platinum-DNA adducts leading to apoptosis",
    "administration": "IV infusion over 2–6 hours; avoid cold exposure during infusion",
    "indications": {
      "cancer_types": [
        "Colorectal Cancer",
        "Pancreatic Cancer",
        "Gastric Cancer"
      ]
    },
    "dosing": {
      "standard": "85–130 mg/m² every 2–3 weeks",
      "adjustments": [
        "Reduce for neuropathy",
        "Modify for hepatic dysfunction"
      ]
    },
    "sideEffects": {
      "common": [
        "Peripheral neuropathy",
        "Cold sensitivity",
        "Nausea",
        "Fatigue",
        "Diarrhea"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function",
        "Renal function"
      ],
      "frequency": "Prior to each cycle",
      "precautions": [
        "Monitor neurological symptoms",
        "Avoid cold exposure"
      ]
    },
    "interactions": {
      "drugs": [
        "NSAIDs",
        "5-Fluorouracil",
        "Capecitabine"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "ESMO Guidelines"
    ],
    "summary": "Oxaliplatin is a platinum-based alkylating agent used primarily in colorectal cancer and other solid tumors.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "neuropathy": "Acute cold-induced neuropathy is common; dose-limiting cumulative sensory neuropathy also occurs",
      "hypersensitivity": "Anaphylactic reactions can occur, especially after multiple doses"
    },
    "pharmacokinetics": {
      "excretion": "Renal (~50%)",
      "half_life": "Approx. 9–25 hours (terminal: up to 273 h due to tissue binding)",
      "metabolism": "Non-enzymatic conversion to active derivatives"
    },
    "contraindications": [
      "Hypersensitivity to platinum compounds"
    ],
    "routineMonitoring": [
      "CBC",
      "Renal function",
      "Neurologic assessment"
    ],
    "preTreatmentTests": [
      "Renal function tests",
      "Baseline neurologic exam"
    ],
    "isChemotherapy": true,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:07:34.644Z",
    "updatedAt": "2025-05-12T06:11:05.553Z"
  },
  {
    "id": "bc54e7b8-d8a1-4d2d-b4a5-87ff873e917d",
    "name": "Margetuximab",
    "brandNames": [
      "Margenza"
    ],
    "classification": "HER2 Monoclonal Antibody",
    "mechanism": "Fc‑engineered anti-HER2 antibody enhancing ADCC",
    "administration": "15 mg/kg IV every 3 weeks",
    "indications": {
      "cancer_types": [
        "Metastatic HER2‑Positive Breast Cancer"
      ]
    },
    "dosing": {
      "standard": "15 mg/kg IV every 3 weeks"
    },
    "sideEffects": {
      "common": [
        "Infusion reactions",
        "Fatigue",
        "Nausea"
      ]
    },
    "monitoring": {
      "labs": [
        "LVEF"
      ],
      "frequency": "Every 3 months"
    },
    "interactions": {
      "drugs": [
        "Other HER2-targeted agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:43:46.667Z",
    "updatedAt": "2025-04-16T20:43:46.667Z"
  },
  {
    "id": "9f0b25f1-85ec-44c0-9055-99bec566eae2",
    "name": "Belantamab Mafodotin",
    "brandNames": [
      "Blenrep"
    ],
    "classification": "BCMA Antibody-Drug Conjugate",
    "mechanism": "Targets BCMA to deliver MMAF and induce apoptosis",
    "administration": "2.5 mg/kg IV every 3 weeks",
    "indications": {
      "cancer_types": [
        "Relapsed/Refractory Multiple Myeloma"
      ]
    },
    "dosing": {
      "standard": "2.5 mg/kg IV every 3 weeks"
    },
    "sideEffects": {
      "common": [
        "Ocular toxicity",
        "Thrombocytopenia",
        "Infusion reactions"
      ]
    },
    "monitoring": {
      "labs": [
        "Eye exam",
        "CBC"
      ],
      "frequency": "Every cycle"
    },
    "interactions": {
      "drugs": [
        "Other microtubule inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:43:46.667Z",
    "updatedAt": "2025-04-16T20:43:46.667Z"
  },
  {
    "id": "8f1e65b0-8daa-4d60-8be5-e7cd562bec2d",
    "name": "Trastuzumab",
    "brandNames": [
      "Herceptin"
    ],
    "classification": "HER2 Monoclonal Antibody",
    "mechanism": "Binds to HER2 receptor to inhibit proliferation of HER2-overexpressing tumor cells",
    "administration": "IV infusion; first dose over 90 minutes, reduce time if tolerated",
    "indications": {
      "cancer_types": [
        "HER2-Positive Breast Cancer",
        "HER2-Positive Gastric Cancer"
      ]
    },
    "dosing": {
      "standard": "8 mg/kg loading dose, then 6 mg/kg every 3 weeks",
      "adjustments": [
        "No dose reduction for toxicity"
      ]
    },
    "sideEffects": {
      "common": [
        "Cardiotoxicity",
        "Infusion reactions",
        "Pneumonitis",
        "Diarrhea"
      ]
    },
    "monitoring": {
      "labs": [
        "Cardiac function",
        "LVEF monitoring"
      ],
      "frequency": "Every 3 months",
      "precautions": [
        "Regular cardiac monitoring",
        "Hold for EF decline"
      ]
    },
    "interactions": {
      "drugs": [
        "Anthracyclines",
        "Other cardiotoxic agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "BC Cancer Protocols"
    ],
    "summary": "Trastuzumab is a monoclonal antibody against the HER2/neu (ERBB2) receptor, used in HER2-positive breast and gastric cancer.",
    "blackBoxWarning": "Risk of cardiomyopathy and heart failure; baseline and follow-up echocardiography recommended.",
    "specialConsiderations": {
      "cardiotoxicity": "Dilated cardiomyopathy; do not combine with anthracyclines simultaneously",
      "infusion_reactions": "Common during first dose; monitor closely"
    },
    "pharmacokinetics": {
      "excretion": "Unknown",
      "half_life": "Approx. 6 days (varies by dosing schedule)",
      "metabolism": "Proteolysis"
    },
    "contraindications": [
      "Known hypersensitivity to trastuzumab or components"
    ],
    "routineMonitoring": [
      "Echocardiogram",
      "Infusion-related symptoms"
    ],
    "preTreatmentTests": [
      "HER2 status",
      "Baseline cardiac function"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:03:53.037Z",
    "updatedAt": "2025-05-12T06:18:27.944Z"
  },
  {
    "id": "aa32bba9-6922-4db4-85a8-6c0ada70fe65",
    "name": "Imatinib",
    "brandNames": [
      "Gleevec"
    ],
    "classification": "BCR-ABL Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits BCR-ABL, c-KIT, PDGFR kinases",
    "administration": "400 mg orally once daily",
    "indications": {
      "cancer_types": [
        "Chronic Myeloid Leukemia",
        "GIST"
      ]
    },
    "dosing": {
      "standard": "400 mg PO once daily"
    },
    "sideEffects": {
      "common": [
        "Edema",
        "Nausea",
        "Muscle cramps",
        "Rash"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "LFT"
      ],
      "frequency": "Monthly initially"
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Grapefruit"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:44:47.925Z",
    "updatedAt": "2025-04-16T20:44:47.925Z"
  },
  {
    "id": "9ebda1b4-ab81-413a-9a34-ba16a67d2128",
    "name": "Dasatinib",
    "brandNames": [
      "Sprycel"
    ],
    "classification": "BCR-ABL Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits BCR-ABL and SRC family kinases",
    "administration": "100 mg orally once daily",
    "indications": {
      "cancer_types": [
        "Chronic Myeloid Leukemia",
        "Ph+ ALL"
      ]
    },
    "dosing": {
      "standard": "100 mg PO once daily"
    },
    "sideEffects": {
      "common": [
        "Pleural effusion",
        "Cytopenias",
        "Diarrhea",
        "Headache"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "LFT"
      ],
      "frequency": "Monthly"
    },
    "interactions": {
      "drugs": [
        "PPIs",
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:44:47.925Z",
    "updatedAt": "2025-04-16T20:44:47.925Z"
  },
  {
    "id": "76e1acf2-19bd-4f64-b125-98bbeea88edf",
    "name": "Sunitinib",
    "brandNames": [
      "Sutent"
    ],
    "classification": "Multi‑Targeted TKI",
    "mechanism": "Inhibits VEGFR, PDGFR, KIT, FLT3, CSF‑1R, RET",
    "administration": "50 mg orally once daily (4 weeks on, 2 weeks off)",
    "indications": {
      "cancer_types": [
        "Renal Cell Carcinoma",
        "GIST",
        "Pancreatic NET"
      ]
    },
    "dosing": {
      "standard": "50 mg PO daily; 4 weeks on, 2 weeks off"
    },
    "sideEffects": {
      "common": [
        "Hypertension",
        "Hand-foot syndrome",
        "Fatigue",
        "Diarrhea"
      ]
    },
    "monitoring": {
      "labs": [
        "BP",
        "LFT",
        "TSH"
      ],
      "frequency": "Every cycle"
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Sunitinib is a multikinase inhibitor targeting VEGFR, PDGFR, and others. It is used in renal cell carcinoma, pancreatic neuroendocrine tumors, and GISTs.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "cardiac_toxicity": "Monitor for hypertension and signs of heart failure",
      "thyroid_dysfunction": "Can induce hypothyroidism; monitor thyroid function"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~61%), urine (~16%)",
      "half_life": "40–60 hours",
      "metabolism": "Primarily CYP3A4"
    },
    "contraindications": [
      "Severe cardiac dysfunction",
      "Uncontrolled hypertension"
    ],
    "routineMonitoring": [
      "BP",
      "Thyroid function",
      "CBC"
    ],
    "preTreatmentTests": [
      "LFTs",
      "Thyroid panel"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:44:47.925Z",
    "updatedAt": "2025-05-12T06:16:16.523Z"
  },
  {
    "id": "c2d3e4f5-6a7b-4c8d-9e0f-1a2b3c4d5e6f",
    "name": "Vimseltinib",
    "brandNames": [
      "Romvimza"
    ],
    "classification": "CSF1R Inhibitor",
    "mechanism": "Inhibits colony-stimulating factor 1 receptor (CSF1R) to reduce tumor-associated macrophages",
    "administration": "Oral administration",
    "indications": {
      "conditions": [
        "Tenosynovial giant cell tumor (TGCT) where surgical resection would cause severe morbidity"
      ]
    },
    "dosing": {
      "standard": "30 mg orally once daily"
    },
    "sideEffects": {},
    "monitoring": {},
    "interactions": {},
    "referenceSources": [
      "https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:52:50.191Z",
    "updatedAt": "2025-04-16T20:52:50.191Z"
  },
  {
    "id": "193e2aa9-26aa-497f-9003-3756e4463d5e",
    "name": "Camidanlumab Tesirine",
    "brandNames": [],
    "classification": "CD25 Antibody-Drug Conjugate",
    "mechanism": "",
    "administration": "",
    "indications": {},
    "dosing": {
      "standard": "30 μg/kg IV every 3 weeks"
    },
    "sideEffects": {},
    "monitoring": {},
    "interactions": {},
    "referenceSources": [],
    "summary": "Camidanlumab tesirine is an anti-CD25 antibody-drug conjugate investigated for relapsed/refractory Hodgkin lymphoma.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "hepatotoxicity": "Monitor LFTs during treatment",
      "myelosuppression": "Expected based on ADC mechanism"
    },
    "pharmacokinetics": {
      "excretion": "Unknown",
      "half_life": "Investigational – varies",
      "metabolism": "Expected proteolytic degradation"
    },
    "contraindications": [
      "None established (investigational)"
    ],
    "routineMonitoring": [
      "CBC",
      "Liver enzymes"
    ],
    "preTreatmentTests": [
      "CD25 expression (if applicable)",
      "Baseline labs"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:49:37.589Z",
    "updatedAt": "2025-05-12T05:48:11.409Z"
  },
  {
    "id": "c83d3f0f-3b10-479e-bc96-e3934956920c",
    "name": "Vimseltinib",
    "brandNames": [
      "Romvimza"
    ],
    "classification": "CSF1R Inhibitor",
    "mechanism": "Inhibits colony-stimulating factor 1 receptor (CSF1R) to reduce tumor-associated macrophages",
    "administration": "Oral administration",
    "indications": {
      "conditions": [
        "Tenosynovial giant cell tumor (TGCT) where surgical resection would cause severe morbidity"
      ]
    },
    "dosing": {
      "standard": "30 mg orally once daily"
    },
    "sideEffects": {},
    "monitoring": {},
    "interactions": {},
    "referenceSources": [
      "https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:53:37.597Z",
    "updatedAt": "2025-04-16T20:53:37.597Z"
  },
  {
    "id": "4bef229c-cbcb-4c29-8ad9-43760118cab8",
    "name": "Talquetamab",
    "brandNames": [
      "Talvey"
    ],
    "classification": "GPRC5D/CD3 Bispecific Antibody",
    "mechanism": "Targets GPRC5D on multiple myeloma cells and CD3 on T-cells to induce cytotoxicity",
    "administration": "Subcutaneous injection",
    "indications": {
      "conditions": [
        "Relapsed or refractory multiple myeloma after ≥4 prior therapies"
      ]
    },
    "dosing": {
      "standard": "0.4 mg/kg weekly or 0.8 mg/kg biweekly"
    },
    "sideEffects": {},
    "monitoring": {},
    "interactions": {},
    "referenceSources": [
      "https://www.fda.gov/drugs/news-events-human-drugs/fda-grants-accelerated-approval-talquetamab"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:53:37.597Z",
    "updatedAt": "2025-04-16T20:53:37.597Z"
  },
  {
    "id": "6dbad9e7-241f-4457-b4e5-53df02870937",
    "name": "Repotrectinib",
    "brandNames": [
      "Augtyro"
    ],
    "classification": "ROS1/NTRK Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits ROS1 and NTRK kinases to prevent oncogenic signaling in fusion-positive cancers",
    "administration": "Oral capsules",
    "indications": {
      "conditions": [
        "ROS1-positive non-small cell lung cancer (NSCLC)"
      ]
    },
    "dosing": {
      "standard": "160 mg orally once daily for 14 days, then 160 mg twice daily"
    },
    "sideEffects": {},
    "monitoring": {},
    "interactions": {},
    "referenceSources": [
      "https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-repotrectinib-ros1-positive-nsclc"
    ],
    "summary": "",
    "blackBoxWarning": null,
    "specialConsiderations": {},
    "pharmacokinetics": {},
    "contraindications": [],
    "routineMonitoring": [],
    "preTreatmentTests": [],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:54:04.589Z",
    "updatedAt": "2025-04-16T20:54:04.589Z"
  },
  {
    "id": "df9f5c22-2e9d-4eaf-9c1d-81029a8a4a76",
    "name": "Elranatamab",
    "brandNames": [
      "Elrexfio"
    ],
    "classification": "BCMA/CD3 Bispecific Antibody",
    "mechanism": "Engages BCMA on myeloma cells and CD3 on T-cells to promote immune-mediated cytotoxicity",
    "administration": "Subcutaneous injection",
    "indications": {
      "conditions": [
        "Relapsed or refractory multiple myeloma after ≥6 prior therapies"
      ]
    },
    "dosing": {
      "standard": "76 mg weekly for 6 doses, then 76 mg every 2 weeks"
    },
    "sideEffects": {},
    "monitoring": {},
    "interactions": {},
    "referenceSources": [
      "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-elranatamab-relapsed-or-refractory-multiple-myeloma"
    ],
    "summary": "Elranatamab is a BCMA-directed bispecific antibody for relapsed or refractory multiple myeloma.",
    "blackBoxWarning": "Cytokine release syndrome and immune effector cell-associated neurotoxicity are major concerns. REMS program applies.",
    "specialConsiderations": {
      "crs_monitoring": "Hospitalization and monitoring required after initial dose",
      "neurologic_monitoring": "Watch for signs of neurotoxicity, e.g., confusion or tremor"
    },
    "pharmacokinetics": {
      "excretion": "Unknown",
      "half_life": "Approx. 5–7 days (estimated)",
      "metabolism": "Proteolytic degradation"
    },
    "contraindications": [
      "Active CNS disease",
      "Pregnancy"
    ],
    "routineMonitoring": [
      "CRS signs",
      "Neurologic status",
      "CBC"
    ],
    "preTreatmentTests": [
      "BCMA expression (if applicable)",
      "CBC and chemistries"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:54:04.589Z",
    "updatedAt": "2025-05-12T05:53:05.108Z"
  },
  {
    "id": "7534094a-7f63-4ed2-aa4e-7bf925e1fecc",
    "name": "Abemaciclib",
    "brandNames": [
      "Verzenio"
    ],
    "classification": "CDK4/6 Inhibitor",
    "mechanism": "Inhibits CDK4 and CDK6 to block cell cycle progression",
    "administration": "150 mg orally twice daily",
    "indications": {
      "cancer_types": [
        "HR‑Positive, HER2‑Negative Breast Cancer"
      ]
    },
    "dosing": {
      "standard": "150 mg PO twice daily"
    },
    "sideEffects": {
      "common": [
        "Diarrhea",
        "Neutropenia",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "LFT"
      ],
      "frequency": "Monthly"
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Inducers"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Abemaciclib is a selective CDK4/6 inhibitor used in HR+/HER2- breast cancer, typically in combination with endocrine therapy.",
    "blackBoxWarning": "May cause severe diarrhea, neutropenia, hepatotoxicity, and thromboembolic events. Monitor closely and adjust dose if needed.",
    "specialConsiderations": {
      "pregnancy": "Avoid during pregnancy due to potential fetal harm",
      "hepatic_impairment": "Dose adjustment may be needed in moderate to severe impairment"
    },
    "pharmacokinetics": {
      "excretion": "Mainly via feces",
      "half_life": "17–38 hours",
      "metabolism": "Primarily hepatic via CYP3A4"
    },
    "contraindications": [
      "Known hypersensitivity to abemaciclib or its components",
      "Pregnancy and breastfeeding"
    ],
    "routineMonitoring": [
      "Complete blood count (CBC) every 2 weeks for the first 2 months, then monthly",
      "Liver function tests (ALT, AST, bilirubin)",
      "Signs of thrombosis and diarrhea"
    ],
    "preTreatmentTests": [
      "Baseline CBC",
      "Liver function panel",
      "Pregnancy test (if applicable)"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:43:46.667Z",
    "updatedAt": "2025-05-12T05:17:10.786Z"
  },
  {
    "id": "af385854-4fad-4d2f-ae27-2e0469ae9c13",
    "name": "Dasatinib",
    "brandNames": [
      "Sprycel"
    ],
    "classification": "BCR-ABL Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits BCR-ABL and SRC family kinases",
    "administration": "100 mg orally once daily",
    "indications": {
      "cancer_types": [
        "CML",
        "Ph+ ALL"
      ]
    },
    "dosing": {
      "standard": "100 mg PO once daily"
    },
    "sideEffects": {
      "common": [
        "Pleural effusion",
        "Cytopenias",
        "Diarrhea",
        "Headache"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "LFT"
      ],
      "frequency": "Monthly"
    },
    "interactions": {
      "drugs": [
        "PPIs",
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Dasatinib is a tyrosine kinase inhibitor used to treat Ph+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Contraindicated—teratogenic",
      "QT_prolongation": "Monitor ECG and correct electrolytes",
      "pleural_effusion": "Common and may require diuretics or steroids"
    },
    "pharmacokinetics": {
      "excretion": "Feces (85%), urine (4%)",
      "half_life": "3–5 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Hypersensitivity to dasatinib",
      "Long QT syndrome"
    ],
    "routineMonitoring": [
      "CBC",
      "ECG",
      "Pleural symptoms"
    ],
    "preTreatmentTests": [
      "Ph+ status",
      "Electrolytes",
      "ECG"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:43:46.667Z",
    "updatedAt": "2025-05-12T05:51:24.099Z"
  },
  {
    "id": "70fc3df9-0993-41ae-80a2-e39c5d50881f",
    "name": "Alpelisib",
    "brandNames": [
      "Piqray"
    ],
    "classification": "PI3K Inhibitor",
    "mechanism": "Inhibits PI3Kα isoform in PIK3CA-mutant breast cancer",
    "administration": "Oral tablet, take with food",
    "indications": {
      "cancer_types": [
        "HR-Positive, HER2-Negative Breast Cancer"
      ]
    },
    "dosing": {
      "standard": "300 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Hyperglycemia",
        "Diarrhea",
        "Rash",
        "Nausea"
      ]
    },
    "monitoring": {
      "labs": [
        "Blood glucose",
        "Liver function"
      ],
      "frequency": "Every 2 weeks initially, then monthly",
      "precautions": [
        "Monitor for hyperglycemia and rash"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Antidiabetics"
      ]
    },
    "referenceSources": [
      "FDA prescribing information",
      "NCCN Guidelines"
    ],
    "summary": "Alpelisib is a PI3K-alpha inhibitor used in HR+/HER2-, PIK3CA-mutated breast cancer in combination with endocrine therapy.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "rash": "Consider prophylactic antihistamines",
      "pregnancy": "Avoid use due to potential fetal harm",
      "hyperglycemia": "Common and may be severe—monitor fasting glucose regularly"
    },
    "pharmacokinetics": {
      "excretion": "Feces and urine",
      "half_life": "8–9 hours",
      "metabolism": "Primarily hepatic (CYP3A4, UGT)"
    },
    "contraindications": [
      "Severe hypersensitivity reactions to alpelisib"
    ],
    "routineMonitoring": [
      "Blood glucose",
      "LFTs",
      "Dermatologic exams"
    ],
    "preTreatmentTests": [
      "PIK3CA mutation testing",
      "Fasting glucose",
      "LFTs"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:11:33.187Z",
    "updatedAt": "2025-05-12T05:20:59.730Z"
  },
  {
    "id": "a8751773-e693-4c6c-bc94-6b0d7be24d47",
    "name": "Abiraterone Acetate",
    "brandNames": [
      "Zytiga"
    ],
    "classification": "Androgen Biosynthesis Inhibitor",
    "mechanism": "Inhibits CYP17 to block androgen production",
    "administration": "Oral tablet, take on empty stomach + prednisone",
    "indications": {
      "cancer_types": [
        "Metastatic Castration-Resistant Prostate Cancer"
      ]
    },
    "dosing": {
      "standard": "1000 mg orally once daily + prednisone 5 mg twice daily"
    },
    "sideEffects": {
      "common": [
        "Hypertension",
        "Hypokalemia",
        "Fluid retention",
        "Liver toxicity"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "Electrolytes",
        "Blood pressure"
      ],
      "frequency": "Every 2–4 weeks",
      "precautions": [
        "Monitor for mineralocorticoid excess"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "CYP2D6 substrates"
      ]
    },
    "referenceSources": [
      "FDA prescribing information",
      "NCCN Guidelines"
    ],
    "summary": "Abiraterone acetate is an androgen biosynthesis inhibitor used in combination with prednisone for the treatment of metastatic prostate cancer.",
    "blackBoxWarning": "Risk of mineralocorticoid excess (e.g., hypertension, hypokalemia), hepatotoxicity, and adrenal insufficiency. Coadministration with glucocorticoids is essential.",
    "specialConsiderations": {
      "pregnancy": "Contraindicated in pregnancy. Male patients with female partners of reproductive potential should use effective contraception.",
      "hepatic_impairment": "Avoid in severe hepatic impairment (Child-Pugh C); monitor LFTs regularly"
    },
    "pharmacokinetics": {
      "excretion": "Primarily fecal (88%), minor urinary (5%)",
      "half_life": "12 ± 5 hours",
      "metabolism": "Hepatic via CYP3A4"
    },
    "contraindications": [
      "Pregnancy",
      "Severe hepatic impairment",
      "Known hypersensitivity to abiraterone acetate or any excipients"
    ],
    "routineMonitoring": [
      "Liver function tests (ALT, AST, bilirubin) prior to treatment and every 2 weeks for 3 months, then monthly",
      "Serum potassium and blood pressure regularly during treatment"
    ],
    "preTreatmentTests": [
      "Serum transaminases and bilirubin",
      "Serum potassium",
      "Blood pressure",
      "Pregnancy test (if applicable)"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:12:37.737Z",
    "updatedAt": "2025-05-12T05:17:42.174Z"
  },
  {
    "id": "a1b2c3d4-9f8e-4d3c-b2a1-0e9f8d7c6b5a",
    "name": "Alectinib",
    "brandNames": [
      "Alecensa"
    ],
    "classification": "ALK Tyrosine Kinase Inhibitor",
    "mechanism": "Selective ALK inhibitor blocking ALK-mediated signaling",
    "administration": "Oral capsule, take with food",
    "indications": {
      "cancer_types": [
        "ALK-Positive Non-Small Cell Lung Cancer"
      ]
    },
    "dosing": {
      "standard": "600 mg orally twice daily",
      "adjustments": [
        "Reduce for hepatic dysfunction"
      ]
    },
    "sideEffects": {
      "common": [
        "Hepatotoxicity",
        "Bradycardia",
        "Photosensitivity",
        "Myalgia"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "CPK levels",
        "EKG"
      ],
      "frequency": "Every 2-4 weeks",
      "precautions": [
        "Monitor for liver toxicity and cardiac effects"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "QT prolonging agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Alectinib is a highly selective ALK tyrosine kinase inhibitor used in ALK-positive non-small cell lung cancer (NSCLC), particularly in metastatic settings.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Use effective contraception; fetal harm cannot be ruled out",
      "cardiotoxicity": "May cause bradycardia or QT prolongation",
      "hepatic_impairment": "Dose adjustment may be required in moderate to severe impairment"
    },
    "pharmacokinetics": {
      "excretion": "Feces (98%)",
      "half_life": "32.5 hours",
      "metabolism": "Hepatic via CYP3A4"
    },
    "contraindications": [
      "Hypersensitivity to alectinib or any excipients"
    ],
    "routineMonitoring": [
      "Liver function tests (ALT, AST, bilirubin)",
      "Heart rate and ECG (QTc interval)",
      "Creatine kinase levels (for myopathy)",
      "Eye exams (visual disturbances)"
    ],
    "preTreatmentTests": [
      "Baseline ECG and heart rate",
      "Baseline LFTs",
      "ALK mutation status via genetic testing"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:37:33.956Z",
    "updatedAt": "2025-05-12T05:18:39.742Z"
  },
  {
    "id": "1d878189-6be4-4101-9694-af94d034fd2f",
    "name": "Adagrasib",
    "brandNames": [
      "Krazati"
    ],
    "classification": "KRAS Inhibitor",
    "mechanism": "Specifically inhibits KRAS G12C mutant protein to prevent cell proliferation",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "KRAS G12C-Mutant Non-Small Cell Lung Cancer"
      ]
    },
    "dosing": {
      "standard": "600 mg orally twice daily"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Diarrhea"
      ],
      "serious": [
        "QT prolongation",
        "Hepatotoxicity"
      ]
    },
    "monitoring": {
      "labs": [
        "EKG",
        "Liver function",
        "Renal function"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for cardiac toxicity and liver function"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "QT prolonging agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Adagrasib is a KRAS G12C inhibitor used for non-small cell lung cancer (NSCLC) with KRAS G12C mutations.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Avoid use in pregnancy; potential for fetal harm",
      "hepatic_impairment": "Use with caution; limited data available"
    },
    "pharmacokinetics": {
      "excretion": "Feces (major), urine (minor)",
      "half_life": "24 hours (approximate)",
      "metabolism": "Primarily CYP3A4"
    },
    "contraindications": [
      "Hypersensitivity to adagrasib or formulation components"
    ],
    "routineMonitoring": [
      "LFTs",
      "Pulmonary symptoms",
      "Signs of hepatotoxicity"
    ],
    "preTreatmentTests": [
      "KRAS G12C mutation testing",
      "Baseline LFTs"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T17:48:19.057Z",
    "updatedAt": "2025-05-12T05:20:06.502Z"
  },
  {
    "id": "6e6cd0e0-c7d2-42c4-a2f4-c73351c1b9ef",
    "name": "Panobinostat",
    "brandNames": [
      "Farydak"
    ],
    "classification": "HDAC Inhibitor",
    "mechanism": "Inhibits histone deacetylases, leading to apoptosis of cancer cells",
    "administration": "Oral capsule, take with food",
    "indications": {
      "cancer_types": [
        "Multiple Myeloma"
      ]
    },
    "dosing": {
      "standard": "20 mg orally on days 1, 3, 5, 8, 10, 12 of a 21-day cycle"
    },
    "sideEffects": {
      "common": [
        "Diarrhea",
        "Fatigue",
        "Thrombocytopenia",
        "Cardiotoxicity"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "EKG",
        "Liver function"
      ],
      "frequency": "Every cycle",
      "precautions": [
        "Monitor QT prolongation and blood counts"
      ]
    },
    "interactions": {
      "drugs": [
        "QT prolonging agents",
        "CYP3A inhibitors"
      ]
    },
    "referenceSources": [
      "FDA prescribing information",
      "NCCN Guidelines"
    ],
    "summary": "Panobinostat is a histone deacetylase inhibitor used in relapsed or refractory multiple myeloma in combination with other agents.",
    "blackBoxWarning": "Severe diarrhea and cardiac toxicities including arrhythmias and ECG changes. QT prolongation requires close ECG monitoring.",
    "specialConsiderations": {
      "diarrhea": "May be severe and lead to dehydration and electrolyte imbalance",
      "qt_prolongation": "Baseline and periodic ECG monitoring required"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~44%), urine (~29%)",
      "half_life": "Approx. 30 hours",
      "metabolism": "Primarily CYP3A4"
    },
    "contraindications": [
      "QT prolongation",
      "Uncontrolled diarrhea"
    ],
    "routineMonitoring": [
      "ECG",
      "Electrolytes",
      "GI symptoms"
    ],
    "preTreatmentTests": [
      "ECG",
      "Electrolytes",
      "CBC"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:11:33.187Z",
    "updatedAt": "2025-05-12T06:11:33.736Z"
  },
  {
    "id": "85635b74-082c-42f2-9b67-7b1eba1d1d5e",
    "name": "Afatinib",
    "brandNames": [
      "Gilotrif"
    ],
    "classification": "EGFR Tyrosine Kinase Inhibitor",
    "mechanism": "Blocks EGFR tyrosine kinase to inhibit tumor cell proliferation",
    "administration": "Oral tablet, take on an empty stomach",
    "indications": {
      "cancer_types": [
        "EGFR-Mutant Non-Small Cell Lung Cancer"
      ]
    },
    "dosing": {
      "standard": "40 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Diarrhea",
        "Rash",
        "Paronychia",
        "Stomatitis"
      ]
    },
    "monitoring": {
      "labs": [
        "Renal function",
        "Liver function",
        "EKG"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for severe diarrhea and skin toxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "P-gp inhibitors",
        "CYP3A4 inducers"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Afatinib is a second-generation EGFR tyrosine kinase inhibitor used in EGFR-mutated NSCLC.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "diarrhea": "Frequent and potentially severe; early management is critical",
      "pregnancy": "Contraindicated due to teratogenicity",
      "ocular_toxicity": "Monitor for signs of keratitis"
    },
    "pharmacokinetics": {
      "excretion": "Feces (85%), urine (4%)",
      "half_life": "37 hours",
      "metabolism": "Non-CYP mediated (primarily via glutathione conjugation)"
    },
    "contraindications": [
      "Hypersensitivity to afatinib or excipients"
    ],
    "routineMonitoring": [
      "Skin and GI symptoms",
      "LFTs",
      "Electrolytes"
    ],
    "preTreatmentTests": [
      "EGFR mutation testing",
      "Baseline LFTs"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:02:35.252Z",
    "updatedAt": "2025-05-12T05:20:47.858Z"
  },
  {
    "id": "8101bdfb-8b1b-4839-9cb3-4637259d6029",
    "name": "AMG 757",
    "brandNames": [
      "Experimental"
    ],
    "classification": "DLL3/CD3 T-Cell Engager",
    "mechanism": "Binds DLL3 and CD3 to activate T-cells against small cell lung cancer",
    "administration": "IV infusion over 30 minutes",
    "indications": {
      "cancer_types": [
        "Small Cell Lung Cancer"
      ]
    },
    "dosing": {
      "standard": "IV infusion every 2 weeks"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Hypotension"
      ],
      "serious": [
        "Cytokine release syndrome",
        "Neutropenia"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Blood pressure",
        "Neurologic exam"
      ],
      "frequency": "Before each cycle",
      "precautions": [
        "Monitor for CRS and neutropenia"
      ]
    },
    "interactions": {
      "drugs": [
        "Steroids",
        "Immunosuppressive agents"
      ]
    },
    "referenceSources": [
      "Clinical Trials",
      "NCCN Guidelines"
    ],
    "summary": "AMG 757 is an investigational bispecific T-cell engager (BiTE) targeting DLL3 in small cell lung cancer and neuroendocrine tumors.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Avoid due to investigational status and unknown risks",
      "cytokine_release_syndrome": "Monitor for infusion-related reactions and cytokine storm"
    },
    "pharmacokinetics": {
      "excretion": "Unknown",
      "half_life": "Unknown – investigational agent",
      "metabolism": "Expected proteolytic degradation"
    },
    "contraindications": [
      "None known (investigational)"
    ],
    "routineMonitoring": [
      "Vital signs during infusion",
      "Cytokine markers if available"
    ],
    "preTreatmentTests": [
      "DLL3 expression testing (if available)"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:02:07.453Z",
    "updatedAt": "2025-05-12T05:21:08.336Z"
  },
  {
    "id": "376db79e-f94e-4430-993e-b94063cb2b60",
    "name": "Amivantamab",
    "brandNames": [
      "Rybrevant"
    ],
    "classification": "EGFR-MET Bispecific Antibody",
    "mechanism": "Targets EGFR and MET receptors to inhibit tumor growth",
    "administration": "IV infusion over 2–4 hours",
    "indications": {
      "cancer_types": [
        "NSCLC with EGFR Exon20 Insertion"
      ]
    },
    "dosing": {
      "standard": "1050–1400 mg IV weekly for 4 weeks, then every 2 weeks"
    },
    "sideEffects": {
      "common": [
        "Infusion reactions",
        "Rash",
        "Paronychia"
      ]
    },
    "monitoring": {
      "labs": [
        "Electrolytes",
        "Skin assessment"
      ],
      "frequency": "Each cycle",
      "precautions": [
        "Premedicate to reduce infusion reactions"
      ]
    },
    "interactions": {
      "drugs": [
        "Immunosuppressive agents"
      ]
    },
    "referenceSources": [
      "FDA prescribing information"
    ],
    "summary": "Amivantamab is a bispecific EGFR-MET antibody used in non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Avoid due to potential fetal harm",
      "infusion_reaction": "High risk during first dose; premedicate and monitor"
    },
    "pharmacokinetics": {
      "excretion": "Unknown",
      "half_life": "11.3 days",
      "metabolism": "Proteolytic catabolism"
    },
    "contraindications": [
      "Severe hypersensitivity to amivantamab"
    ],
    "routineMonitoring": [
      "Infusion-related reactions",
      "Skin and nail toxicity",
      "Lung function for ILD"
    ],
    "preTreatmentTests": [
      "EGFR exon 20 insertion mutation testing"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:14:33.068Z",
    "updatedAt": "2025-05-12T05:21:44.243Z"
  },
  {
    "id": "41de1af5-12d0-481b-ac3b-a46d665f4a55",
    "name": "Atezolizumab",
    "brandNames": [
      "Tecentriq"
    ],
    "classification": "PD-L1 Checkpoint Inhibitor",
    "mechanism": "Binds to PD-L1, blocking its interaction with PD-1 to restore T-cell activity",
    "administration": "IV infusion over 60 minutes",
    "indications": {
      "cancer_types": [
        "NSCLC",
        "Triple-Negative Breast Cancer"
      ]
    },
    "dosing": {
      "standard": "1200 mg IV every 3 weeks"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Diarrhea"
      ],
      "serious": [
        "Pneumonitis",
        "Immune-mediated adverse events"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "Thyroid function"
      ],
      "frequency": "Every 3 weeks",
      "precautions": [
        "Monitor for immune-related adverse events"
      ]
    },
    "interactions": {
      "drugs": [
        "Systemic corticosteroids",
        "Immunosuppressive agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Atezolizumab is a PD-L1 immune checkpoint inhibitor used in various cancers including NSCLC, urothelial carcinoma, and triple-negative breast cancer.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Avoid use during pregnancy",
      "immune_reactions": "Can cause immune-related adverse events (e.g., colitis, hepatitis, endocrinopathies)"
    },
    "pharmacokinetics": {
      "excretion": "Not characterized",
      "half_life": "27 days",
      "metabolism": "Proteolytic degradation"
    },
    "contraindications": [
      "Known hypersensitivity to atezolizumab"
    ],
    "routineMonitoring": [
      "Liver enzymes",
      "Thyroid function tests",
      "Pulmonary symptoms (ILD risk)"
    ],
    "preTreatmentTests": [
      "PD-L1 expression (for some indications)",
      "Baseline LFTs and TSH"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T19:59:46.283Z",
    "updatedAt": "2025-05-12T05:22:09.775Z"
  },
  {
    "id": "24701b0b-aa57-469c-bb8a-fc37cb4a3f26",
    "name": "Axicabtagene Ciloleucel",
    "brandNames": [
      "Yescarta"
    ],
    "classification": "CAR-T Therapy",
    "mechanism": "Autologous anti-CD19 CAR-T cells for aggressive B-cell lymphomas",
    "administration": "IV infusion over 30 minutes",
    "indications": {
      "cancer_types": [
        "Large B-Cell Lymphoma",
        "Mantle Cell Lymphoma"
      ]
    },
    "dosing": {
      "standard": "One-time IV infusion"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Hypogammaglobulinemia"
      ],
      "serious": [
        "Cytokine release syndrome",
        "Neurologic toxicity",
        "Infections"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function",
        "Neurologic exam"
      ],
      "frequency": "Before and after infusion",
      "precautions": [
        "Monitor for CRS and neurotoxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "Steroids",
        "Tocilizumab"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Axicabtagene ciloleucel is a CD19-directed CAR T-cell therapy used for relapsed/refractory large B-cell lymphoma.",
    "blackBoxWarning": "Cytokine release syndrome (CRS) and neurotoxicity are serious risks. Treatment must occur in a certified facility.",
    "specialConsiderations": {
      "CRS": "Tocilizumab should be available before infusion; monitor for hypotension and fever",
      "neurologic_events": "May present as confusion, tremors, or seizures; monitor closely"
    },
    "pharmacokinetics": {
      "excretion": "N/A",
      "half_life": "Not applicable – living cells expand in vivo",
      "metabolism": "N/A"
    },
    "contraindications": [
      "Uncontrolled active infection",
      "Pregnancy"
    ],
    "routineMonitoring": [
      "Vitals post-infusion (for CRS)",
      "Neurological assessment"
    ],
    "preTreatmentTests": [
      "CD19 expression in tumor",
      "Baseline CBC and chemistries"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T17:49:15.246Z",
    "updatedAt": "2025-05-12T05:23:51.977Z"
  },
  {
    "id": "811ad258-a012-40e8-b7da-32ca9ea52764",
    "name": "Axitinib",
    "brandNames": [
      "Inlyta"
    ],
    "classification": "VEGFR Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits VEGFR‑1, ‑2, ‑3",
    "administration": "5 mg orally twice daily",
    "indications": {
      "cancer_types": [
        "Renal Cell Carcinoma"
      ]
    },
    "dosing": {
      "standard": "5 mg PO twice daily"
    },
    "sideEffects": {
      "common": [
        "Hypertension",
        "Diarrhea",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "BP"
      ],
      "frequency": "Weekly initial, then every cycle"
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Axitinib is a VEGF receptor tyrosine kinase inhibitor used in advanced renal cell carcinoma.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "bleeding": "Use with caution in patients with risk of hemorrhage",
      "hypertension": "Very common; monitor BP regularly"
    },
    "pharmacokinetics": {
      "excretion": "Feces (41%), urine (12%)",
      "half_life": "2.5–6.1 hours",
      "metabolism": "CYP3A4/5, CYP1A2, CYP2C19"
    },
    "contraindications": [
      "Severe hepatic impairment",
      "Uncontrolled hypertension"
    ],
    "routineMonitoring": [
      "Blood pressure",
      "Renal and hepatic function"
    ],
    "preTreatmentTests": [
      "Baseline BP",
      "LFTs and renal panel"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:43:46.667Z",
    "updatedAt": "2025-05-12T05:24:03.555Z"
  },
  {
    "id": "bef4f49e-1411-48c6-a942-e8caf296869b",
    "name": "Bevacizumab",
    "brandNames": [
      "Avastin"
    ],
    "classification": "VEGF Monoclonal Antibody",
    "mechanism": "Binds VEGF to inhibit angiogenesis in tumors",
    "administration": "IV infusion",
    "indications": {
      "cancer_types": [
        "Colorectal Cancer",
        "NSCLC",
        "Ovarian Cancer",
        "Glioblastoma",
        "Cervical Cancer"
      ]
    },
    "dosing": {
      "ranges": [
        "5–10 mg/kg every 2 weeks",
        "10 mg/kg every 2 weeks",
        "15 mg/kg every 3 weeks",
        "5–15 mg/kg every 2–3 weeks"
      ]
    },
    "sideEffects": {
      "common": [
        "Hypertension",
        "Bleeding",
        "GI perforation",
        "Proteinuria",
        "Wound healing complications"
      ]
    },
    "monitoring": {
      "labs": [
        "BP",
        "Urinalysis",
        "CBC",
        "Wound healing",
        "Urine protein"
      ],
      "frequency": "Before or during each infusion"
    },
    "interactions": {
      "drugs": [
        "NSAIDs",
        "Anti-angiogenic agents",
        "Sunitinib",
        "Antiplatelets"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information",
      "Clinical Trials"
    ],
    "summary": "Bevacizumab is a monoclonal antibody against VEGF, used in solid tumors like colorectal, lung, renal, and glioblastoma.",
    "blackBoxWarning": "Risk of GI perforation, impaired wound healing, and serious bleeding events.",
    "specialConsiderations": {
      "hypertension": "May require antihypertensive treatment",
      "wound_healing": "Hold therapy before major surgery and resume only after healing"
    },
    "pharmacokinetics": {
      "excretion": "Unknown",
      "half_life": "20 days",
      "metabolism": "Proteolytic degradation"
    },
    "contraindications": [
      "Recent major surgery",
      "Uncontrolled hypertension"
    ],
    "routineMonitoring": [
      "Blood pressure",
      "Proteinuria",
      "Wound healing status"
    ],
    "preTreatmentTests": [
      "BP measurement",
      "Urinalysis for protein"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:25:51.650Z",
    "updatedAt": "2025-05-12T05:24:21.247Z"
  },
  {
    "id": "81a7fa6a-2f85-4cbf-b29c-1c31a7f91b11",
    "name": "Binimetinib",
    "brandNames": [
      "Mektovi"
    ],
    "classification": "MEK Inhibitor",
    "mechanism": "Inhibits MEK1/2 to block downstream MAPK signaling",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "BRAF V600E-Mutant Melanoma",
        "Colorectal Cancer"
      ]
    },
    "dosing": {
      "standard": "45 mg orally twice daily"
    },
    "sideEffects": {
      "common": [
        "Retinopathy",
        "Cardiotoxicity",
        "Rash",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "Ophthalmologic exam",
        "Liver function",
        "EKG"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor for visual and cardiac side effects"
      ]
    },
    "interactions": {
      "drugs": [
        "BRAF inhibitors",
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Binimetinib is a MEK inhibitor used in combination with encorafenib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Contraindicated due to teratogenicity",
      "ocular_toxicity": "Risk of retinal pigment epithelial detachment",
      "cardiac_toxicity": "Monitor LVEF before and during therapy"
    },
    "pharmacokinetics": {
      "excretion": "Feces (62%), urine (31%)",
      "half_life": "3.5 hours",
      "metabolism": "Primarily via glucuronidation (UGT1A1)"
    },
    "contraindications": [
      "Hypersensitivity to binimetinib"
    ],
    "routineMonitoring": [
      "LVEF",
      "Ocular exams",
      "Liver enzymes"
    ],
    "preTreatmentTests": [
      "BRAF V600 mutation testing",
      "Baseline ECG and ophthalmology exam"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:10:14.269Z",
    "updatedAt": "2025-05-12T05:29:13.899Z"
  },
  {
    "id": "7113b259-3e7b-43d8-a0bf-c6b5bc428dde",
    "name": "Blinatumomab",
    "brandNames": [
      "Blincyto"
    ],
    "classification": "CD19/CD3 Bispecific Antibody",
    "mechanism": "Redirects T-cells to kill CD19-expressing leukemia cells",
    "administration": "IV continuous infusion",
    "indications": {
      "cancer_types": [
        "Acute Lymphoblastic Leukemia"
      ]
    },
    "dosing": {
      "standard": "9 mcg/day continuous IV infusion for 7 days, then 28 mcg/day"
    },
    "sideEffects": {
      "common": [
        "Fever"
      ],
      "serious": [
        "Cytokine release syndrome",
        "Neurotoxicity",
        "Neutropenia"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function",
        "Neurologic exam"
      ],
      "frequency": "Before each cycle",
      "precautions": [
        "Monitor for CRS and neurotoxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "Steroids",
        "Immunosuppressive agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Blinatumomab is a bispecific CD19-directed CD3 T-cell engager (BiTE) used in B-cell precursor acute lymphoblastic leukemia (ALL).",
    "blackBoxWarning": "Cytokine release syndrome (CRS) and neurotoxicity are common and potentially fatal. Hospitalization required for first cycle.",
    "specialConsiderations": {
      "CRS": "Premedicate with dexamethasone; monitor for fever and hypotension",
      "pregnancy": "Contraindicated due to fetal risk",
      "neurologic_events": "Can cause encephalopathy, seizures, confusion"
    },
    "pharmacokinetics": {
      "excretion": "Unknown",
      "half_life": "2.1 hours (requires continuous infusion)",
      "metabolism": "Proteolytic degradation"
    },
    "contraindications": [
      "Hypersensitivity to blinatumomab or excipients"
    ],
    "routineMonitoring": [
      "Vitals during infusion",
      "Neurologic status",
      "Electrolytes"
    ],
    "preTreatmentTests": [
      "CD19 expression",
      "Neurologic exam"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:01:40.780Z",
    "updatedAt": "2025-05-12T05:29:31.841Z"
  },
  {
    "id": "c6d7e8f9-0a1b-4c2d-8e9f-1a2b3c4d5e6f",
    "name": "Brexucabtagene Autoleucel",
    "brandNames": [
      "Tecartus"
    ],
    "classification": "CAR-T Therapy",
    "mechanism": "CD19-directed genetically modified T‑cell therapy",
    "administration": "One‑time IV infusion",
    "indications": {
      "cancer_types": [
        "Mantle Cell Lymphoma"
      ]
    },
    "dosing": {
      "standard": "One-time IV infusion"
    },
    "sideEffects": {
      "common": [
        "Cytokine release syndrome",
        "Neurologic toxicity",
        "Neutropenia",
        "Infections"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function",
        "Neurologic exam"
      ],
      "frequency": "Before and after infusion",
      "precautions": [
        "Monitor for CRS and neurotoxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "Steroids",
        "Tocilizumab"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Brexucabtagene autoleucel is an autologous CD19-directed CAR T-cell therapy used in mantle cell lymphoma and B-cell precursor ALL.",
    "blackBoxWarning": "Risk of cytokine release syndrome (CRS) and neurologic toxicities; requires REMS certification.",
    "specialConsiderations": {
      "crs": "Premedicate and monitor closely post-infusion; manage with tocilizumab as needed",
      "neurotoxicity": "Can cause confusion, tremors, or encephalopathy; requires neurologic monitoring"
    },
    "pharmacokinetics": {
      "excretion": "N/A",
      "half_life": "Not applicable – genetically modified cells expand and persist in vivo",
      "metabolism": "N/A"
    },
    "contraindications": [
      "Active CNS involvement",
      "Pregnancy"
    ],
    "routineMonitoring": [
      "Vital signs",
      "Neurologic status",
      "Infection signs"
    ],
    "preTreatmentTests": [
      "CD19 antigen testing",
      "Baseline CBC, chemistries"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:37:33.956Z",
    "updatedAt": "2025-05-12T05:47:28.980Z"
  },
  {
    "id": "3a37fc6f-2c20-4744-8a7c-c6beeeb9e13f",
    "name": "Brigatinib",
    "brandNames": [
      "Alunbrig"
    ],
    "classification": "ALK Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits ALK and ROS1 tyrosine kinases in lung cancer",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "ALK-Positive Non-Small Cell Lung Cancer"
      ]
    },
    "dosing": {
      "standard": "90 mg once daily for 7 days, then increase to 180 mg daily"
    },
    "sideEffects": {
      "common": [
        "Hypertension",
        "Muscle pain"
      ],
      "serious": [
        "Interstitial lung disease",
        "Bradycardia"
      ]
    },
    "monitoring": {
      "labs": [
        "Blood pressure",
        "Liver function",
        "EKG"
      ],
      "frequency": "Every 2-4 weeks",
      "precautions": [
        "Monitor for pulmonary toxicity and hypertension"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "QT prolonging agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Brigatinib is an ALK tyrosine kinase inhibitor used in ALK-positive non-small cell lung cancer (NSCLC).",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "hypertension": "Monitor BP regularly",
      "hyperglycemia": "Monitor fasting glucose",
      "pulmonary_toxicity": "Can occur within days of initiation; monitor for dyspnea and cough"
    },
    "pharmacokinetics": {
      "excretion": "Feces (65%), urine (25%)",
      "half_life": "25 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Severe hypersensitivity to brigatinib"
    ],
    "routineMonitoring": [
      "Respiratory symptoms",
      "BP",
      "Blood glucose"
    ],
    "preTreatmentTests": [
      "ALK mutation testing",
      "Baseline BP and fasting glucose"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T17:51:48.265Z",
    "updatedAt": "2025-05-12T05:47:41.171Z"
  },
  {
    "id": "a6e4e78b-a5d6-4fa8-837a-6ca16bc5de65",
    "name": "Cabozantinib",
    "brandNames": [
      "Cabometyx"
    ],
    "classification": "Multi‑Targeted TKI",
    "mechanism": "Inhibits MET, VEGFR, AXL, RET, ROS1",
    "administration": "60 mg orally once daily",
    "indications": {
      "cancer_types": [
        "Renal Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "Thyroid Cancer"
      ]
    },
    "dosing": {
      "standard": "60 mg PO once daily"
    },
    "sideEffects": {
      "common": [
        "Diarrhea",
        "Fatigue",
        "Palmar-plantar erythrodysesthesia"
      ]
    },
    "monitoring": {
      "labs": [
        "LFT"
      ],
      "frequency": "Every cycle"
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Cabozantinib is a VEGFR tyrosine kinase inhibitor used in renal cell carcinoma and medullary thyroid carcinoma.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "diarrhea": "Common and dose-limiting",
      "hypertension": "Common and may be severe",
      "wound_healing": "Hold before major surgery and delay restart until adequate healing"
    },
    "pharmacokinetics": {
      "excretion": "Feces (54%), urine (27%)",
      "half_life": "99 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Severe hypersensitivity to cabozantinib"
    ],
    "routineMonitoring": [
      "BP",
      "Electrolytes",
      "GI symptoms"
    ],
    "preTreatmentTests": [
      "BP",
      "LFTs",
      "Renal panel"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:43:46.667Z",
    "updatedAt": "2025-05-12T05:48:11.409Z"
  },
  {
    "id": "e183039e-0257-4aab-9d4f-0987281ac996",
    "name": "Regorafenib",
    "brandNames": [
      "Stivarga"
    ],
    "classification": "VEGF Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits multiple tyrosine kinases involved in tumor angiogenesis and oncogenesis",
    "administration": "Oral tablet, take on an empty stomach",
    "indications": {
      "cancer_types": [
        "Colorectal Cancer",
        "GIST",
        "Hepatocellular Carcinoma"
      ]
    },
    "dosing": {
      "standard": "160 mg orally once daily for 3 weeks on, 1 week off"
    },
    "sideEffects": {
      "common": [
        "Hand–foot skin reaction",
        "Fatigue",
        "Hypertension",
        "Diarrhea"
      ]
    },
    "monitoring": {
      "labs": [
        "Liver function",
        "Blood pressure"
      ],
      "frequency": "Every cycle",
      "precautions": [
        "Monitor LFTs and BP"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Anticoagulants"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information",
      "ESMO Guidelines"
    ],
    "summary": "Regorafenib is a multi-kinase inhibitor targeting VEGFR, PDGFR, and other kinases, used in metastatic colorectal cancer, GIST, and hepatocellular carcinoma (HCC).",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "hepatotoxicity": "Monitor LFTs closely; hepatotoxicity can be fatal",
      "dermatologic_toxicity": "Hand-foot skin reaction is common and may require dose adjustment"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~71%), urine (~19%)",
      "half_life": "28 hours",
      "metabolism": "CYP3A4, UGT1A9"
    },
    "contraindications": [
      "Severe hepatic impairment"
    ],
    "routineMonitoring": [
      "LFTs",
      "Dermatologic exam",
      "CBC"
    ],
    "preTreatmentTests": [
      "Baseline liver function tests"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:32:46.783Z",
    "updatedAt": "2025-05-12T06:14:08.633Z"
  },
  {
    "id": "e82877f2-4db1-4f12-b29a-d28505eeb9e7",
    "name": "Capecitabine",
    "brandNames": [
      "Xeloda"
    ],
    "classification": "Antimetabolite",
    "mechanism": "Oral prodrug converted to 5-FU in tumor cells to inhibit DNA synthesis",
    "administration": "Oral administration; take within 30 minutes after meals",
    "indications": {
      "cancer_types": [
        "Colorectal Cancer",
        "Breast Cancer",
        "Gastric Cancer"
      ]
    },
    "dosing": {
      "standard": "1000–1250 mg/m² twice daily for 14 days every 21 days"
    },
    "sideEffects": {
      "common": [
        "Hand-foot syndrome",
        "Diarrhea",
        "Nausea",
        "Stomatitis",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function",
        "Renal function"
      ],
      "frequency": "Every cycle",
      "precautions": [
        "Monitor for hand-foot syndrome",
        "DPD testing recommended"
      ]
    },
    "interactions": {
      "drugs": [
        "Warfarin",
        "Phenytoin",
        "Leucovorin",
        "Allopurinol"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "BC Cancer Protocols"
    ],
    "summary": "Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), used in the treatment of colorectal, breast, and gastric cancers.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "pregnancy": "Contraindicated due to teratogenicity",
      "hand_foot_syndrome": "Common adverse effect; may require dose modification",
      "dihydropyrimidine_dehydrogenase_deficiency": "Increased toxicity risk; consider genotyping"
    },
    "pharmacokinetics": {
      "excretion": "Urine (approximately 95%)",
      "half_life": "0.85 hours",
      "metabolism": "Converted to 5-FU in the liver and tumor tissue"
    },
    "contraindications": [
      "Severe renal impairment",
      "Known DPD deficiency"
    ],
    "routineMonitoring": [
      "CBC",
      "Renal function",
      "Signs of hand-foot syndrome"
    ],
    "preTreatmentTests": [
      "DPD activity (if available)",
      "Renal function"
    ],
    "isChemotherapy": true,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:06:59.803Z",
    "updatedAt": "2025-05-12T05:49:04.418Z"
  },
  {
    "id": "f5b8b2c2-921a-4e59-a94a-f5fd108d5ec2",
    "name": "Ponatinib",
    "brandNames": [
      "Iclusig"
    ],
    "classification": "BCR-ABL Tyrosine Kinase Inhibitor",
    "mechanism": "Inhibits BCR-ABL including T315I mutation",
    "administration": "Oral tablet, take with or without food",
    "indications": {
      "cancer_types": [
        "CML",
        "Ph+ ALL"
      ]
    },
    "dosing": {
      "standard": "15–45 mg orally once daily"
    },
    "sideEffects": {
      "common": [
        "Hypertension",
        "Arterial thrombosis",
        "Pancreatitis"
      ]
    },
    "monitoring": {
      "labs": [
        "Lipid profile",
        "Liver enzymes"
      ],
      "frequency": "Every cycle",
      "precautions": [
        "Risk of vascular events"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A inhibitors",
        "Antihypertensives"
      ]
    },
    "referenceSources": [
      "FDA prescribing information"
    ],
    "summary": "Ponatinib is a third-generation BCR-ABL tyrosine kinase inhibitor effective against T315I-mutant chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL).",
    "blackBoxWarning": "Arterial occlusions, venous thromboembolism, and hepatotoxicity are serious risks. Use only in patients who have failed prior TKIs or have T315I mutation.",
    "specialConsiderations": {
      "hepatotoxicity": "Monitor LFTs frequently; may require dose interruption or reduction",
      "vascular_events": "Monitor for signs of arterial or venous thrombosis; manage cardiovascular risk factors"
    },
    "pharmacokinetics": {
      "excretion": "Feces (~87%), urine (~5%)",
      "half_life": "Approx. 24 hours",
      "metabolism": "Primarily CYP3A4"
    },
    "contraindications": [
      "Severe hepatic impairment",
      "Uncontrolled hypertension"
    ],
    "routineMonitoring": [
      "Blood pressure",
      "LFTs",
      "Cardiovascular status"
    ],
    "preTreatmentTests": [
      "T315I mutation status (if applicable)",
      "LFTs",
      "Cardiovascular risk assessment"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:15:45.744Z",
    "updatedAt": "2025-05-12T06:13:09.377Z"
  },
  {
    "id": "1c0860cc-0d28-4764-ac5d-223498273db6",
    "name": "Ciltacabtagene Autoleucel",
    "brandNames": [
      "Carvykti"
    ],
    "classification": "CAR-T Therapy",
    "mechanism": "Genetically modified autologous T cells targeting BCMA in myeloma cells",
    "administration": "IV infusion over 30-60 minutes",
    "indications": {
      "cancer_types": [
        "Relapsed/Refractory Multiple Myeloma"
      ]
    },
    "dosing": {
      "standard": "One-time IV infusion"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Neutropenia"
      ],
      "serious": [
        "Cytokine release syndrome",
        "Neurotoxicity",
        "Infections"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function",
        "Neurologic exam"
      ],
      "frequency": "Before and after infusion",
      "precautions": [
        "Monitor for CRS and neurotoxicity"
      ]
    },
    "interactions": {
      "drugs": [
        "Steroids",
        "Tocilizumab"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Ciltacabtagene autoleucel is a BCMA-directed CAR T-cell therapy approved for relapsed/refractory multiple myeloma.",
    "blackBoxWarning": "Risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).",
    "specialConsiderations": {
      "crs": "Monitor for fever, hypotension, hypoxia; requires tocilizumab availability",
      "pregnancy": "Avoid due to live cell therapy and unknown risks",
      "neurotoxicity": "Monitor for confusion, tremors, aphasia"
    },
    "pharmacokinetics": {
      "excretion": "N/A",
      "half_life": "Not applicable – living cell therapy",
      "metabolism": "N/A"
    },
    "contraindications": [
      "Active infection",
      "Pregnancy"
    ],
    "routineMonitoring": [
      "Vitals post-infusion",
      "Neurologic assessment",
      "CRS symptoms"
    ],
    "preTreatmentTests": [
      "BCMA expression (if applicable)",
      "CBC, chemistries"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T17:48:19.057Z",
    "updatedAt": "2025-05-12T05:49:32.262Z"
  },
  {
    "id": "27daff3b-732a-4c3b-813b-32951c62949f",
    "name": "Cisplatin",
    "brandNames": [
      "Platinol"
    ],
    "classification": "Platinum Chemotherapy",
    "mechanism": "Forms DNA crosslinks and inhibits DNA replication",
    "administration": "Infuse over 1-2 hours with hydration",
    "indications": {
      "cancer_types": [
        "Lung Cancer",
        "Bladder Cancer",
        "Testicular Cancer"
      ]
    },
    "dosing": {
      "standard": "50-100 mg/m² every 3-4 weeks",
      "adjustments": [
        "Reduce dose for renal impairment",
        "Hydration protocol required"
      ]
    },
    "sideEffects": {
      "common": [
        "Nephrotoxicity",
        "Nausea & vomiting",
        "Ototoxicity"
      ],
      "serious": []
    },
    "monitoring": {
      "labs": [
        "Renal function",
        "Electrolytes"
      ],
      "frequency": "Prior to each cycle",
      "precautions": [
        "Hearing tests"
      ]
    },
    "interactions": {
      "drugs": [
        "Aminoglycosides",
        "NSAIDs",
        "Loop Diuretics"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "BC Cancer Protocols"
    ],
    "summary": "Cisplatin is a platinum-based chemotherapy agent that forms DNA cross-links, inhibiting DNA replication. It is used in various solid tumors including testicular, ovarian, bladder, and lung cancers.",
    "blackBoxWarning": "Severe nephrotoxicity, ototoxicity, and nausea/vomiting are dose-limiting. Requires aggressive hydration and monitoring.",
    "specialConsiderations": {
      "hydration": "Aggressive IV hydration and diuretics recommended to prevent nephrotoxicity",
      "pregnancy": "Contraindicated due to teratogenicity",
      "antiemetics": "Highly emetogenic—requires premedication"
    },
    "pharmacokinetics": {
      "excretion": "Primarily renal",
      "half_life": "20–30 hours (terminal)",
      "metabolism": "Non-enzymatic conversion in plasma"
    },
    "contraindications": [
      "Preexisting renal impairment",
      "Hearing loss",
      "Hypersensitivity to platinum agents"
    ],
    "routineMonitoring": [
      "Renal function",
      "Electrolytes (Mg, K)",
      "Audiometry (if indicated)",
      "CBC"
    ],
    "preTreatmentTests": [
      "Renal panel",
      "Electrolytes",
      "Audiogram (baseline if at risk)"
    ],
    "isChemotherapy": true,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T17:13:59.122Z",
    "updatedAt": "2025-05-12T05:50:08.771Z"
  },
  {
    "id": "2f2b9cef-d6dd-4ec1-9a4b-a319ceaef3bd",
    "name": "Darbepoetin Alfa",
    "brandNames": [
      "Aranesp"
    ],
    "classification": "Erythropoiesis-Stimulating Agent (ESA)",
    "mechanism": "Stimulates erythropoiesis by acting like erythropoietin",
    "administration": "Subcutaneous injection or IV administration",
    "indications": {
      "cancer_types": [
        "Anemia due to Chemotherapy"
      ]
    },
    "dosing": {
      "standard": "2.25 mcg/kg weekly or 500 mcg every 3 weeks"
    },
    "sideEffects": {
      "common": [
        "Hypertension",
        "Seizures"
      ],
      "serious": [
        "Thromboembolism",
        "Pure red cell aplasia"
      ]
    },
    "monitoring": {
      "labs": [
        "Hemoglobin",
        "Iron studies",
        "Blood pressure"
      ],
      "frequency": "Every 2-4 weeks",
      "precautions": [
        "Discontinue if no response after 8 weeks",
        "Monitor BP closely"
      ]
    },
    "interactions": {
      "drugs": [
        "Iron supplementation",
        "Antihypertensive agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "ASCO Guidelines"
    ],
    "summary": "Darbepoetin alfa is a long-acting erythropoiesis-stimulating agent used in anemia due to chemotherapy or chronic kidney disease.",
    "blackBoxWarning": "Increased risk of cardiovascular events, stroke, and tumor progression if used to target Hb > 11 g/dL.",
    "specialConsiderations": {
      "iron_status": "Ensure adequate iron before and during therapy",
      "thromboembolism": "Increased risk with higher hemoglobin targets"
    },
    "pharmacokinetics": {
      "excretion": "Unknown",
      "half_life": "21 hours (IV), 49 hours (SC)",
      "metabolism": "Proteolysis"
    },
    "contraindications": [
      "Uncontrolled hypertension",
      "Pure red cell aplasia"
    ],
    "routineMonitoring": [
      "Hemoglobin",
      "Iron panel",
      "BP"
    ],
    "preTreatmentTests": [
      "Hb level",
      "Iron status",
      "BP"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T17:51:27.495Z",
    "updatedAt": "2025-05-12T05:51:17.981Z"
  },
  {
    "id": "d2f6b3c8-1e4a-42a7-b8d9-f0c2e6a5b3c4",
    "name": "Datopotamab Deruxtecan",
    "brandNames": [
      "Dato‑DXd"
    ],
    "classification": "Trop‑2 Antibody‑Drug Conjugate",
    "mechanism": "Delivers a topoisomerase inhibitor to Trop‑2 expressing cells",
    "administration": "IV infusion over 30–60 minutes",
    "indications": {
      "cancer_types": [
        "Triple-Negative Breast Cancer",
        "Non-Small Cell Lung Cancer"
      ]
    },
    "dosing": {
      "standard": "6 mg/kg IV every 3 weeks"
    },
    "sideEffects": {
      "common": [
        "Interstitial lung disease",
        "Neutropenia",
        "Nausea",
        "Fatigue"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC",
        "Liver function"
      ],
      "frequency": "Every 3 weeks",
      "precautions": [
        "Monitor for lung toxicity and neutropenia"
      ]
    },
    "interactions": {
      "drugs": [
        "CYP3A4 inhibitors",
        "Nephrotoxic drugs"
      ]
    },
    "referenceSources": [
      "Clinical Trials",
      "NCCN Guidelines"
    ],
    "summary": "Datopotamab deruxtecan is an antibody-drug conjugate targeting TROP2, under investigation for use in solid tumors such as breast and lung cancer.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "eye_toxicity": "Conjunctivitis and keratitis reported in trials",
      "ILD_pneumonitis": "Monitor respiratory symptoms closely; may require corticosteroids"
    },
    "pharmacokinetics": {
      "excretion": "Unknown",
      "half_life": "Investigational",
      "metabolism": "Expected proteolytic degradation"
    },
    "contraindications": [
      "None established"
    ],
    "routineMonitoring": [
      "Pulmonary function",
      "Ocular symptoms"
    ],
    "preTreatmentTests": [
      "TROP2 expression (if applicable)",
      "Baseline imaging"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:37:33.956Z",
    "updatedAt": "2025-05-12T05:51:32.141Z"
  },
  {
    "id": "12a51ba1-6e7d-411b-bbb8-15d85b32ec64",
    "name": "Denosumab",
    "brandNames": [
      "Xgeva"
    ],
    "classification": "RANKL Inhibitor",
    "mechanism": "Inhibits osteoclast activity via RANKL blockade",
    "administration": "Subcutaneous injection",
    "indications": {
      "cancer_types": [
        "Bone Metastases",
        "Multiple Myeloma"
      ]
    },
    "dosing": {
      "standard": "120 mg subcutaneously every 4 weeks"
    },
    "sideEffects": {
      "common": [
        "Fatigue",
        "Hypocalcemia"
      ],
      "serious": [
        "Osteonecrosis of the jaw"
      ]
    },
    "monitoring": {
      "labs": [
        "Calcium",
        "Renal function",
        "Dental exam"
      ],
      "frequency": "Every 4 weeks",
      "precautions": [
        "Monitor calcium levels",
        "Assess for jaw osteonecrosis"
      ]
    },
    "interactions": {
      "drugs": [
        "Calcium supplements",
        "Nephrotoxic drugs"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "ASCO Guidelines"
    ],
    "summary": "Denosumab is a RANKL inhibitor used to prevent skeletal-related events in patients with bone metastases and to treat osteoporosis.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "hypocalcemia": "Risk increased in patients with renal impairment; supplement calcium and vitamin D",
      "jaw_osteonecrosis": "Avoid invasive dental procedures if possible"
    },
    "pharmacokinetics": {
      "excretion": "Not characterized",
      "half_life": "25–28 days",
      "metabolism": "Reticuloendothelial system"
    },
    "contraindications": [
      "Hypocalcemia",
      "Pregnancy"
    ],
    "routineMonitoring": [
      "Calcium, phosphate, magnesium",
      "Dental exam (prior to initiation)"
    ],
    "preTreatmentTests": [
      "Serum calcium",
      "Renal function",
      "Dental assessment"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T17:43:45.390Z",
    "updatedAt": "2025-05-12T05:51:39.304Z"
  },
  {
    "id": "f7cfffe7-54f7-4a08-a619-6e4122383521",
    "name": "Rituximab",
    "brandNames": [
      "Rituxan"
    ],
    "classification": "CD20 Monoclonal Antibody",
    "mechanism": "Binds CD20 on B‑cells to induce ADCC and CDC",
    "administration": "375 mg/m² IV weekly for 4 doses",
    "indications": {
      "cancer_types": [
        "Non-Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia"
      ]
    },
    "dosing": {
      "standard": "375 mg/m² IV weekly for 4 doses"
    },
    "sideEffects": {
      "common": [
        "Infusion reactions",
        "Neutropenia",
        "Fever"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC"
      ],
      "frequency": "Every cycle"
    },
    "interactions": {
      "drugs": [
        "Other B-cell targeting agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Rituximab is a chimeric anti-CD20 monoclonal antibody used in B-cell non-Hodgkin lymphomas, chronic lymphocytic leukemia (CLL), and autoimmune conditions like rheumatoid arthritis.",
    "blackBoxWarning": "Risk of progressive multifocal leukoencephalopathy (PML), infusion reactions, and hepatitis B reactivation.",
    "specialConsiderations": {
      "infusion_reactions": "Premedicate with corticosteroids and antihistamines; monitor closely during first infusion",
      "hepatitis_B_reactivation": "Screen for HBV before initiation"
    },
    "pharmacokinetics": {
      "excretion": "Unknown (not renally excreted)",
      "half_life": "18–22 days",
      "metabolism": "Proteolytic degradation"
    },
    "contraindications": [
      "Active severe infection",
      "Known hypersensitivity to murine proteins"
    ],
    "routineMonitoring": [
      "CBC",
      "HBV status",
      "Signs of infusion reactions"
    ],
    "preTreatmentTests": [
      "HBV serology",
      "CBC",
      "ECG if high cardiac risk"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:43:46.667Z",
    "updatedAt": "2025-05-12T06:14:44.156Z"
  },
  {
    "id": "36160043-b700-44dc-af3e-6f44e380e388",
    "name": "Rituximab",
    "brandNames": [
      "Rituxan"
    ],
    "classification": "CD20 Monoclonal Antibody",
    "mechanism": "Binds CD20 on B‑cells to induce ADCC and CDC",
    "administration": "375 mg/m² IV weekly for 4 doses",
    "indications": {
      "cancer_types": [
        "Non-Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia"
      ]
    },
    "dosing": {
      "standard": "375 mg/m² IV weekly for 4 doses"
    },
    "sideEffects": {
      "common": [
        "Infusion reactions",
        "Neutropenia",
        "Fever"
      ]
    },
    "monitoring": {
      "labs": [
        "CBC"
      ],
      "frequency": "Every cycle"
    },
    "interactions": {
      "drugs": [
        "Other B-cell targeting agents"
      ]
    },
    "referenceSources": [
      "NCCN Guidelines",
      "FDA prescribing information"
    ],
    "summary": "Rituximab is a chimeric anti-CD20 monoclonal antibody used in B-cell non-Hodgkin lymphomas, chronic lymphocytic leukemia (CLL), and autoimmune conditions like rheumatoid arthritis.",
    "blackBoxWarning": "Risk of progressive multifocal leukoencephalopathy (PML), infusion reactions, and hepatitis B reactivation.",
    "specialConsiderations": {
      "infusion_reactions": "Premedicate with corticosteroids and antihistamines; monitor closely during first infusion",
      "hepatitis_B_reactivation": "Screen for HBV before initiation"
    },
    "pharmacokinetics": {
      "excretion": "Unknown (not renally excreted)",
      "half_life": "18–22 days",
      "metabolism": "Proteolytic degradation"
    },
    "contraindications": [
      "Active severe infection",
      "Known hypersensitivity to murine proteins"
    ],
    "routineMonitoring": [
      "CBC",
      "HBV status",
      "Signs of infusion reactions"
    ],
    "preTreatmentTests": [
      "HBV serology",
      "CBC",
      "ECG if high cardiac risk"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:44:47.925Z",
    "updatedAt": "2025-05-12T06:14:44.156Z"
  },
  {
    "id": "3866c219-92fc-4ebd-98e6-37bd8c94c4ed",
    "name": "Neratinib",
    "brandNames": [
      "Nerlynx"
    ],
    "classification": "Tyrosine kinase inhibitor (TKI) targeting HER2/EGFR",
    "mechanism": "Irreversibly inhibits HER2, HER4, and EGFR tyrosine kinases, blocking downstream signaling pathways",
    "administration": "Oral: 240 mg once daily with food for metastatic cancer; empty stomach for adjuvant therapy",
    "indications": {
      "approved": [
        "Extended adjuvant HER2+ breast cancer",
        "Metastatic HER2+ breast cancer"
      ],
      "off_label": [
        "HER2-mutated NSCLC (investigational)"
      ]
    },
    "dosing": {
      "standard": "240 mg daily",
      "renal_adjustment": "No adjustment for mild-moderate; avoid in severe",
      "hepatic_adjustment": "Reduce to 80 mg in severe impairment"
    },
    "sideEffects": {
      "common": [
        "Diarrhea (95%)",
        "Nausea",
        "Fatigue",
        "Abdominal pain"
      ],
      "serious": [
        "Hepatotoxicity",
        "Severe dehydration from diarrhea"
      ]
    },
    "monitoring": {
      "baseline": [
        "LFTs",
        "ECG",
        "Hydration status"
      ],
      "during_treatment": [
        "Weekly LFTs x3 months",
        "Diarrhea management monitoring"
      ]
    },
    "interactions": {
      "caution": [
        "PPIs (reduce absorption)",
        "QT-prolonging agents"
      ],
      "contraindicated": [
        "Strong CYP3A4 inducers"
      ]
    },
    "referenceSources": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208051s005s006lbl.pdf"
    ],
    "summary": "Oral HER2/EGFR TKI for HER2+ breast cancer with mandatory antidiarrheal prophylaxis, notable for high-grade diarrhea requiring proactive management",
    "blackBoxWarning": "Boxed warning for severe diarrhea and hepatotoxicity",
    "specialConsiderations": {
      "dose_escalation": "120 mg → 160 mg → 240 mg over 2 weeks",
      "diarrhea_prophylaxis": "Loperamide x56 days with dose escalation"
    },
    "pharmacokinetics": {
      "excretion": "Feces (97%)",
      "half_life": "7-17 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Severe hepatic impairment (Child-Pugh C)",
      "Hypersensitivity reactions"
    ],
    "routineMonitoring": [
      "Daily diarrhea assessment",
      "Monthly LFTs"
    ],
    "preTreatmentTests": [
      "HER2 IHC/FISH",
      "Pregnancy test",
      "Baseline ECG"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-05-12T11:43:03.561Z",
    "updatedAt": "2025-05-12T11:43:03.561Z"
  },
  {
    "id": "bb75976c-aaea-4b96-a422-fbfad97a86fe",
    "name": "Neratinib",
    "brandNames": [
      "Nerlynx"
    ],
    "classification": "Tyrosine kinase inhibitor (TKI) targeting HER2/EGFR",
    "mechanism": "Irreversibly inhibits HER2, HER4, and EGFR tyrosine kinases, blocking downstream signaling pathways",
    "administration": "Oral: 240 mg once daily with food for metastatic cancer; empty stomach for adjuvant therapy",
    "indications": {
      "approved": [
        "Extended adjuvant HER2+ breast cancer",
        "Metastatic HER2+ breast cancer"
      ],
      "off_label": [
        "HER2-mutated NSCLC (investigational)"
      ]
    },
    "dosing": {
      "standard": "240 mg daily",
      "renal_adjustment": "No adjustment for mild-moderate; avoid in severe",
      "hepatic_adjustment": "Reduce to 80 mg in severe impairment"
    },
    "sideEffects": {
      "common": [
        "Diarrhea (95%)",
        "Nausea",
        "Fatigue",
        "Abdominal pain"
      ],
      "serious": [
        "Hepatotoxicity",
        "Severe dehydration from diarrhea"
      ]
    },
    "monitoring": {
      "baseline": [
        "LFTs",
        "ECG",
        "Hydration status"
      ],
      "during_treatment": [
        "Weekly LFTs x3 months",
        "Diarrhea management monitoring"
      ]
    },
    "interactions": {
      "caution": [
        "PPIs (reduce absorption)",
        "QT-prolonging agents"
      ],
      "contraindicated": [
        "Strong CYP3A4 inducers"
      ]
    },
    "referenceSources": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208051s005s006lbl.pdf"
    ],
    "summary": "Oral HER2/EGFR TKI for HER2+ breast cancer with mandatory antidiarrheal prophylaxis, notable for high-grade diarrhea requiring proactive management",
    "blackBoxWarning": "Boxed warning for severe diarrhea and hepatotoxicity",
    "specialConsiderations": {
      "dose_escalation": "120 mg → 160 mg → 240 mg over 2 weeks",
      "diarrhea_prophylaxis": "Loperamide x56 days with dose escalation"
    },
    "pharmacokinetics": {
      "excretion": "Feces (97%)",
      "half_life": "7-17 hours",
      "metabolism": "CYP3A4"
    },
    "contraindications": [
      "Severe hepatic impairment (Child-Pugh C)",
      "Hypersensitivity reactions"
    ],
    "routineMonitoring": [
      "Daily diarrhea assessment",
      "Monthly LFTs"
    ],
    "preTreatmentTests": [
      "HER2 IHC/FISH",
      "Pregnancy test",
      "Baseline ECG"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-05-12T11:51:12.722Z",
    "updatedAt": "2025-05-12T11:51:12.722Z"
  },
  {
    "id": "97aa9385-f530-438a-a1a6-894a7ed3d3f0",
    "name": "Nedaplatin",
    "brandNames": [
      "Aqupla"
    ],
    "classification": "Second-generation platinum-based alkylating agent",
    "mechanism": "Forms DNA intra- and inter-strand crosslinks, inhibiting DNA replication and transcription, leading to apoptosis in rapidly dividing tumor cells",
    "administration": "Intravenous infusion: 80–100 mg/m² over 1–2 hours every 3–4 weeks with pre- and post-hydration",
    "indications": {
      "approved": [
        "Esophageal squamous cell carcinoma (Japan)",
        "Non-small cell lung cancer (China)",
        "Head and neck cancers (regional use)"
      ],
      "off_label": [
        "Cervical cancer (investigational)",
        "Ovarian cancer (substitution for cisplatin)"
      ]
    },
    "dosing": {
      "standard": "80–100 mg/m² IV every 3–4 weeks",
      "renal_adjustment": "Reduce dose if CrCl <60 mL/min; avoid if <40 mL/min",
      "hepatic_adjustment": "No dose adjustment generally required"
    },
    "sideEffects": {
      "common": [
        "Nausea",
        "Vomiting",
        "Thrombocytopenia",
        "Anemia",
        "Mild nephrotoxicity"
      ],
      "serious": [
        "Severe myelosuppression",
        "Anaphylactic reactions",
        "Ototoxicity",
        "Interstitial pneumonitis (rare)"
      ]
    },
    "monitoring": {
      "baseline": [
        "CBC with differential",
        "Renal function (CrCl, BUN, Creatinine)",
        "Audiometry",
        "Electrolytes (Mg, K, Ca)",
        "Performance status"
      ],
      "during_treatment": [
        "Weekly CBC",
        "Renal function prior to each cycle",
        "Monitor for signs of hypersensitivity",
        "Ongoing audiologic evaluation (if needed)"
      ]
    },
    "interactions": {
      "caution": [
        "Concurrent nephrotoxic agents (e.g., aminoglycosides, amphotericin B)",
        "Other myelosuppressive therapies"
      ],
      "contraindicated": [
        "Live attenuated vaccines (e.g., MMR, varicella) during therapy"
      ]
    },
    "referenceSources": [
      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460931/",
      "https://www.jstage.jst.go.jp/article/jjco/36/4/36_4_224/_pdf"
    ],
    "summary": "Nedaplatin is a second-generation platinum analog developed to reduce nephrotoxicity compared to cisplatin. It retains similar efficacy and is mainly approved in Japan and China for esophageal and lung cancers, with regional use in head and neck malignancies. It is also being explored in gynecologic cancers. Requires hydration and close hematologic monitoring due to significant myelosuppression.",
    "blackBoxWarning": null,
    "specialConsiderations": {
      "hydration": "Pre- and post-hydration essential to minimize renal toxicity",
      "emetogenic_potential": "Moderate (30–90%) — antiemetic prophylaxis recommended",
      "myelosuppression_management": "Dose delay or reduction based on nadir blood counts; use G-CSF as appropriate"
    },
    "pharmacokinetics": {
      "excretion": "Renal excretion >90% — dose-dependent clearance",
      "half_life": "2–5 hours",
      "metabolism": "Primarily via non-enzymatic hydrolysis"
    },
    "contraindications": [
      "Severe renal impairment (CrCl <40 mL/min)",
      "Pre-existing significant bone marrow suppression",
      "Known hypersensitivity to platinum compounds"
    ],
    "routineMonitoring": [
      "CBC with differential (weekly)",
      "Renal function tests (before each cycle)",
      "Electrolytes (Mg, K, Ca)",
      "Signs of hypersensitivity or ototoxicity"
    ],
    "preTreatmentTests": [
      "CBC",
      "Renal function panel (CrCl)",
      "Audiometry",
      "Baseline electrolytes"
    ],
    "isChemotherapy": true,
    "isImmunotherapy": false,
    "isTargetedTherapy": false,
    "isOrphanDrug": false,
    "createdAt": "2025-04-16T20:03:53.037Z",
    "updatedAt": "2025-05-12T13:56:14.153Z"
  },
  {
    "id": "6bb2f908-398d-46e6-86a9-65920fc706e7",
    "name": "Mosunetuzumab",
    "brandNames": [
      "Lunsumio"
    ],
    "classification": "CD20/CD3 bispecific monoclonal antibody",
    "mechanism": "Engages CD3+ T-cells and CD20+ B-cells, triggering T-cell-mediated cytotoxicity and immune synapse formation",
    "administration": "IV step-up dosing: Day 1 (1 mg), Day 8 (2 mg), Day 15 (60 mg); subsequent cycles: 30–60 mg every 21 days",
    "indications": {
      "approved": [
        "Relapsed/refractory follicular lymphoma after ≥2 prior systemic therapies"
      ],
      "off_label": [
        "Diffuse large B-cell lymphoma (DLBCL) under investigation in Phase III trials"
      ]
    },
    "dosing": {
      "standard": "Cycle 1: Day 1 (1 mg), Day 8 (2 mg), Day 15 (60 mg); subsequent cycles: 30–60 mg Day 1 of each 21-day cycle",
      "renal_adjustment": "No data available — monitor closely",
      "hepatic_adjustment": "No data available — use with caution in hepatic dysfunction"
    },
    "sideEffects": {
      "common": [
        "Cytokine release syndrome (CRS, ~39%)",
        "Fatigue",
        "Rash"
      ],
      "serious": [
        "Grade ≥3 CRS (1.4%)",
        "Immune effector cell-associated neurotoxicity syndrome (ICANS)"
      ]
    },
    "monitoring": {
      "baseline": [
        "Tumor burden assessment",
        "CRP",
        "LFTs",
        "HBV/HCV serology"
      ],
      "during_treatment": [
        "Vital signs every 4–6 hours for ≥48h post-infusion during Cycle 1",
        "CRS grading and intervention readiness (tocilizumab availability)",
        "Neurologic checks daily for 10 days during initial cycle"
      ]
    },
    "interactions": {
      "caution": [
        "CYP450 substrate drugs — potential metabolic alteration during cytokine release"
      ],
      "contraindicated": [
        "Concomitant use of immunosuppressants or CAR T-cell therapy"
      ]
    },
    "referenceSources": [
      "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma"
    ],
    "summary": "Mosunetuzumab is the first-in-class CD20/CD3 bispecific antibody approved for relapsed follicular lymphoma. It activates T-cells to kill malignant B-cells and offers step-up dosing with the potential for outpatient administration. CRS is the key toxicity.",
    "blackBoxWarning": "Cytokine release syndrome (CRS) — monitor closely during initial cycles and have tocilizumab readily available.",
    "specialConsiderations": {
      "CRS_management": "Administer tocilizumab for grade ≥2 CRS; consider corticosteroids for persistent symptoms",
      "neuro_monitoring": "Daily neurologic exam during Cycle 1 and after CRS events",
      "inpatient_monitoring": "Hospitalize patients at high risk for severe CRS for initial step-up dosing"
    },
    "pharmacokinetics": {
      "excretion": "Proteolytic degradation; not renally excreted",
      "half_life": "~4 days",
      "metabolism": "Target-mediated drug disposition and proteolysis"
    },
    "contraindications": [
      "Active systemic infection",
      "Concurrent malignancy requiring active treatment"
    ],
    "routineMonitoring": [
      "Daily vitals during Cycle 1",
      "CRP monitoring",
      "Neurologic function assessment"
    ],
    "preTreatmentTests": [
      "HBV/HCV screening",
      "CD20 expression confirmation via tumor biopsy",
      "Baseline CRP and liver function tests"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": true,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T20:01:02.252Z",
    "updatedAt": "2025-05-12T13:58:06.651Z"
  },
  {
    "id": "1a6857b4-f188-4c85-a455-493069743889",
    "name": "Lutetium-177 PSMA-617",
    "brandNames": [
      "Pluvicto"
    ],
    "classification": "PSMA-targeted β-emitting radioligand therapy",
    "mechanism": "Binds prostate-specific membrane antigen (PSMA) on tumor cells and delivers cytotoxic β-radiation from Lutetium-177, inducing DNA damage and cell death",
    "administration": "Intravenous: 7.4 gigabecquerels (GBq) every 6 weeks for up to 6 total cycles",
    "indications": {
      "approved": [
        "PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) after androgen receptor pathway inhibition and taxane-based chemotherapy"
      ],
      "off_label": [
        "PSMA-positive salivary gland carcinoma",
        "Other PSMA+ tumors under investigation"
      ]
    },
    "dosing": {
      "standard": "7.4 GBq IV every 6 weeks x6 cycles",
      "renal_adjustment": "Avoid if eGFR <30 mL/min/1.73 m²",
      "hepatic_adjustment": "No adjustment required"
    },
    "sideEffects": {
      "common": [
        "Xerostomia (dry mouth, ~40%)",
        "Fatigue",
        "Nausea",
        "Anemia"
      ],
      "serious": [
        "Grade ≥3 myelosuppression",
        "Acute kidney injury",
        "Secondary malignancies (MDS/AML)"
      ]
    },
    "monitoring": {
      "baseline": [
        "PSMA-PET/CT scan",
        "CBC with differential",
        "Renal function (eGFR)",
        "Liver function tests",
        "Bone marrow reserve"
      ],
      "during_treatment": [
        "CBC weekly during first cycle, then monthly",
        "Renal function prior to each cycle",
        "Periodic PSMA-PET to assess response"
      ]
    },
    "interactions": {
      "caution": [
        "Use with other nephrotoxic agents",
        "Concomitant bone marrow suppressive drugs"
      ],
      "contraindicated": [
        "Concurrent chemotherapy or investigational radioligands",
        "PSMA-negative disease"
      ]
    },
    "referenceSources": [
      "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf"
    ],
    "summary": "Lutetium-177 PSMA-617 (Pluvicto) is the first FDA-approved radioligand therapy targeting PSMA in advanced prostate cancer. It prolongs survival in PSMA+ mCRPC patients and delivers systemic β-radiation directly to tumor cells, requiring PSMA-PET confirmation before use.",
    "blackBoxWarning": "Radiation exposure risk — handle with proper radiopharmaceutical precautions and patient safety protocols",
    "specialConsiderations": {
      "radiation_safety": "Patients should follow 48-hour radiation hygiene precautions, including double flushing and avoiding close contact with young children or pregnant individuals",
      "renal_precautions": "Hydration before and after therapy is advised to reduce renal retention",
      "imaging_requirement": "PSMA-PET/CT scan is mandatory to confirm PSMA-positivity prior to therapy"
    },
    "pharmacokinetics": {
      "excretion": "Renal (~60% within 24 hours via urine)",
      "half_life": "6.7 days (Lu-177)",
      "metabolism": "Minimal metabolism; mostly intact excretion"
    },
    "contraindications": [
      "PSMA-negative tumors",
      "Concurrent chemotherapy",
      "Severe renal impairment (eGFR <30 mL/min/1.73 m²)"
    ],
    "routineMonitoring": [
      "Monthly CBC",
      "Renal function prior to each cycle",
      "PSMA-PET every 3 months"
    ],
    "preTreatmentTests": [
      "PSMA-PET/CT",
      "CBC",
      "Renal function panel (eGFR, Cr)",
      "Bone marrow reserve evaluation"
    ],
    "isChemotherapy": false,
    "isImmunotherapy": false,
    "isTargetedTherapy": true,
    "isOrphanDrug": true,
    "createdAt": "2025-04-16T17:48:19.057Z",
    "updatedAt": "2025-05-12T13:59:58.819Z"
  }
]